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ABSTRACT 
 
The complexity of the pathophysiology of tennis elbow is reflected by the lack of 
consensus on management and remains a therapeutic challenge. This study was a 
prospective randomised, assessor-blinded trial. 64 patients with tennis elbow referred by 
their GP to either the physiotherapy, orthopaedic or MSK CAT services, subject to 
eligibility criteria, were randomised into one of 3 treatment arms: injection, ultrasound 
or exercise, to which the assessor remained blinded. The outcome measures of thermal 
difference, median frequency (MDF), patient-rated tennis elbow evaluation 
questionnaire (PRTEE), pain-free grip strength (PFG) and patient preference were 
assessed twice at baseline, at 10 days, 6 weeks and 6 months and analysed as an 
intention to treat analysis.  
 
In the short term of 6 weeks injection was the most effective treatment demonstrating 
both statistically significant and minimum clinically important differences (MCID) for 
PFG and PRTEE in comparison to ultrasound and exercise. Patients had a strong 
preference for injection and a strong aversion for exercise. No statistically significant 
differences were found between ultrasound and exercise although a MCID was found in 
favour of ultrasound for thermal difference and MDF at 10 days. In to the long term of 6 
months, although this was on a limited subgroup, no statistically significant differences 
were found between any of the groups. A MCID was found in favour of ultrasound for 
MDF and a MCID was found in favour of exercise over injection for all aspects of 
PRTEE and over ultrasound for PRTEE pain only. 
 
This research supports the superior effectiveness of injection in the short term of 6 
weeks and should be advocated for patients who present early with severe limiting pain 
and have important short term goals, although patients need to be warned that a 1/3
rd
 
will have a recurrence of symptoms within 6 months. In contrast, for those patients who 
present with moderate to low pain physiotherapy including exercise and/ or ultrasound 
should be advocated. Thermal difference is a sensitive outcome measure for tennis 
elbow. Continuous 3 MHz therapeutic ultrasound at 2W/cm
2
 for 5 minutes utilises 
thermal effects which optimise the healing process and demonstrate an accumulative 
effect of ultrasound in to the long term. Further research on the effectiveness of a 
combination of injection with physiotherapy is required.  
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CHAPTER 1: INTRODUCTION 
 
Tennis elbow is the most commonly diagnosed elbow condition (Vicenzino and Wright, 
1996) and is defined by lateral elbow pain on palpation of the common extensor origin 
and pain on resisted wrist extension. It is generally considered to be due to repetitive 
microtrauma from the overuse of the wrist extensors and subsequent failure of the 
tendon to heal. Although it has a well-defined clinical presentation and there is an 
abundance of research on tennis elbow, the complexities of both the underlying 
aetiological and pathophysiological processes remain in contention. Specifically, 
whether inflammation is an integral part of the pathogenesis. 
 
Although a myriad of therapeutic interventions are available for the treatment of tennis 
elbow, of the comparatively few randomised controlled trials which have been 
undertaken, no one treatment has been proven to be universally effective; generating 
little consensus on management (Bisset et al., 2005) which accounts for tendon 
problems remaining a therapeutic challenge (Gaujoux-Viala et al., 2009). Additional 
well designed pragmatic trials are required to provide evidence for the efficacy of 
physiotherapeutic interventions (Smidt et al., 2003). 
 
Outcome measures in previous studies have consistently been a form of questionnaire 
and grip strength, rather than physiological measures of temperature and muscle 
function which would be more directly relevant to current conservative treatment on 
tennis elbow. Thermography and electromyography (EMG) have not been used to 
evaluate the treatment effects of injection therapy, ultrasound or physiotherapy 
rehabilitation to date. Previously published protocols for both have inherent 
fundamental flaws and deficiencies. Through the development of a novel scientifically 
robust model, for thermography, and application of concepts in a unique way, for EMG, 
these measures have been standardised, as part of this thesis, in an optimum manner 
which negate these inherent potential variables. Subsequently, the use of these 
innovative developments has enabled a more robust trial providing details which are 
directly clinically relevant to the increase in temperature and reduction of muscle 
function seen in this patient group. Through thermographic and EMG evaluation this 
study has the potential to identify whether the alterations in muscle function and 
disability found in tennis elbow are fully reversible solely through pain relief by 
 2 
injection therapy or ultrasound or whether rehabilitation is a prerequisite to reversibility 
and subsequently prevention of recurrence. Although the use of a combination of 
conservative treatments is the norm in clinical practice it is important that the specific 
elements of treatment are evaluated to identify their individual effectiveness prior to 
evaluation of possible interactions.  
 
A systematic review on ultrasound by van der Windt et al. (1999) concluded that tennis 
elbow was the only condition for which there was favourable weak evidence for its use. 
Low intensity ultrasound is advocated in practice, which does not utilise the thermal 
effects of the available high superficial doses. However, previous work by Williams 
(2003) found high dose ultrasound to be highly effective in the short term. 
 
Thermographic evaluation of tennis elbow has allowed an indirect analysis of the 
potential inflammatory nature of this condition. Current research proposes that tennis 
elbow is an angiofibroblastic tendinosis which is distinctly non-inflammatory 
(Kraushaar and Nirschl, 1999), however corticosteroid injections only known 
mechanism of action to relieve pain and diminish disability is by a reduction in 
inflammation (Cyriax, 1984). Other mechanisms of pain relief by corticosteroids have 
not been established (Speed, 2001). Due to the fact that injection therapy has been 
proven to be the best treatment option in the short-term for tennis elbow patients with 
success rates of 92% (Smidt et al., 2002) one is left with a clinical dilemma due to the 
lack of an inflammatory pathology. 
  
Thermographic analysis should provide more evidence on the debate on both the nature 
of tennis elbow and action of injection therapy. Surface EMG should allow more 
detailed analysis of muscle function and provide improved knowledge of the 
pathogenesis of tennis elbow over time.  
 
 
 
 
 
 
 
 
 3 
CHAPTER 2: AIMS AND OBJECTIVES 
 
The primary aim of this study is to evaluate the effectiveness of current conservative 
treatments relevant to tennis elbow (which include ultrasound, injection therapy, and 
physiotherapy rehabilitation) in the short-term of 10 days and 6 weeks. 
The secondary aim is to evaluate treatment effectiveness in the long-term of 6 months.  
 
The objectives are to:  
1. investigate whether thermal and EMG changes show a relationship with function 
and disability.  
2. investigate the immediate effects, 10 days, on temperature using thermographic 
analysis and on muscle function using EMG with any treatment and subsequently 
comparison of the different treatment groups. 
3. investigate the sustainability, up to 6 months, of thermographic and EMG changes 
in the different treatment groups.  
4. determine whether temperature using thermography and muscle function using 
EMG can be altered solely by injection and ultrasound alone or by physiotherapy 
exercise rehabilitation. 
 
The aims and objectives were addressed through a pragmatic prospective randomised, 
assessor-blinded trial of 64 patients who were referred by their GP to either the 
physiotherapy, orthopaedic or MSK CAT services of Ashton, Leigh and Wigan PCT or 
Wrightington, Wigan and Leigh NHS Trust.  
 
This thesis has been structured sequentially to direct the reader logically through the 
area of research. Chapter 3 reviews the literature on the anatomy and physiology of 
extensor carpi radialis brevis (ECRBr), the pathophysiology of tennis elbow, the 3 
commonest treatments for tennis elbow: corticosteroid injection, ultrasound and 
physiotherapy exercise rehabilitation and the outcome measures of thermography, pain 
free grip strength, electromyography and patient-rated tennis elbow evaluation 
questionnaire (PRTEE). Chapter 4 describes the protocol developments for both 
thermography and electromyography. Chapter 5 tests these protocols on a healthy 
sample to identify normative data. These normative studies also evaluate the thermal 
effects of ultrasound versus sham ultrasound on a single healthy individual. Chapter 6 
details the methods of the randomised trial and the internal pilot, of the first 20 patients. 
 4 
The internal pilot was carried out to test procedures on the clinical tennis elbow 
population, identify minimum clinically important differences (MCID) and to evaluate 
the sample size through analysis of the stability of data. This chapter also includes an 
illustrative single case history. Chapter 7 explores the results of the clinical trial which 
are discussed in chapter 8 alongside the clinical implications and limitations with the 
conclusions drawn in chapter 9.      
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CHAPTER 3: LITERATURE REVIEW 
 
Preparatory work included a literature review which was undertaken to determine the 
current evidence available on tennis elbow and subsequently identify any pertinent gaps 
in the knowledge regarding the current clinical practice for this condition. This chapter 
has been structured to lead the reader sequentially through the anatomy, function and 
physiology of ECRBr, tennis elbow, aetiology and pathology, current treatments and 
therapeutic effects of injection, ultrasound and exercise therapy and the outcome 
measures of thermography, pain free grip strength, electromyography and patient-rated 
tennis elbow evaluation questionnaire.  
 
This comprised of a comprehensive online literature search of Cochrane, Pedro, 
PubMed, Cinahl (1982-2011), Medline (1992-2011), AMed (1985- 2011) and Embase 
(1992-2011) databases. Key words used were tennis elbow, lateral epicondylitis, 
common extensor tendinopath* +/- injection, exercise, ultrasound, outcome measures or 
steroid injection.   
 
3.1 Anatomy, function and physiology of extensor carpi radialis 
brevis 
 
Within the area of the lateral epicondyle there are complex intimate relationships 
between the tendons, fascia and muscles. On review of the functional anatomy and 
biomechanics the clinical significance of the comparatively large forces which are 
repeatedly exerted on both the origin and tendon of extensor carpi radialis brevis 
(ECRBr) can be seen.   
 
ECRBr arises from the anterolateral aspect of the lateral epicondyle of the humerus by 
the common extensor tendon (CET), with extensor carpi ulnaris (ECU), extensor 
digitorum (ED) and extensor carpi radialis longus (ECRL), and the radial collateral 
ligament (RCL). Superficially the ECRBr tendon is continuous with the antebrachial 
fascia and with the intermuscular septum between the ED muscle and itself distally. 
Both ED and ECU attach to the fascia and part of both ECRL and ED also attach to the 
septum. ECRBr runs deep to ECRL, with brevis’s muscle belly lying more distally, 
before it inserts through a flat tendon into the radial aspect of the dorsal surface of the 
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base of the 3
rd
 metacarpal, distal to the styloid process, and to the adjacent part of the 
base of the 2
nd
 metacarpal (Williams and Warwick, 1980).  
 
Milz et al. (2004) examined 12 cadavers and reported that the entheses of the CET and 
the RCL are fused. This single enthesis aids stress dissipation through both the tendon 
and ligament. Furthermore, the RCL is also fused with the annular ligament which 
wraps around the radial head which further supplements force transmission over a larger 
area.  
 
The extensibility of tendons varies with only 1-2% lengthening of extensor carpi 
radialis (ECR) in animals (Kjaer, 2004). ECRBr is a vascular tendon which does not 
procure it’s nutrition from a synovial sheath.     
 
Although pathological changes have been reported in the other extensors and indeed 
twenty-six different causes of non-specific lateral elbow pain have been suggested, 
ranging from Panner’s disease (avascular necrosis of the lateral epicondyle) to radial 
tunnel syndrome and cervical referral (Noteboom et al., 1994) the origin of ECRBr 
accounts for 90% of all cases of tennis elbow (Cyriax, 1982). ECRBr as the primary site 
has been confirmed by extensive work on over 600 surgical cases by Nirschl (1992).  
 
ECRBr is distinguished from the other extensors for a number of reasons (Stoeckart et 
al., 1989): the tenoperiosteal junction on the lateral epicondyle of ECRBr is small when 
compared to that of both ECRL and ECU. In addition, forces are concentrated to both 
the tendon and tenoperiosteal junction of ECRBr through the contraction of ECRL and 
ED, which both arise from this tendon, through active elbow flexion as the origin of 
ECRBr is above the elbow joint and lengthening of ECRBr in pronation with wrist 
flexion and ulnar deviation. The fascial origin of ECRBr is equally small when 
compared to ED and ECU and should there be anatomical variation and poor 
development of the fascia the forces generated by ED, for example, may be transferred 
to a greater degree to the origin and tendon of ECRBr rather than the fascia. 
 
Although ECRBr is a wrist extensor and radial deviator, it has been shown to be 
strongly activated during grasping and pinching activities, acting as a synergist, 
stabilising the wrist by preventing the flexion moment when the finger flexors are 
activated. 
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The extracellular matrix (ECM), of which collagen fibrils and proteoglycans are a 
universal feature, plays an important role, especially in tendons, in the force 
transmission and maintenance of tissue structure. Evidence is evolving that tendons are 
dynamic structures which adapt, both structurally and functionally, to the mechanical 
loads they are subjected to through collagen turnover, metabolic activity and circulatory 
responses. This process is termed mechanotransduction and the increase in type I 
collagen turnover, occurring in response to mechanical loading through training, may 
reflect both damage repair and physiological adaptation. It is speculated that this 
upregulation initially allows reorganisation of the tissue followed by a net synthesis 
through prolonged training which potentially alters tissue strength (Kjaer, 2004). Type I 
fibres are termed slow oxidative fibres due to their slow contraction velocity which can 
produce a moderate force and are very fatigue resistant.  
 
Tendons have a relatively limited vascularity comprising of only 1-2% of the ECM and 
the effects of mechanical loading on blood flow remain unclear and indeed whether it 
adequately meets the oxidative needs of the tendon during exercise. It should be noted 
that with regard to vascularity and morphology, tendons can be very heterogeneous 
along their length and subsequently any adaptive collagen responses are 
correspondingly region specific. 
 
These morphological and physiological adaptations, which occur due to the long-term 
functional demands a muscle is placed under, are shown by ECRBr in the dominant 
elbow having a higher proportion of Type I muscle fibres in comparison to the 
nondominant elbow which could be attributed to the repetitive use of the dominant hand 
in gripping (Fugl-Meyer et al., 1982). 
 
With age accumulation of advanced glycation end products lead to a number of 
changes: a stiffer and more load-resistant tendon, a reduced ability of adaptation due to 
a markedly reduced collagen turn-over rate and also an upregulation in fibroblast 
connective tissue growth factor which leads to fibrosis (Kjaer, 2004). 
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3.2 Tennis elbow 
 
Tennis elbow or lateral epicondylitis is a common significant problem with an estimated 
incidence in the region of 4-7 per 1000 patients seen in general practice per year (Smidt 
et al., 2002). Saunders (2002) reported that 9% of all peripheral and soft tissue 
injections undertaken in a General Practice during 1991-1999 were for tennis elbow. 
Furthermore, from epidemiology studies Verhaar (1994) found a yearly incidence of 
between 1-2% of the adult general population and that only half of these patients would 
seek medical attention. Overend et al. (1999) reported 35-61% of cases were work 
related whilst 5-8% were tennis related. 
 
Tennis elbow is almost invariably experienced in the dominant hand occurring in equal 
proportions of male and female patients with a mean age of between 35 -50 years 
(Vicenzino and Wright, 1996). It is defined by lateral elbow pain on palpation of the 
common extensor origin and pain on resisted wrist extension.  
 
The natural evolution of tennis elbow is generally considered to be self- limiting with 
spontaneous recovery occurring commonly around one year after onset. This was 
supported by Assendelft et al. (2003) who reported 80% of patients who had tennis 
elbow for at least 4 weeks became asymptomatic after one year in a general practice 
trial of expectant waiting policy. However, in contrast Bot et al. (2005) reported from a 
large observational cohort study including 181 patients with elbow complaints poor 
recovery; only13% reported recovery at 3 months and 34% at 12 months with only a 
further 24% and 21% of the remainder, respectively, reporting substantial improvement. 
This research included a variety of elbow complaints, although they reported that tennis 
elbow was the most common elbow complaint found in their population and 54% of 
patients reported previous symptoms within the past year. They found predictors of 
longer duration of symptoms before GP consultation, musculoskeletal comorbidities 
and using retreating as a coping style were associated with poorer outcomes of pain and 
disability. In addition, at 3 months less social support and at 12 months previous history 
and using worrying as a coping style were associated with poorer outcomes. Smidt et al. 
(2006) prospectively evaluated 349 patients to identify prognostic indicators associated 
with pain. They reported high baseline pain severity, long duration and concomitant 
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shoulder pain as indicators for poor outcome at 1 month and concomitant neck pain for 
poor outcome at 12 months.  
 
Predisposing factors influencing the frequency of tendon overload include both intrinsic 
and extrinsic factors. Extrinsic factors include overuse, technique and equipment. 
Intrinsic factors include genetic, age, gender (protective female hormones) and 
concomitant chronic disease such as hypertension, diabetes and hyperlipidemia. High 
body weight (waist girth lipids) and muscle flexibility are also specified as moderately 
important factors but it must be noted that these are associations rather than based on 
demonstratable cause and effect relationships (Kjaer, 2004 and Malliaras, 2008). 
 
3.3 Aetiology and pathology of tennis elbow 
 
Although it has a well-defined clinical presentation and there is a wealth of research on 
this condition, the complexities of the underlying pathophysiological and aetiological 
processes remain in contention. In particular, whether inflammation is an integral part of 
the pathogenesis and whether tennis elbow is a self-limiting disorder. 
 
The view from histological studies was a non inflammatory and degenerative process 
leading to a disorganised and immature tendon repair termed angiofibroblastic 
tendinosis (Kraushaar and Nirshl, 1999) which was characterised by 4 key changes: 
increased cell numbers and ground substance, neovascularisation, increased 
neurochemical concentration and disorganised and immature collagen. This occurs 
when a tendon has failed to heal after an injury or after repetitive microtrauma through 
overuse. However, it should be noted that these histological results may not be 
representative of the tennis elbow population as a whole as the biopsies researched are 
those from a specific sub-population of recalcitrant tennis elbow requiring surgery. 
Furthermore, the pathological appearances may be iatrogenic in nature having been 
confounded by previous conservative therapy such as steroid injection therapy.  
 
Although these studies found acute inflammatory markers to almost invariably be 
absent, chronic inflammatory cells were occasionally scattered in the surrounding 
muscular and fibrous connective tissue which led to the authors to categorise stage one 
tennis elbow as probably inflammatory. Kjaer (2004) found it difficult to completely 
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exclude an inflammatory component due to a number of factors: clinical observation of 
swelling and warmth, the proven positive effect of anti-inflammatory drugs and 
corticosteroids. It still remains unknown whether inflammation precedes degeneration 
in the more acute phase of this condition (Speed, 2001). 
 
In addition, Milz et al. (2004) assessed 12 normal cadaver elbows, 6 cadavers with a 
mean age of 47 years and 6 cadavers with a mean age of 84 years. They found that 
fibrocartilage was a constant feature in all entheses, regardless of age, and furthermore 
reported that the elderly entheses demonstrated extensive microscopic damage. This led 
them to conclude that both these appearances may simply be a normal feature, which 
reflects functional adaptation to not only the tensile forces but also the shear and 
compressive forces implicated at the enthesis, rather than evidence of a pathological 
tendinosis.   
 
On an ECM level it is hypothesised that the adaptive mechanism is driven by 
biochemical and physiological processes regulated by an exercise induced increase in 
collagen degradation followed by an increase in synthesis in cases where recovery time 
is too short to allow for physiological adaptation from repeated loading. This suggests 
that overuse conditions are a mismatch between degrading and synthesis biochemical 
processes. The other proposed mechanism is repair processes of resultant tissue damage 
following repeated microtrauma in particular when a tendon is subjected to high and 
sudden loads near the structural limit (Kjaer, 2004).  
 
Unfortunately, most research at this level (Kjaer, 2004) has used animal models, and 
with ultrasound muscle has been widely researched, with the notable exception of a few 
human lower limb tendinopathies with achilles tendon in particular. Some of this work 
can be extrapolated but it is important to note their very different tendon specific roles 
and subsequently the differences in the area of pathology being at the tenoperiosteal 
junction of ECRBr compared to the musculotendinous junction of the achilles tendon.  
 
It is also important to note that with the absence of acute inflammatory markers the 
histopathological studies fail to explain the pain mechanisms involved although recently 
neovascularisation has been proposed to be a source of pain due to the close association 
between the microvasculature, neural structures and neurochemicals at the 
tenoperiosteal junction of ECRBr. Equally of interest is that no clear relationship 
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between pain and pathology has been found: no correlation has been found on Doppler 
ultrasound between the amount of neovascularisation and pain severity or dysfunction, 
asymptomatic tendon damage has been found on ultrasonography and symptoms can be 
evident despite normal imaging (Khan et al., 2000).  
 
It has been proposed that the pain mechanisms are due to central sensitisation and the 
triggering of nociceptors by neurotransmitters or biochemical irritation due to the 
noxious products of cellular activity (Kraushaar and Nirschl, 1999 and Khan et al., 
2000). Using microdialysis in overused achilles and patellar tendons a raised level of 
glutamate was found at rest. Substance P has been found at the origin of ECRBr. 
Despite the exact role being unknown, glutamate is both an excitatory neurotransmitter 
pain modulator in the central nervous system and has an additive nociceptive role to 
substance P (Kjaer, 2004). Substance P also has a very powerful influence on 
vasoactivity which controls thermal emission and can be monitored by thermography.  
 
Alterations in sympathetic nervous system function has been proposed as a contributory 
factor in the pathogenesis of tennis elbow as thermographic studies have identified 
characteristic hot spots at the lateral epicondyles of symptomatic patients. Whilst it has 
been suggested that these hot spots support an inflammatory, vascular pathology 
(Thomas et al., 1992) others advocate they may reflect subtle alterations in 
microvascular control (Vicenzino and Wright, 1996). 
 
Fatigue of the wrist extensor muscles is also thought to be a contributory factor in the 
pathogenesis of tennis elbow. Hagg and Milerad (1997) evaluated forearm fatigue in 
healthy individuals during simulated gripping work by EMG. They found that the 
fatigue effects were generally larger on the extensor side.  
 
Until the true nature of the underlying pathological processes of tennis elbow is fully 
understood the goals of therapeutic treatment remain in contention which is 
demonstrated by the wide array of treatments advocated. 
 
Coombes et al. (2008) presented a model of the current understanding of tennis elbow 
which integrated 3 interrelated components: tendon pathology, pain system dysfunction 
and motor system impairments and through evaluation of the relative expression of each 
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of the components specific treatments can be targeted at the individual patient. Due to 
the heterogeneity of the clinical presentation with high variability between patients and 
over the course of symptoms they propose a multimodal approach to the treatment of 
tennis elbow.   
 
3.4 Current treatments 
 
A myriad of therapeutic interventions are available for the treatment of tennis elbow and 
a systematic literature review identified 2629 potential studies on physiotherapeutic 
interventions for this condition (Bisset et al., 2005). Of these studies, 28 randomised 
controlled trials (RCTs) could be identified with acceptable quality of >50% on a 
modified Physiotherapy Evidence Database (PeDro). Most notably, the 2 criteria of 
intention to treat analysis and concealment of subject allocation were absent in 93% and 
86% of papers respectively. This was supported by Cowan et al. (2007) who reported 
that 92% of the published prospective randomised therapeutic trials on tennis elbow 
were considered to be of low quality/ level II according to the Oxford levels of evidence 
with inadequate recruitment descriptions, power calculation, randomisation, blinding, 
participant flow and follow up.  
 
Despite the large number of trials undertaken on tennis elbow no one treatment has been 
proven to be universally effective generating little consensus on its management (Bisset 
et al., 2005). This review supported the systematic review of 23 RCTs by Smidt et al. 
(2003) who used the Amsterdam-Maastricht consensus list to assess the methodological 
quality of the papers, weighting each paper in relation to their internal validity, clinical 
relevance and statistical significance and power. However, although they reported 
insufficient evidence for most physiotherapeutic interventions, weak evidence for the 
efficacy of ultrasound was found. It remains questionable whether the contradictory 
treatment effects among studies are determined through actual clinical differences or are 
due to methodological quality or insufficient power.   
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3.4.1: Injection 
 
Regardless of the fact that the rationale for the use of corticosteroid injections remains 
in contention and that the long term efficacy is lacking, injections remain the mainstay 
of treatment for tennis elbow (Speed, 2001) and have been identified in the literature as 
giving the most consistent benefit in the short term (Smidt et al., 2002 and Smidt and 
van der Windt, 2006). There remains no consensus on the optimum dosage, volume, 
drug, time or technique for injection. Haslock et al. (1995) received 172 returned 
questionnaires out of 200 consultant rheumatologists and reported a wide divergence in 
almost all aspects of injection therapy practice.  
 
Smidt et al. (2002) undertook a systematic review on corticosteroid injection therapy for 
lateral epicondylitis which combined a comprehensive search up to July 1999 and an 
additional search of Medline over the previous 2 years which failed to find any 
supplementary papers. Thirteen randomised controlled trials, from 248 abstracts and 29 
papers, were identified and their methodological quality assessed using the Amsterdam-
Maastricht consensus list. Unfortunately, most studies were found to have poor internal 
validity with a prevalence of inadequate control, poor co-intervention reporting and lack 
of blinding. Of these only 2 studies, 3 trials, obtained a relatively high validity score: 
Hay et al. (1999) and Price et al. (1991). They concluded that evidence showed 
statistically significant and clinically relevant differences for pain, global improvement 
and grip strength, demonstrating superior effectiveness for corticosteroids, over placebo, 
local anaesthetic and conservative treatment, in the short-term ( 6 weeks). However, 
no significant beneficial effects were extended into either the intermediate (6 weeks to 6 
months) or the long-term ( 6 months). In contrast, there were more favourable long-
term outcomes, of pain relief and increased grip strength, with physiotherapy and 
medication. Adverse effects are reported as 11-58% of cases with post injection pain 
and 17-40% of cases with skin atrophy, but irrespective of whether patients had 
received a corticosteroid injection or control treatment. 
 
Hay et al. (1999) evaluated the efficacy of 20mg of methylprednisolone with 0.5ml of 
1% lidocaine injections versus a 2 week course of naproxen 500mg or placebo vitamin 
C tablets taken twice daily. They undertook a multicentered pragmatic randomised 
controlled trial in primary care on 164 patients who had not presented with tennis elbow 
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in the previous 12 months. The median duration of symptoms was 9 weeks. 
Unfortunately, patients with cervical dysfunction and bilateral symptoms, whose tennis 
elbow could potentially be due to referred pain or neurodynamic dysfunction rather than 
true tennis elbow, were not excluded. If the baseline data is observed only 42-48% of 
cases had definite pain on resisted wrist extension and only 28-43% had definite 
tenderness. As tennis elbow is defined by lateral elbow pain on palpation of the 
common extensor origin and pain on resisted wrist extension this highlights the question 
of potential misdiagnosis. Although, patients were randomly allocated and formed 
homogenous groups at baseline, as all patients were prescribed with co-dydramol and an 
advice sheet the use of a placebo tablet group as a control is questionable.  A blind 
observer recorded relevant outcome measures of patient’s global assessment of change, 
pain free grip strength (PFG), pain, severity, function and disability questionnaire, pain 
on resisted wrist and 3
rd
 finger extension and local tenderness at 4 weeks, 6 and 12 
months. Using an intention to treat analysis they concluded that injection was 
significantly superior in the short term at 4 weeks, with a success rate of 82% compared 
to 48% in the naproxen group and 50% in the analgesia group. However, a good 
outcome was reported in all groups at a year (84%, 85% and 82% respectively).   
 
Price et al. (1991) undertook a two-phased double-blinded study on tennis elbow 
comparing the use of 2ml 1% lignocaine with 10mg triamcinolone or 25mg 
hydrocortisone, made up to 2ml with 1% lignocaine, injections. Twenty-seven to thirty 
patients were randomly allocated to each group and included patients with recently 
failed treatment. All injections were performed by the same physician and repeated at 4 
weeks if necessary. Two blinded observers recorded the outcome measures of visual 
analogue scale (VAS), tenderness and pain-weighted grip strength at 4, 8 and 24 weeks. 
The intention to treat analysis was appropriate and they reported that, although not 
statistically significant, more rapid relief was gained with 10mg triamcinalone rather 
than 25mg hydrocortisone and triamcinalone required significantly less repeat 
injections. Both steroid injections were statistically significantly better than lignocaine 
alone. However, at 6 months there was no difference between groups. They also 
undertook a second study which compared the use of 10mg with 20mg of triamcinolone 
and found no statistically significant difference between the 2 dosages.  
 
Barr et al. (2009) undertook a systematic review on the efficacy of corticosteroid 
injection compared with physiotherapeutic interventions for tennis elbow using the 
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PEDro searching to the end of 2009. They identified 5 randomised controlled trials: 
Smidt et al. (2002), Bisset et al. (2006), Verhaar et al. (1996), Uzunca et al. (2007) and 
Tonks et al. (2007). Of interest is that this latest review did not include Halle (1986), as 
identified by Smidt et al. (2002) who compared injection with physiotherapy including 
ultrasound, transcutaneous electrical nerve stimulation, ice massage, tennis elbow cuff 
and advice and a degree of variation is evident in the assessed quality between the 
reviewers who used PEDro (Barr et al., 2009) and the Amsterdam-Maastricht, (Smidt et 
al., 2002 and van der Windt et al., 1999) validity scores; Verhaar et al. (1996) 7/10 
compared to 5/12 respectively. They concluded that corticosteroid injections are 
effective in the short term and physiotherapy is effective in the intermediate through to 
the long term. However, they advise that due to the limited number of high quality 
RCTs and the differences in physiotherapeutic interventions conclusions must be 
interpreted with caution.   
 
Smidt et al. (2002) conducted a robust randomised controlled trial in primary care. A 
good sample size of 185 patients with tennis elbow were randomly allocated to 3 
groups: corticosteroid, physiotherapy or wait and see. Block randomisation was 
undertaken after prestratification for both duration +/-13 weeks and research centre and 
although acknowledged, despite randomisation, slight differences between the groups 
were apparent. The sample only included patients who were symptomatic for at least 6 
weeks with a resultant range from 8-21 weeks and 25-40% of patients had had previous 
episodes of lateral elbow pain (greatest in the injection group). Although this was a 
pragmatic trial, between 14-29% of cases had concomitant neck disorders (greatest in 
the injection group) which questions the potential involvement of cervical referred pain 
and neurodynamics in the diagnosis,.  All doctors received injection technique training 
and although 72 physiotherapists undertook the exercise training, such a large number 
has the potential to question the intercare provider reliability of technique. Three 
blinded assessors undertook all assessments and a reproducibility study found good to 
excellent agreement. The wait and see group were seen once by their GP for advice and 
if necessary paracetamol and naproxen were prescribed. The patients were then 
‘encouraged to await further spontaneous recovery’. The use of medication, although 
acknowledged, could influence the results and preclude the true picture of the natural 
history of tennis elbow. The injection group received a maximum of 3 injections, 
described as peppering every tender spot until resisted wrist extension was 
asymptomatic, using a 2ml volume of 1ml triamcinolone (10mg) with 1ml of 2% 
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lidocaine. A median volume of 0.9ml was used which equates to possibly only 0.45ml 
of triamcinolone being injected which equates to 4.5mg of triamcinalone. Saunders 
(2002) recommends using 0.25ml of kenalog 40, i.e.: 10mg triamcinalone. However, 
27% of patients required 2 repeat injections and 15% required 3 injections. The 
physiotherapy group who received 9 treatments of 1:4 pulsed ultrasound (7.5 minutes of 
2Wcm
2
), deep transverse frictions and the Pienimaki exercise programme, (see Chapter 
6.1.4.3 Physiotherapy rehabilitation, p.78 and Appendix 11.15, p.195) included a large 
number of variables. Also, it should be noted that only 9 treatments were given over 6 
weeks whereas in clinical practice ultrasound would be given at a minimum of twice 
weekly. Outcome measures were recorded at baseline, 3, 6, 12, 26 and 52 weeks and 
included a modified pain-free function questionnaire, both pain-free and maximal grip 
strengths and pressure-pain threshold. They concluded that injection was the best 
treatment option in the short-term of 6 weeks with success rates of 92% for injection 
compared with 47% for physiotherapy and 32% for wait and see. The differences 
between the injection group and both the physiotherapy and wait and see groups were 
significant and clinically relevant. However, at intermediate (6 months) through to long 
term (1 year) physiotherapy, with a 91% success rate, was significantly more effective 
than injection, with a 69% success rate, and although more effective than wait and see, 
with a 83% success rate, the difference was not significant. These results were 
interpreted as wait and see combined with naproxen is probably the most cost effective 
treatment for patients with tennis elbow in the long term, although physiotherapy may 
be useful. However, a patient may argue that pain relief and ability to function without 
limitation in the short-term is equally of paramount importance for them as a year is a 
long time to wait with pain and disability associated with potential loss of economic 
productivity. 
 
The cost effectiveness of corticosteroid injection, physiotherapy or wait and see from 
this trial was evaluated by Korthals-de Bos et al. (2004) and they reported that the 
difference in costs and effects showed no dominance and it was consequently difficult 
to decide which was the optimum treatment.    
 
Bisset et al. (2006) undertook a randomised controlled trial which compared 10mg 
triamcinolone acetonide with 1ml 1% lidocaine injection plus a repeat injection after 2 
weeks if required versus 8x 30 minute sessions over 6 weeks of elbow mobilisation with 
movement and exercise plus a home exercise programme using theraband and self 
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manipulation versus a wait and see group who were reassured that their tennis elbow 
would settle and received advice on activity modification; remaining active without pain 
aggravation, analgesia use, heat, cold and brace if needed. All patients received an 
information booklet outlining tennis elbow and advice on self management including 
ergonomics. 198 patients with symptoms of at least 6 weeks and who had not received 
any treatment within the past 6 months were recruited through advertisements and 
media releases and randomised into the 3 groups. Such recruitment methods could limit 
the generalisation of these findings although median duration was reported at 22 weeks. 
Outcome measures of severity of elbow complaint, pain severity, PFG, pain free 
function questionnaire and global improvement were recorded at 3, 6, 12, 26 and 52 
weeks by blinded assessors. Through the use of an intention to treat analysis they found 
that injection was significantly better than both physiotherapy or wait and see and that 
physiotherapy was significantly better than the wait and see group in the short term at 6 
weeks with a number needed to treat (NNT) of 3. However, at 12 through to 52 weeks 
physiotherapy was significantly better than injection. At 52 weeks there was no 
significant difference between physiotherapy and wait and see. They highlighted higher 
recurrence rates for injection and reported physiotherapy patients sought significantly 
less other treatment at 21%.  
 
Verhaar et al. (1996) compared Cyriax physiotherapy, (12 sessions of deep transverse 
frictions and Mill’s manipulation over 4 weeks), and 1ml 1% triamcinalone acetate with 
1ml 1% lidocaine injection randomising a total of 106 patients, who were referred to the 
hospital with tennis elbow by their GP over the course of a year. Duration was for a 
mean of 33 weeks and mean treatments of 1 injection and 8 physiotherapy treatments 
were reported. Patients who had received up to 3 injections within the past 6 months 
were eligible as were those with concomitant cervical symptoms. The authors report 
that patients with cervical symptoms were more likely to be associated with a poor 
outcome which gives strength to the importance of accurate diagnosis and appropriate 
treatment accordingly. Outcome measures of pain severity, mean grip strength, resisted 
wrist and 3
rd
 finger extension, local tenderness and patient satisfaction were assessed at 
6 and 52 weeks, unfortunately, although acknowledged, not by an independent observer. 
An intention to treat analysis was used. They concluded that injection was significantly 
more effective at 6 weeks. However, by 1 year no significant differences were found.  
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Uzunca et al. (2007) compared 1cc methylprednisolone with 1cc prilocaine versus 15 
sessions of pulsed electromagnetic field therapy (PEMF) over 3 weeks versus sham 
PEMF on 60 patients. Outcome measures of VAS with rest, activity, night and resisted 
wrist extension and supination were recorded at 3 and 12 weeks. They found VAS 
levels during activity and on resisted wrist extension were significantly better with 
injection compared to PEMF. Only pain levels on resisted wrist extension and 
supination were significantly better with PEMF compared to sham PEMF. At 12 weeks 
PEMF had better pain levels during rest, activity and night compared to injection 
although this was not significant.  
 
Their 5th study reviewed was Tonks et al. (2007) which was research undertaken by the 
author preliminary for a Masters degree and continued after completion to increase 
power. It was a randomised controlled trial on 48 tennis elbow patients comparing a 
10mg triamcinolone with 2% lignocaine injection versus Pienimaki exercise programme 
versus injection plus Pienimaki exercise programme versus no treatment. Outcome 
measures of PFG, patient rated forearm evaluation questionnaire and extensor weight 
strength were assessed at 7 weeks. Significant improvement in all outcome measures for 
injection only were found, for both efficacy and effectiveness, compared with 
physiotherapy only, injection plus physiotherapy and no treatment. 
 
Bisset et al. (2007) combined the data set from Bisset et al. (2006) and Smidt et al. 
(2002) to analyse subgroup effects on treatment outcome. It must be noted that the 2 
physiotherapy packages were not comparable with pulsed ultrasound, deep friction 
massage and exercise versus mobilisation with movement and exercise and the need for 
additional treatment was 81% and 21% respectively. The outcome measures used were 
global improvement, pain severity and PFG, although due to different instrumentation 
used for the latter it was converted to a percentage of the unaffected maximum grip 
strength which Stratford et al. (1993) reported does not correlate as highly as the raw 
scores. Unfortunately due to significant differences in the outcome measures at baseline, 
which could not be explained, only global improvement and pain severity were used for 
the analysis. At 6 weeks injection was reported to be significantly superior to both 
physiotherapy and wait and see and physiotherapy was superior to wait and see but by 1 
year injection was significantly worse than both physiotherapy and wait and see. For 
pain severity physiotherapy remained significantly better than wait and see, although 
not a clinically important difference, but not for global improvement.  
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Bisset et al. (2007) evaluated subgroups, of manual, non-manual and non-workers, and 
at 6 weeks small effects of baseline pain severity on pain outcome were found; patients 
who presented with more severe pain were reported to not respond significantly better 
with physiotherapy than wait and see. A significant interaction was found for outcome 
for global improvement, at 1 year, with the success rate for injection reported as 
significantly worse when compared to wait and see for only non manual workers. The 
explanation for this remains in question with suggestions of a possible chance finding to 
both manual workers and non workers resting more. However, when the employment 
status is observed there is a higher percentage of non manual workers, at 45.5% of the 
whole, which would give this sub group the best chance of statistical power, which is 
one of the issues around low numbers in subgroup analysis. Alternatively, there could 
potentially be a higher incidence of concomitant neck and potential neurodynamic 
involvement with desk based non manual workers for which injection is unlikely to be 
beneficial. When the data is observed there is also a lower percentage, although not 
significant, for the non workers which may imply that manual workers are simply 
unable to work with tennis elbow and are subsequently more compliant with treatment 
than those which can continue with non manual work and activities of daily living. Or it 
could support the association of tennis elbow with the inability to acquire the typically 
greater wrist extensor strength in the dominant arm (Strizac et al., 1983) which both the 
non manual and non workers would be more likely to present with rather than the 
manual workers. 
 
Gaujoux-Viala et al. (2009) also undertook a systematic review and a meta-analysis to 
evaluate the efficacy and safety of steroid injections for both shoulder and elbow 
tendonitis (64.3%) up to April 2008. From 218 papers 20 RCTs were identified with the 
data from 16 papers analysed for pain and 7, (3 elbow papers), for function. The tennis 
elbow trials included were Saartok et al. (1986), Price et al. (1991), Hay et al. (1999), 
Smidt et al. (2002), Lewis et al. (2005), Bisset et al. (2006) and Tonks et al. (2007). The 
pooled analysis found only short term efficacy for pain and function in favour of steroid 
injection versus control. In comparison at long term follow up no difference for pain 
was found and steroid injection was less effective than pooled other treatment for 
function in particular. The effect size (ES) for pain at 1-3 weeks was 1.18, 4-8 weeks 
1.3, 12-24 weeks -0.38 and 48 weeks 0.07. The ES for function was 0.2, 0.66,-0.27 and 
0.00 respectively. The ES is a standardised measure of change derived from dividing the 
mean change from baseline by the SD of the baseline values. An ES of 0.2 is considered 
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small, 0.5 moderate and 0.8 large or important and >1.2 as very large.  They reported 
that steroid injections were more effective in acute or subacute, (< 12 weeks), tendonitis 
and concluded that the optimum timing for injection may be in the early weeks of 
symptoms. Safety was assessed using the number needed to harm, which is the number 
of patients treated to find an additional adverse event in the treatment group in 
comparison to the control group. They found that transient pain after 10.7% of 
injections was the main side effect and concluded that steroid injections are well 
tolerated with only minor and infrequent side effects. For non-steroidal anti-
inflammatory drugs (NSAID) gastrointestinal upset was reported in 3.9%.  
 
Lewis et al. (2005) studied pain intensity and medication use diaries of 164 patients 
with a new episode of tennis elbow during the 5 days following treatment of injection, 
naproxen or placebo. 95% of patients received their randomised treatment and good 
compliance was found with 92% of diaries completed. Although at baseline the 
injection group had both higher pain scores and medication use, with adjustment for 
baseline pain severity the pain scores were significantly lower in the injection group 
compared to placebo by day 3 and compared to naproxen by day 4.  Post injection pain 
was evident in 62% of patients in the injection group although the mean pain score 
increase of 0.5 points was not significant and one would question any clinical 
importance. They concluded that post injection pain was modest and perceived as 
acceptable. 
 
The latest systematic review and meta-analysis using pain scores evaluating the efficacy 
and safety of corticosteroids and other injections for tendinopathy was undertaken by 
Coombes et al. (2010). Of the 3824 hits identified from the search only 41 RCTs met 
the inclusion criteria of scoring >50% on a modified PeDro scale, of which 17 were for 
tennis elbow. The efficacy for tennis elbow was assessed by 18 analyses from 12 trials 
on 1171 participants: Saartok et al. (1986), Price et al. (1991), Haker and Lundeberg 
(1993), Hay et al. (1999), Verhaar et al. (1999), Newcomer et al. (2001), Okcu et al. 
(2002), Smidt et al. (2002), Bisset et al. (2006), Tonks et al. (2006) and Lindenhovius et 
al. (2008). They reported consistent findings from pooled data from 3 trials with 
sufficient homogeneity Smidt et al. (2002), Bisset et al. (2006) and Tonks et al. (2006) 
for pain relief with steroid injections favoured compared with no intervention for tennis 
elbow in the short term (0-12 weeks) with a standardised mean difference (SMD) 1.44. 
No intervention was favoured at intermediate term (13-26 weeks) SMD -0.4 and long 
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term (52 weeks) SMD -0.31. This was mirrored by the function analysis with SMDs of 
1.5, -0.51 and      -0.31 respectively. The SMD is the difference in mean effects between 
groups divided by the pooled standard deviation (SD). The injection data of Smidt et al. 
(2002), Bisset et al. (2006) and Tonks et al. (2006) was also analysed compared to 
physiotherapy: function SMDs of 1.29, -0.64 and -0.57 and pain SMDs of significant 
heterogeneity at short term, due to the array of different interventions used in the 
physiotherapy groups, -0.56 and -0.48. They also reported poorer outcomes with 
repeated steroid injections, mean of 4.3 injections with a range of 3-6 within 6 months 
than with a single injection. When injection was used in combination with either 
NSAIDs or physiotherapy, as is the norm in clinical practice, no differences in effect 
were reported with these cointerventions. In comparison, non corticosteroid injections, 
such as sodium hyaluronate may be of benefit for tennis elbow treatment in the long 
term with a short term SMD 3.91, intermediate SMD 2.89 and long term SMD 3.91 
when compared to placebo. 
 
Newcomer et al. (2001) assessed the efficacy of 5ml of a 4:1 mix of 0.25% marcaine 
with 6mg betamethasone injection or sham injection (5ml 0.25% marcaine) in 
combination with rehabilitation in a double blind study on 39 patients. Rehabilitation 
included instruction in ice massage, avoidance of activities and a progressive concentric 
and eccentric strengthening programme for both wrist flexors and extensors. Due to the 
evidence of spontaneous recovery, particularly with patients with such a short duration 
of symptoms, it is questionable whether a local anaesthetic injection and rehabilitation 
is a true control. Equally an injection of 5ml is atypical of the injections given in U.K. 
clinical practice. Unfortunately, the sample size was small and only included patients 
with acute tennis elbow with durations of less than 4 weeks which would lead to limited 
generalisation of the findings. This was further exacerbated due to the recruitment by 
word of mouth and advertisement in local health and racquet clubs which has the 
potential to increase the proportion of sport related cases above the generally accepted 
5-8%. Patients were stratified by age and sex before randomisation. Outcome measures 
of VAS, functional pain questionnaire and painless grip strength were recorded at 4 and 
8 weeks although the long term 6 month data collection was only by telephone and 
excluded the objective measure. Baseline characteristics appeared homogenous and an 
intention to treat analysis was undertaken. They reported no significant differences in 
outcome up to 6 months, with the exception of a significant reduction in the pain VAS 
from 8 weeks to 6 months in the experimental group. As acknowledged, this result is in 
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contrast to the conclusion drawn from the systematic review (Smidt et al. 2002) that 
corticosteroids are superiorly effective in the short term. These results could potentially 
be attributed to the drugs used or to the risk of a Type II error having occurred. 
Subsequently, they highlighted a need for the study to be repeated with a more chronic 
sample and that injection with or without rehabilitative therapy is needed to address the 
efficacy of injection +/- rehabilitative therapy. Two trials are currently underway to 
evaluate whether the addition of physiotherapy as a co-intervention can reduce the high 
rate of recurrence associated with injection alone (Coombes et al., 2009 and Olaussen et 
al. 2009).  
 
3.4.1.1: Therapeutic effects of injection on tissue healing 
 
Corticosteroid injections only known mechanism of action to relieve pain and diminish 
disability is by a reduction in inflammation (Cyriax, 1984). Other mechanisms of pain 
relief by corticosteroids have not been established (Speed, 2001) although it has been 
suggested to be attributed to alteration in noxious chemical release and their subsequent 
effect on nociceptors (Paavola et al., 2002). Due to the proven positive effect of both 
anti-inflammatory drugs and potent anti-inflammatory corticosteroid injections and 
furthermore, that injection therapy has been proven to be the best treatment option in the 
short-term for tennis elbow patients with success rates of 92% (Smidt et al., 2002) one 
is left with a clinical dilemma due to the lack of an inflammatory pathology. Of equal 
consideration is the suggestion that corticosteroid injections inhibit collagen and ECM 
production (Paavola et al., 2002) which may be in part responsible for the high 
recurrence rate found in tennis elbow.  
  
It has been suggested that the mechanical disruption caused by the injection itself, 
regardless of the chemical used, may transform a failed intrinsic healing process into an 
extrinsic response. However, this is challenged by Price et al. (1991) who undertook a 
two-phased double-blinded study as previously discussed. They reported that both 10mg 
triamcinalone and 25mg hydrocortisone, made up to 2ml with 1% lignocaine, injections 
were statistically significantly better than lignocaine alone. 
 
Although the chemical injected must have the potential to modify the pathological 
process of the tendon, it remains questionable whether a chemical could fully restore 
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functional quality as this is interdependent with the forces delivered to the tendon. More 
recently, it has been hypothesised that corticosteroids shut down protein synthesis 
(Riley, 2010) and this would support the theories which suggest that overuse conditions, 
such as tennis elbow are a mismatch between degrading and synthesis biochemical 
processes. 
 
3.4.2: Ultrasound 
 
Ultrasound is the most commonly used treatment modality used by physiotherapists 
(Watson, 2008). Greenfield and Webster (2002) surveyed the treatment of chronic 
lateral epicondylitis in Scotland of 120 physiotherapists with an 80% response rate. 
They found 74.2% always or frequently use ultrasound for this condition with 44.2% 
using pulsed and 30% using continuous.  
 
Ultrasound is the application of mechanical vibration energy at a higher frequency than 
sound to the target tissue. The vibration causes a pressure wave with high and low 
pressure areas which causes tissue molecules to oscillate and generate heat. In addition 
to this thermal component there are important non-thermal effects. As the wave passes 
through the tissue the energy of the wave itself attenuates as energy is transferred to the 
tissue. 
 
All tissues present impedance to sound waves causing reflection at boundary interfaces 
with 99.9% reflected at the steel ultrasound transducer/ air interface. To minimise this a 
gel-based coupling medium is utilised in clinical practice. Furthermore, refraction can 
also occur if the wave does not penetrate the boundary surface at 90
0
. At the skin 
interface the critical angle is approximately 15
0
, i.e.: if the transducer head is at an angle 
>15
0
 to the skin surface the majority of the ultrasound wave will be refracted parallel to 
the skin surface rather than reaching the target tissue. The radiating area is the surface 
area of the ultrasound transducer head through which ultrasound is delivered and due to 
application with the transducer in motion the area of application can be increased by 
varying degrees. For example, 2x the effective radiating area (2x ERA) would be 
applying ultrasound over an area of slightly less than twice the size of the ultrasound 
transducer.   
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The available modes on therapeutic ultrasounds are pulsed or continuous and selection 
is dependent on the current state of the target tissue. After the acute state tissues appear 
to respond more favourably to concentrated energy delivery (Watson, 2006).  
 
Similarly, the intensity in W/cm
2
 is dependent on the current state of the target tissue. 
More chronic conditions require a greater intensity to stimulate a physiological 
response. Furthermore, energy absorption by other tissues through which the ultrasound 
travels to reach the target tissue needs to be taken into consideration. This means that to 
deliver sufficient energy to achieve the therapeutic response in the target tissue a higher 
intensity will need to be delivered at the skin surface. However, as the tenoperiosteal 
junction of ECRBr is superficial this effect will be negligible. Demmink (2007) reported 
that for 3MHz continuous ultrasound induced heat therapy can only exist with settings 
of >1W/cm
2
from thermal image analysis of pig cadaver hind leg. Enwemeka (1989) 
reported that the tenotomised rabbit achilles tendon had a significantly larger cross-
sectional area and tensile strength and energy absorption capacity than controls which 
suggests a higher collagen content following the use of 5 minutes of 1MHz continuous 
ultrasound at 1W/cm
2
 given daily for 9 consecutive days. 
  
The available frequencies are 1 or 3MHz and the selection is dependent on the depth of 
the target tissue in relation to half-value depth, i.e.: the depth at which 50% of 
ultrasound energy is absorbed. The half-value depth of 1MHz is 2.5cm and 0.8cm for 3 
MHz (Draper et al., 1995). Therefore, for superficial lesions (i.e.: 0.8 to 1.6cm depth), 
such as tennis elbow, 3MHz ultrasound is more rapidly absorbed and is subsequently 
the effective frequency of choice. With the use of 1MHz the half-value is greater and is 
therefore more suitable for deeper structures requiring a greater penetration. However, 
all the tennis elbow studies included in van der Windt et al.’s (1999) systematic review 
of ultrasound utilised 1MHz. The reason for this, according to Draper and Picard 
(1995), was that prior to 1994 ultrasound treatment parameters had not been established 
and the ‘newer’ 3MHz frequency had not been researched. The only study published 
after this date was Pienimaki et al. (1996).  Furthermore, when 3MHz is used, as more 
of the energy is absorbed in the superficial structures, little energy reaches the bone and 
subsequently a higher intensity can be used with this frequency to bring about the 
desired temperature increase without additional risk (Draper et al., 1995). This may be 
the reason all 3 studies had to use pulsed ultrasound to limit the energy reaching the 
bone and allow heat dissipation to prevent both periosteal pain during treatment and 
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potential damage and furthermore, this has the potential to account for the limited 
efficacy of ultrasound in these studies. 
 
Large or small treatment heads are available and as the target tissue area in tennis elbow 
is only small in size the small 0.5cm
2
 transducer is appropriate; see figure 6.2 (p. 78) for 
a photograph illustrating the clinical application of ultrasound. Haker and Lundeberg 
(1991) used a 5cm
2
 transducer which would pose a difficulty to maintain the correct 
angle to the skin interface in order to deliver ultrasound to the small anterolateral facet 
of the lateral epicondyle and prevent the majority of the ultrasound wave being reflected 
parallel to the skin surface rather than reaching the target tissue.  
 
A systematic review on ultrasound was undertaken by van der Windt et al. (1999) who 
identified 6 studies on lateral epicondylitis. All 3 placebo-controlled studies obtained a 
relatively high validity score, from 2 independent reviewers using the Amsterdam- 
Maastricht Consensus list for Quality Assessment, and were found to be clinically 
homogenous. Statistical pooling of these three studies found a pooled estimate for the 
difference in success rate of 15% and NNT of 7, which could be considered of some 
importance. Due to the inconsistent results it was concluded that there is weak evidence 
in favour of ultrasound for tennis elbow.  
 
Binder et al. (1985) was the only study to report statistically significant and clinically 
important results in favour of ultrasound. They evaluated the efficacy of pulsed 
ultrasound over placebo in 76 lateral epicondylitis patients. Although equal numbers 
were assigned to each group by an external therapist the randomisation method was not 
stated. Those in the active ultrasound group received 1:4 pulsed 1 MHz at 1-2W/cm
2
 for 
5-10 minutes and the placebo received sham ultrasound of which the procedure was 
unclear. Both treatments were set by an external person ensuring that both patients and 
therapists remained blinded to treatment. However, the procedure for increasing 
intensity was not stated. All patients received 12 treatments over 4-6 weeks with follow 
up at 8 weeks and 12 months. They found a statistically significant improvement greater 
in the ultrasound group (63% significantly improved) over the placebo group (29%) for 
grip strength and pain score.   
 
Haker and Lundeberg (1991) also evaluated the efficacy of pulsed ultrasound over 
placebo but in only 45 lateral epicondylitis patients. Eligibility criteria were appropriate 
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and although randomised the procedure was unclear. Baseline characteristics were 
similar in both groups. Those in the ultrasound group received a total of 10 treatments 
of 1:4 pulsed 1 MHz at 1W/cm
2
 using a 5cm
2
 transducer for 10 minutes at a frequency 
of 2-3x a week and the placebo received sham ultrasound.  By using an identical 
machine which gave sham ultrasound both patient and therapists remained blinded. 
Follow up was at 3 and 12 months. Outcome measures were isometric pronation and 
supination in 90 degrees elbow flexion, vigorimeter test to evaluate PFG through a ratio 
of the affected to the unaffected arm and a lifting test. They found no statistically 
significant difference between ultrasound and placebo. 
 
Lundeberg et al. (1988) reported on 99 patients who were randomly allocated to 3 
groups: continuous ultrasound, placebo ultrasound and rest. The randomisation and 
treatment allocation procedure was unclear. Those in the ultrasound group received a 
total of 10 treatments of continuous 1 MHz at 1W/cm
2 
over 5-6 weeks and the placebo 
received sham ultrasound. Follow up was at 6 weeks and 3 months. A significant 
difference was found between ultrasound and placebo for pain, on a VAS at 3 months, 
but not for global improvement or maximum grip strength. A significant difference was 
found between ultrasound and rest. As will be discussed in chapter 3.5.2 maximum grip 
strength is not as sensitive to change as PFG. 
 
One of the reasons that tennis elbow was the only injury to have some weak evidence 
base may be attributed to the fact that different tissues absorb ultrasound to varying 
degrees with the denser collagen based tissues, such as tendon, being excellent 
absorbers of ultrasound (Watson, 2008). When the treatment parameters for the 3 high 
quality studies are considered the only difference between the positive outcome of the 
Binder et al. (1985) study was that it utilised an increased intensity up to 2W/cm
2
, 
although due to the pulsing this would be reduced markedly. 
 
Bisset et al.’s (2005) systematic review pooled the global improvement data at 3 months 
for Haker and Lundeberg (1991) and Lundeberg et al. (1988). They reported no 
difference between ultrasound and detuned ultrasound with a relative risk of 1.01 
although Lundeberg et al. (1988) found significant pain reduction at 3 months with 
ultrasound when compared to placebo. 
Smidt et al.’s (2003) systematic review pooled the intermediate outcome data from 
Binder et al. (1985) and Lundeberg et al. (1988) and reported a large effect size (SMD-
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0.98) for pain in favour of ultrasound over placebo but concluded that there was 
insufficient evidence to favour ultrasound compared to other interventions.    
 
3.4.2.1: Therapeutic effects of ultrasound on tissue healing 
 
The process of tissue repair is a complex series of chemically mediated consequences 
for which therapeutic ultrasound is pro-inflammatory by acting as an ‘inflammatory 
optimiser’. It has been proposed that the main effect of ultrasound on an injured tissue is 
to stimulate and increase the efficiency of the normal healing process and enhance the 
quality of repair (Watson, 2008). The therapeutic effects can be considered to be either 
thermal or non-thermal in nature. Although both therapeutic effects will be utilised 
concurrently with any ultrasound treatment the specific parameters will influence which 
may dominate.  
 
The mechanical disturbance caused by the pressure wave is responsible for the non 
thermal effects of ultrasound of stable cavitation and acoustic streaming. Stable 
cavitation is the formation of gas bubbles in a fluid which vibrate and acoustic 
streaming is the unidirectional movement of the fluid which causes high velocity 
gradients to develop between the fluid and bubbles or cells. Both these result in a 
change in cell permeability through modification of the cell membrane potential and 
transport mechanisms which have the therapeutic effects of alteration of the release of 
the cell contents, vascular permeability, local blood flow, angiogenesis, protein 
synthesis and collagen content and alignment.    
  
To effectively utilise the thermal effects a relatively high intensity in continuous mode 
is required and will have a greater efficacy in denser collagen based tissues such as 
tendon. Historically, it was generally accepted that a biologically significant thermal 
effect could be achieved if the temperature of the tissue was raised between 40-45
0
C for 
at least 5 minutes (Kitchen, 2002). However, little research has been able to achieve this 
temperature range with ultrasound. This may be explained as the original research was 
undertaken on anaesthetised animals or cadaver tissue samples which could be heated to 
greater temperatures due to a lack of pain sensitivity or vasomotor control to maintain 
homeostasis. More recent research of ultrasound on in vivo human tissue proposes that 
therapeutic thermal effects can be attained with a 1-4
0
C increase from baseline; mild 
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heating (1
0
C) to treat mild inflammation through an increase in metabolism, moderate 
heating (2-3
0
C) to increase blood flow, reduce muscle spasm, pain and chronic 
inflammation and vigorous heating (>/= 4
0
C) to inhibit sympathetic activity and 
decrease collagen viscoelasticity (Draper et al., 1995). The intensity to achieve this 
varies from 1-2W/cm
2 
constant (Michlovitz, 1986). It has been found that the 
temperature stabilises once it has been raised to between 39 and 41
0
C and this has been 
proposed to be due to the cooling effect of the increased blood flow to the area (Bishop 
et al., 2004). 
 
In an in vivo study (Draper et al., 1995) of 24 asymptomatic college students two 
thermistors were inserted in the medial triceps surae: at 2.5 (half-value depth) and 5cm 
depths for half the subjects who received 1MHz and at 0.8 (half-value depth) and 1.6cm 
for those who received 3MHz. Each subject received 4 treatments of continuous 
ultrasound using a 5cm
2 
transducer at 0.5, 1.0, 1.5 and 2W/cm
2 
for 10 minutes. They 
found after treatment, for all doses, at the half- value depth (0.8cm) at 3MHz the heating 
effect was nearly 4x greater than at the half-value depth (2.5cm) at 1MHz. Furthermore, 
3 minutes of 3MHz at 2W/cm
2
 ultrasound was required to raise the temperature by 4
0
C, 
regardless of depth of tissue, although only measured at .8 and 1.6cm depths, for 2x 
ERA.  
 
Draper and Picard (1995) went on to undertake the first in vivo study measuring 
temperature cooling following ultrasound to determine the stretching window, i.e.: the 
time period when tissues are vigorously heated. The temperature was measured at 30 
second intervals using a thermistor inserted 1.2cm deep into the medial triceps surae of 
20 subjects. 3MHz ultrasound at 1.5W/cm
2 
with a 2x ERA was received until the 
temperature increased by 5
0
C. They reported that the temperature was raised an average 
of 5.3
0
C above baseline in an average of 6 minutes and it took 18 +/- 3.5 minutes for the 
temperature to return to baseline. Interestingly, the temperature continued to cool an 
average of 0.8 +/- 0.56
0
C until it stabilised after approximately 25 minutes. Using a 
step-wise nonlinear regression analysis temperature decay as a function of time was 
predicted. They concluded that through the use of ultrasound when the tissue 
temperature is increased by 5
0
C stretching will be effective for an average of 3.3 
minutes. When stretch is continued after heating the greatest lasting increase in tissue 
length occurs due to reorganisation of the collagen during cool down.  
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Another in vivo study (Hayes et al., 2004) of a repeated measures design compared 
continuous 1 and 3MHz ultrasound at 1.5W/cm
2
 with sham using a 5cm
2
 transducer 
applied to an asymptomatic medial calf. Temperature was taken at 10 second intervals 
for 10 minutes unless the temperature stabilised for 1 min, 40
0
C was reached or the 
treatment became uncomfortable, using a thermocouple implanted at 2.5cm. Although 
they found 1MHz did not produce vigorous heating during the 10 minute treatment, 
3MHz produced a 4
0
C increase at a mean of 3.35+/- 1.23 minutes and an increase to 
40
0
C at a mean of 4.13+/- 1.69 minutes at a depth of 2.5cm. These results suggest that 
3MHz can potentially heat 0.5cm deeper than previously theorized. This study also 
reported that 3MHz ultrasound at 1.5W/cm
2
 had to be applied for 2 minutes before the 
temperature increased at a depth of 2.5cm in comparison to sham ultrasound which did 
not show any temperature increase over a 10 minute treatment. 
 
Of the little research available on the therapeutic effects of ultrasound on human tendon, 
an important paper researching the patellar tendon is by Chan et al. (1998) Sixteen 
normal college students received 3MHz continuous ultrasound at 1W/cm
2
 using a 5cm
2
 
transducer at 2x ERA and 4x ERA. Using a thermistor inserted into the medial aspect of 
the patellar tendon the temperature was recorded every 30 seconds during and for 20 
minutes after the 4 minute treatment. The 2 ERA treatment increased 8.3
0
C +/- 1.7
0
C 
compared to the 4 ERA treatment 5.0
0
C +/- 1.0
0
C over the 4 minute treatment. A 
significant difference in the rate of temperature increase during treatment and decrease 
for the first 5 minutes after treatment between treatment size was found (p<.001). 
Furthermore, 50% of tendons had not returned to their baseline temperature after 20 
minutes. They also compared their study with that of Draper et al. (1995) on the 
gastrocnemius muscle and found that, for the 2 ERA, tendon has a 3.45 faster rate of 
temperature increase than muscle. Furthermore, vigorous heating was sustained for 
120% longer than muscle giving a 4 minute stretching window.  
 
Using the rate of heating proposed by Draper and Picard (1995) using the parameters 
used by Binder et al. (1985) of 1MHz at 2W/cm
2
 which with 1:4 pulsed would reduce to 
0.5W/cm
2
 the tissue would be heated at 0.04
0
C per minute and would therefore increase 
the tissue temperature by 0.4
0
C over a 10 minute treatment. However, as the research by 
Draper and Picard (1995) was undertaken on muscle and Chan et al. (1998) not only 
found tendon to have a 3.45 faster rate of temperature increase but also that heating is 
sustained longer in tendon than for muscle it can be postulated that the treatment 
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parameters used by Binder et al. (1985) had the potential to increase the temperature by 
1.38
0
C which could utilise the thermal effects of ultrasound through mild heating.  
 
However, the model only researched down to an intensity of 0.5W/cm
2 
and the 
treatment parameters used by Haker and Lundeberg (1991) of 1 MHz at 1W/cm
2
 which 
with 1:4 pulsed would reduce to 0.2W/cm
2
for 10 minutes is unlikely to have utilised a 
thermal effect and possibly explain the lack of a statistically significant difference 
between ultrasound and placebo. 
 
But in contrast, if the treatment parameters of Lundeberg et al. (1988) of continuous 1 
MHz at 1W/cm
2 
are considered this had the potential to increase the temperature at a 
rate of 0.2
0
C which over 10 minutes gives a potential temperature increase of 2
0
C which 
would utilise the thermal effects of ultrasound through heating. However, only a 
significant difference was found between ultrasound and placebo for pain (VAS) not 
global improvement or maximum grip strength and a significant difference was found 
between ultrasound and rest.       
 
 However, Watson (2008) argues that over the past 15 years the non-thermal effects are 
more effective as ultrasound is ‘relatively inefficient at generating sufficient thermal 
change in the tissues to achieve this therapeutic effect when applied at commonly 
applied clinical doses’. He quotes Garrett et al. (2000) who measured temperature, at 
minute intervals until it returned to baseline after treatment, using 3 thermistors at 5cm 
intervals implanted at a depth of 3cm into the medial triceps surae on 16 healthy 
subjects. This study compared treatments of 20 minutes of continuous 1MHz ultrasound 
at 1.5W/cm
2
 over 40x ERA, (the size of the diathermy drum), with pulsed shortwave 
diathermy. They found that diathermy heated the calf muscle significantly more than 
ultrasound and that return to baseline took 14.88+/- 4.7 minutes for ultrasound 
compared to 38.50+/- 6.61 minutes for diathermy. They concluded that in heating a 
large muscle mass pulsed shortwave diathermy was more effective than 1MHz 
ultrasound and resulted in the muscle retaining heat for longer.  
 
However, one would challenge that it is highly unrealistic in clinical practice to 
ultrasound an area as large as 200cm
2 
as in the Garrett et al. (2000) study and also that 
this study used 1MHz whereas 3MHz has greater heating at half depth than 1MHz. 
Also, this was undertaken on healthy muscle when it is known that tendon, absorbs 
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ultrasound more efficiently whereas pulsed short-wave diathermy is more preferentially 
absorbed in wet, low resistance tissues and therefore most effective in muscle. 
Furthermore, from Chan et al. (1998) there is a significant difference in the rate of 
temperature increase during treatment and decrease for the first 5 minutes after 
treatment between treatment size in favour of 2x ERA over 4x ERA, 50% of tendons 
had not returned to their baseline temperature after 20 minutes, that for the 2 ERA 
tendon has a 3.45 faster rate of temperature increase than muscle and vigorous heating 
was sustained for 120% longer than muscle. Indeed in the discussion of Garrett et al. 
(2000), they quote Chan et al. (1998) as substantiating ultrasound recommendations of 
only treating a maximum area of 2-3x larger than the transducer which would result in 
vigorous heating. So one should argue that ultrasound for large muscle areas is clearly 
less effective than pulsed shortwave diathermy, rather than labelling ultrasound, for all 
conditions carte blanche, an ineffective modality to achieve therapeutic thermal effects.  
 
3.4.3: Exercise therapy 
 
The primary complaint of tennis elbow is pain limited function (Vicenzino and Wright, 
1996). The priority of treatment is to control the pain and subsequently enable earlier 
rehabilitation of the deconditioned musculature (Speed, 2001). Once the pain has been 
addressed a strengthening and flexibility programme is recommended (Burgess, 1990). 
The review by Noteboom et al. (1994) proposed that this is a fundamental element in 
rehabilitation in order to provide controlled stresses to facilitate appropriate tissue 
remodelling. They suggested starting early rehabilitation through a pain free, low load 
and high repetition programme.   
 
From the Greenfield and Webster (2002) survey on the treatment of chronic lateral 
epicondylitis in Scotland 75.8% of physiotherapists always or frequently use 
progressive strengthening exercise for this condition and 88.8% use progressive 
stretching exercise.  
 
Research findings have also been indicative of the therapeutic value of stretching.    Post 
exercise stretching has been hypothesised to be advantageous in both the reconditioning 
of muscles and assisting desensitisation of painful soft tissues (Vincenzino, 2003). 
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Although it is generally accepted that patients with tennis elbow usually present with 
unlimited joint range of movement (Chard and Hazleman, 1989), inadequate forearm 
muscle flexibility is thought to be a contributory factor in patients with tennis elbow. 
Solveborn and Olerud (1996) researched the elbow and wrist range of movement of 123 
patients with tennis elbow using a goniometer. An intratester reliability study had 
previously established the precision of the measuring technique. They reported that 
wrist flexion, pronation and elbow extension were the most reduced range of 
movements, which all affect the wrist extensor length. As the dominant arm tends to be 
stronger and subsequently less flexible this may be partially responsible for the reason 
that the dominant arm is more frequently affected.  
 
A systematic review and meta-analysis on physiotherapy for tennis elbow (Bisset et al., 
2005) found only one study specifically evaluating an exercise programme that satisfied 
the quality criteria. Pienimaki et al. (1996) reported the superior efficacy of a pain free 
progressive strengthening and stretching exercise programme compared to pulsed 1: 5 
1MHz ultrasound at 0.3- 0.7 Wcm
2
 over a 5cm
2
 radiated area for 10- 15 minutes 2-3x a 
week for 6-8 weeks. It should be noted that with the use of these parameters utilisation 
of the therapeutic thermal effects of ultrasound is improbable. The sample was 39 
patients, referred by their GP, who presented with tennis elbow for over 3 months who 
had failed to respond to treatment. Pertinent eligibility criteria were stated and the 
patients were randomly allocated, by drawing lots, to the exercise or ultrasound group 
which were fairly well matched despite being relatively small. The exercise programme 
was clearly stated and shown in a series of photographs to support explanation and was 
supervised by the same physiotherapist throughout. However, several physiotherapists 
undertook the ultrasound treatments. Due to the nature of the treatment interventions 
neither the patients nor therapists could be blinded. Outcome measures were a pain and 
disability questionnaire, maximum isometric grip strength and isokinetic muscle 
performance. An independent and blind physiotherapist assessed the muscle function. 
They concluded that the exercise programme was significantly better than ultrasound in 
both subjective and objective outcomes in the short term of 6-8 weeks. Bisset et al. 
(2005) reported a SMD of 0.97 for pain, as supported by Smidt et al. (2003), but no 
significant difference was found for grip strength, which may be due to maximum grip 
strength being used as an outcome measure instead of PFG.  
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Pienimaki et al. (1998) evaluated long-term efficacy, at a mean of 36 months, by 
following up 30 of these patients. 23 patients responded to a well-structured 
retrospective postal questionnaire and they found that the exercise group patients 
showed beneficial long-term effects compared to those in the ultrasound group. They 
reported that there was no significant change in pain level at 36 months compared to at 
the end of the original treatment, at 6-8 weeks, in either group. They concluded that a 
stretching and strengthening exercise programme may prevent chronicity. It was 
interesting to note that, in contrast to the majority of studies on tennis elbow, that the 
proposed self-limiting nature of tennis elbow was not evident in this sample during the 
36 month follow-up. However, as the data of only 23 out of a population of 39 patients 
was evaluated the possibility of a selective sample, with reduced power and an 
increased risk of bias needs to be considered.  
  
Eccentric exercise programmes have also been advocated following their success in 
research on the achilles tendon in particular. As previously discussed, extrapolation 
from this research should not be undertaken due to the inherent differences between the 
two conditions. In addition, the higher muscle tension developed during eccentric 
exercise is thought to be the primary cause of tendon failure (Croisier et al., 2001). It 
may be that these exercise programmes are beneficial in the more advanced phases of 
strengthening (Kraushaar and Nirschl, 1999). However, a systematic review concluded 
that there was insufficient evidence to support eccentric exercise when compared to 
concentric exercise for tennis elbow (Woodley et al., 2007). 
 
3.4.3.1: Therapeutic effects of exercise on tissue healing 
 
The cyclical tensile loads through controlled low impact repetitive exercise therapy in 
addition to stretching may instigate reorganisation of collagen and up regulate synthesis 
of type I collagen in particular. This will modify both the mechanical and viscoelastic 
properties of the tendon, reduce stress and make it more load resistant. Furthermore if 
the biochemical hypothesis for pain is considered, collagen repair would rebalance the 
biochemical milieu and promote pain relief (Khan et al., 2000).   
 
Although there is no clear relationship between type of training and adaptive responses 
of collagen synthesis, in equine extensor tendon subjected to low-level repetitive stress 
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a higher level of collagen was found when compared to flexor tendon subjected to high 
stress. This suggests the importance of intensity and loading patterns on extracellular 
matrix adaptation. An increase in cross-sectional area and collagen content with an 
increase in both the load-deformation and stress-strain properties of swine digital 
extensor tendons supports that training improves both structural and mechanical 
properties of tendon. However it should be noted, that due to the specificity of tendons 
extrapolation to ECRBr may not be definitive. Of equal importance is that due to the 
variable vascularity and cross-sectional area found along the length of a tendon 
adaptation due to training of a tendon is region specific (Kjaer, 2004).   
 
3.5 Outcome measures 
 
On review of the literature it was apparent that a wide array of outcome measures has 
been used for research on tennis elbow; including general improvement (Smidt et al., 
2002), maximum grip strength (Newcomer et al., 2001), PFG (Haker and Lundeberg 
1991), VAS (Uzunca et al., 2007), questionnaires (Bisset et al., 2005), tenderness (Hay 
et al., 1999), resisted wrist extension (Verhaar et al., 1996) and isokinetic muscle 
performance testing (Pienimaki et al., 1996). Most randomised controlled trials on 
tennis elbow and the efficacy of physiotherapy have consistently used pain scores and 
grip strength (Smidt et al., 2002), rather than measures of temperature and muscle 
function which would be more directly relevant to current conservative treatment. The 
availability of thermography and surface EMG as outcome measures will enable a more 
robust trial providing details which are directly clinically relevant to the reported 
increases in temperature and reduced muscle function in this patient group.  
 
To ensure the internal validity of this study the outcome measures needed to be both 
reliable and valid in addition to be sensitive to change with the minimal clinical 
important difference identified. Validity is the extent an outcome measures what it 
purports to measure and reliability is the extent of consistency and reproducibility of the 
values measured with repeated use under the same conditions. 
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3.5.1 Thermography 
 
This primary outcome measure was selected to enable a more robust trial providing 
details which are directly clinically relevant to the debate on whether inflammation is an 
integral part of the pathogenesis of this patient group and the action of steroid injection 
therapy.  
 
Thermography measures the cutaneous infrared heat emission from the body which is a 
function of subcutaneous perfusion. The thermal camera converts the infrared energy 
into a visible digital image, the thermogram, which maps the temperature distribution of 
the area in question. 
 
The skin is an important thermoregulatory organ with an extensive microcirculation and 
consequently vascular changes in the skin are the most accessible to analyse 
inflammation. Through the use of thermography precise non contact skin surface 
temperature (Tsk) measurement can be determined. Non contact Tsk is advantageous 
due to the avoidance of potential heat transfer from the instrumentation itself leading to 
spurious data (Magdeburg et al., 1986). Subsequently, this measurement tool has the 
ability to monitor underlying inflammatory processes and evaluate the efficacy of 
interventions in superficial structures such as tendons. Infrared thermography is a 
valuable technique for the diagnosis of tennis elbow (Haake et al., 2002). The 
relationship between increased temperature and tenderness in tennis elbow has been 
reported with patients with hotspots having a 9-fold risk for a pressure pain threshold 
<2.5kg and a 1.3-fold risk of pain development on resisted wrist extension (Ammer, 
1995). Thomas et al. (1992) reported infrared thermography as a ‘sensitive, objective 
investigational procedure for the assessment of tennis elbow’. There is high precision of 
the visualisation of inflammatory changes and frequently changes in temperature are 
one of the earliest symptoms of a pathological process (Jung and Zuber, 1998).  
 
The degree of heat emission is associated with skin vascularity, cellular metabolism and 
subcutaneous adipose tissue with the latter effectively acting as an insulator impeding 
any potential heat transfer. The sympathetic nervous system is the controlling 
mechanism for dermal microcirculation and thermal emission. The dermal vessels are 
maintained in a constricted state by vasomotor tone which inhibits heat loss from the 
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higher core temperature. Decreased sympathetic function would increase thermal 
emission due to vessel vasodilation due to receptor fatigue, on account of excessive 
release of a vasoactive substance such as substance P for example (BenEliyahu, 1990). 
In addition, substance P is a neurotransmitter associated with sensory afferent pain 
signals.  
 
The mechanisms for the generation of hotspots include: increased blood flow, potential 
vasodilative chemicals or transient substances and neurotransmitters (Ammer, 2008). 
When inflammatory reactions are present hyperthermic images are evident whereas in 
comparison degenerative processes reveal hypothermic images (Garagiola and Giani, 
1990). In overuse injuries such as tennis elbow there is a contemporaneous presence of 
inflammatory reaction and degenerative process with hyperthermy found when the 
inflammatory reaction predominates.  
 
Hotspots are considered diagnostic of tennis elbow (Ammer, 2008) although the 
reliability of hotspot identification is poor. Ring et al. (2005) reported that there is poor 
reproducibility, even intraoperator, with the usual practice of rectangle selection or free 
drawing of the region of interest (ROI). However, very good reproducibility was 
reported, both intra and interoperator, when described anatomical landmarks were used 
to draw a ROI. Subsequently, to reduce interoperator variability to a minimum a 
protocol using a defined ROI based on anatomical limits is required (Ring, 2002). Even 
so, frequently the specific point location is determined on the thermal image itself, of 
which the accuracy of specific landmark detection is brought into question due to 
inadequate clarity of the thermal image. Subsequently, Selfe et al. (2006) developed an 
anatomic marker system which was reported as an accurate and reliable method for 
thermal data analysis. The advantage of this system are that the landmarks are identified 
on palpation, which is patient specific taking in account for variation in individual size 
and anatomy.  
 
Pizzetti et al. (1984) treated 31 upper limb tendonitis patients with 8 daily 15 minute 
sessions of laser and compared pre and post treatment thermal images. Although the 
authors state that they directed their attention to tennis elbow, unfortunately the actual 
number of patients with tennis elbow was not reported. Similarly, the robustness of the 
thermal analysis also comes into question: by using the same colour gradient scale the 
normal and affected limb were compared and they consistently found ‘a different 
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thermal gradient corresponding to the areas of greatest pain’. Using descriptive reports 
of visual thermal patterns is highly subjective. They reported a direct relationship 
between the state of tendon inflammation, acute versus chronic, and thermal image, i.e.: 
acute tennis elbow can be distinguished from chronic tennis elbow: Tsk +1.5 to 2 
0
C 
higher compared to 0 to + 0.5 
0
C respectively. The thermography was undertaken in a 
standardised environment and although time was allowed for acclimatisation, the 
standardisation of potential confounding variables such as smoking, alcohol, caffeine 
and physical exercise were not alluded to. The mean age of the patients in this study 
was 30 years and no indication of duration of symptoms is given. The authors state that 
most patients had received other forms of treatment including injections and comment 
that 70.9% of patients were playing tennis after the course of treatment. As a mean of 30 
years of age is lower than would be expected in a typical tennis elbow patient one has to 
question the generalisation of these findings to the tennis elbow population as a whole. 
Unfortunately, although this paper was translated, a lack of reported detail is evident 
and the robustness of the protocol of thermographic analysis is brought into question. 
 
Binder et al. (1983) studied 56 tennis elbows from 50 patients who were reported as 
fairly representative of a typical tennis elbow population and 60 age and sex matched 
normal controls. Clinically, severity was assessed using 5 parameters: localised 
tenderness, pain on resisted wrist dorsiflexion, supination/pronation and ability to lift 
different weights on a scale of 1 to 3 and grip strength. Thermographic analysis was 
taken initially and at 6 weeks/ or earlier on discharge. A 15 minute stabilisation period 
was carried out but no attempt to standardise potential confounding patient variables 
was reported. This lack of detail was accentuated throughout the paper. The method of 
data collection was to centre a box, of constant size, over the abnormal area and then 
move it medially so that one side of the box dissected the centre of the abnormality to 
calculate the slope and distance of the thermal gradient. One may question the 
specificity of this procedure of Tsk of the ROI data collection. They found a discrete 
localised hotspot (1-3
0
C) in 53 out of 56 tennis elbows and 3 out of 120 normal 
subjects. Of interest they also found that 30% of patients had a hot spot near the 
unaffected lateral epicondyle and 2 of these 16 patients developed pain at a later date. 
The authors postulated that this may be due to increased use so as to protect the 
symptomatic arm or an ‘underlying susceptibility’ in these patients to tennis elbow. This 
adds support to an additional potential variable for thermal image data analysis if one 
compares the affected with the unaffected elbow.   
 38 
Thomas et al. (1992) studied 26 mainly female tennis elbow patients, 9 of which had 
bilateral symptoms with infrared thermography and isotope bone scan. A mean elbow 
spot temperature of 31.1
0
C, proximal forearm gradient of 1.1
0
C and distal forearm 
gradient of 1.5
0
C was reported compared to 30.5
0
C, 0.6
0
C and 0.7
0
C respectively. They 
reported a hot focus on thermal imaging in 94% of unilateral tennis elbow patients and 
increased epicondylar activity on isotope bone scanning in 71% of patients. They also 
found somatosympathetic responses, peripheral regional cooling, in 54% of patients 
with thermography and reduced perfusion in 58% of patients on blood pool isotope 
bone scan. A somatosympathetic reflex is a reflex sympathetic efferent response 
secondary to painful nociceptor stimulation which is reflected by a cooling response. 
Analysis was visual which is highly subjective and subsequently brings into question 
their conclusions.             
 
3.5.2 Pain free grip strength 
 
The main complaints of tennis elbow patients are pain and decreased grip strength 
(Chard and Hazleman, 1989). By virtue of the methodology PFG is an indirect measure 
of the pain system as it reflects the force required to cause pain rather than a measure of 
strength (Coombes et al., 2008). The use of PFG as an objective quantitative outcome 
measure has been endorsed by a number of studies. Smidt et al. (2002) recommended 
using PFG due to it not only being reliable and relatively easy to execute but that it has 
been associated with other measures of functional disability. Stratford et al. (1993) 
evaluated a number of outcome measures on a representative sample of 40 patients with 
tennis elbow. They found that PFG and pain free function questionnaire (PFFQ) were 
the most valid outcome measures of change over time in tennis elbow patients. High 
reliability coefficients for PFG (0.87) and PFFQ (0.93) had previously been reported 
(Stratford et al., 1987).   
 
In consideration of sample size PFG and PFFQ were more efficient when compared 
with other measures such as maximum grip strength and VAS. With 64 and 63 versus 
8063 and 119 patients per group needed respectively, considering the risk of committing 
a Type I error set at 5% and the probability of committing a Type II error of 20% 
(Stratford et al., 1993). Type I error is the standard significance level to risk accepting a 
false significant difference between interventions when one does not actually exist. 
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Type II error is that through a lack of statistical power the study does not have the 
capacity to demonstrate a significant difference between interventions when one may 
actually exist. Also, PFG and pain free function correlated significantly with the 
patient’s global impression of change: correlation coefficient r = 0.59 whilst maximum 
grip strength did not: r = 0.07. Previous analysis by the same authors in 1987 had 
already demonstrated that maximum grip strength was not as sensitive to change. 
Regrettably on review of the research on tennis elbow, maximum grip strength was used 
frequently, 11 in comparison to 14 for PFG (Bisset et al., 2005) and consequently one 
must question the value of such studies. Stratford et al. had also found that ratios of grip 
strength with the uninvolved arm did not correlate as highly as the raw scores. 
 
Newcomer et al. (2005) evaluated the sensitivity of a number of outcome measures for 
tennis elbow and reported good sensitivity with a standardised response mean (SRM) of 
0.8. A SRM enables the responsiveness of different outcome measures to be compared 
through assessing the relative magnitude of change and is derived from dividing the 
mean change from baseline by the SD of the change. The higher the mean the greater 
the sensitivity with <0.5 considered insensitive and >0.8 large. A moderate ES of 0.6 
was also reported.  
 
When attempting to determine a minimum clinically important difference (MCID) a real 
change in outcome must be at least the smallest detectable difference (SDD) of an 
outcome measure. Smidt et al. (2002) assessed the interobserver reproducibility, within 
their robust RCT, of a number of outcome measures including PFG. During follow-up 
from 3 to 52 weeks, to ensure a wide range of patients with varying severity, a random 
sample of 50 patients were assessed by 2 independent research physiotherapists. The 
SDD for PFG was reported as 1.4kg. This was well below the predefined acceptable 
difference between observers of 10%. 
 
3.5.3 Electromyography  
 
EMG is the recording of the electrical signal produced by the depolarisation of motor 
units, change in cell membrane potentials, during a muscle contraction. Surface EMG is 
the summation of all motor unit action potential trains from all active motor units within 
the pick up area of the electrode. A muscle fatigues as it tries to maintain a sustained 
submaximal contraction which is recorded as a decrease in the frequency of the surface 
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EMG signal. This frequency shift is caused by the slowing of the sodium and potassium 
ion movement across the cell membranes reducing the motor unit firing rate. The degree 
of fatigue can be quantified by analysing the median frequency (MDF) which is the 
middle frequency of the magnitude or power versus frequency graphs (De Luca, 1997). 
See graph 4.1 (p.58) for an example of the power spectral density (PSD) and MDF 
comparing the use of single and double differential electrodes. The MDF was calculated 
every second for the duration of the contraction and plotted overtime to demonstrate the 
rate of fatigue. See graph 5.3 (p.64) for an example of a steady decrease in MDF over 
70 seconds, for a 50% maximal grip contraction, illustrating substantial fatigue.  
 
The MDF during a sustained contraction is both a sensitive and reliable measure of 
fatigue (De Luca, 1984). This measure was selected by reason that it allowed a direct 
measure of ECRBr muscle fatigue which is thought to be a contributory factor in the 
pathogenesis of tennis elbow. Consequently, surface EMG allowed more detailed 
analysis of muscle function and provided improved knowledge of the pathogenesis of 
tennis elbow over time. 
 
Both wrist flexors and extensors are recruited in gripping with ECRBr playing a key 
role in stabilisation of the wrist preventing the flexion moment around the wrist. Hagg 
and Milerad (1997) evaluated forearm fatigue in 9 healthy females during intermittent 
25% maximum gripping work by EMG and found greater fatigue in ECR when 
compared with the flexors. They proposed that the greater fatigue was a factor of the 
pathogenesis of tennis elbow and was related to the impeded blood flow caused by the 
static loading. It is thought that this local ischaemia will also affect the poorly 
vascularised corresponding tendons leading to a degenerative tendinosis after an initial 
inflammatory stage. 
 
There was a dearth of research on fatigue in tennis elbow until recent work by 
Alizadehkhaiyat et al. (2007) explored both the strength and fatigability of selected 
upper limb muscle groups; including ECR (Brevis and Longus examined together), 
extensor digitorum communis and flexor carpi ulnaris and flexor digitorum superficialis 
using surface electrodes during grip strength at 50% maximum voluntary contraction 
(MVC) at 90 degrees elbow flexion until exhaustion. The normative study was 
undertaken on 6 healthy subjects who were age matched but not gender matched to a 
typical tennis elbow population. Although they found the wrist extensors significantly 
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weaker than the wrist flexors, in contrast to Hagg and Milerad (1997) they found no 
significant difference in fatigue on normalised median frequency slope. A potential 
reason for this difference is that Hagg and Milerad (1997) tested at 25% MVC whereas 
at 50% maximum there is equal activity in both flexor and extensor groups whereas at 
lower percentages greater extensor activity is present (Mogk and Keir, 2003). The 
authors made no attempt to distinguish between ECRBr and ECRL and comment that 
any conclusions need to be regarded with caution due to possible crosstalk with surface 
EMG, i.e.: the data collected may have originated from other muscles in close proximity 
to the muscle in question rather than ECRBr and ECRL respectively. Chapter 4.3 (p.53) 
discusses the issue of cross talk and how it was addressed in the clinical trial. 
This technique was then used to compare 16 patients with dominant arm tennis elbow 
with 16 age and gender matched controls. They reported a 25% reduction in grip 
strength in the tennis elbow group compared to the control group and a significant 11% 
greater grip strength in the dominant compared to the non dominant side of the control 
group. However, no significant difference between the affected and unaffected side of 
the tennis elbow group was found. In contrast, clinical experience suggests a reduction 
in grip strength of the affected elbow to be typically evident in tennis elbow which is 
supported by research finding pain free grip strength reduced by 43-64% (Coombes et 
al., 2008). One may question their technique of assessing grip strength in 90 degrees 
flexion whereas testing in extension has been shown to be a more sensitive measure 
(Stratford et al., 1993), as discussed later in Chapter 4.2 (p.52), and likewise use of 
maximum grip strength not pain free grip strength and subsequent potential lack of 
statistical power of the study due to the small numbers involved. They further report a 
significantly reduced activity of ECR in the tennis elbow group but no significant 
differences in fatigability of forearm muscles between the control and tennis elbow 
group. This contrasts to Bauer and Murray (1999) who found earlier, longer and 
increased extensor activity during tennis in 16 tennis elbow patients compared to 
controls. The authors comment that the lack of fatigue findings may be in part due to the 
reduced ECR activity found in their study. Another issue to be raised is that due to the 
ambiguity of methods of recruitment and unreported symptom duration the 
generalisation of findings to the tennis elbow population as a whole is questionable. 
Alizadehkhaiyat et al. (2008) followed up the motor function of patients who had been 
asymptomatic for a minimum of 6 months in a subsequent study. They reported that, 
albeit with the exception of the finger extensors, weakness persisted in the entire upper 
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limb when compared with the controls implying incomplete functional recovery despite 
pain attenuation. They suggested that tennis elbow patients increase finger extension 
strength as compensation for the wrist extensor weakness. 
 
Unfortunately, Alizadehkhaiyat et al. (2007) report conflicting evidence with respect to 
the scarce research available on this subject and they have only added to the controversy 
of the pathogenesis of tennis elbow. Through applying several concepts in a novel 
manner a more sensitive protocol was developed which aims to allow more specific and 
detailed analysis of ECRBr function and provide improved knowledge of this muscle’s 
role in the pathogenesis of tennis elbow over time. 
 
3.5.4 Patient – rated tennis elbow evaluation questionnaire  
 
Overend et al. (1999) developed this tool to assist the clinician in understanding the 
impact of tennis elbow on a patient. The objective of the patient-rated tennis elbow 
evaluation questionnaire (PRTEE) is to provide an uncomplicated, standardised, 
quantitative description of pain and functional disability, which can be completed in 5 
minutes, (Appendix 11.8). Due to the patient being requested to describe their average 
arm symptoms over the past week accurate memory recall is ensured, within this 
timeframe, whilst avoiding the potential for erroneous responses from any acute 
fluctuations in symptoms. The questionnaire is devised of five questions which assess 
pain and ten questions assessing function, using a ten-point scale with 0 being no pain/ 
no difficulty to 10 being worst pain imaginable/ unable to do. Therefore, the higher the 
score (maximum 100) the greater the pain severity and degree of dysfunction. The 
function subscale score is divided by 2 so that both pain and disability contribute 50% 
each to the total. 
 
The use of a patient completed functional questionnaire has the advantage of limiting 
potential observer bias, which may occur if the researcher was to question the patient 
and then fill in their responses (Turchin et al., 1998). 
 
Overend et al. (1999) determined the interclass correlation coefficients (ICC) for test- 
retest reliability for 47 patients with unilateral tennis elbow for at least 3 weeks who 
were part of a trial investigating PFG and bracing. ICC is the ratio of the variance 
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amongst the subjects over the total variance (subject, observer and random error 
variability) with 1= perfect reliability and 0= no reliability. Patients completed a patient 
rated forearm evaluation questionnaire (PRFEQ), the forerunner to the PRTEE with a 
maximum score of 10, after clarification of the instructions and a reminder that the 
responses were to be based on the average symptoms over the past week and after a 
PFG measure. They were then provided with a 2
nd
 copy with a stamped addressed 
envelope to be completed at the same time the following day. 3 subgroup comparisons 
were evaluated; male: female, subacute: chronic and work: non-workers. The concurrent 
validity; the degree to which one outcome measure score correlates with another 
outcome measure score when given on the same occasion, was also assessed through 
correlation with the PFG. 
 
It was interesting to note that the mean scores overall and for subscales were 
significantly higher for females and the mean scores overall and for function were 
significantly higher for non workers. No differences were found for the stage of 
condition. For the reliability analyses the overall (ICC=0.89) was excellent with 
subscales of pain (ICC=0.89) and function (ICC=0.83). On subgroup analysis reliability 
coefficients were all excellent (ICC>0.75) with no significant differences for the 
reliability coefficients for male: female or stage of conditions. However, they reported 
that the ICCs overall and for the pain subscale for the working subgroup were 
significantly  lower than the  non workers. PFG was  significantly  related to  overall 
(r=-0.36) and both pain (r=-0.37) and function (r=-0.30) subscales with fair correlations. 
However, the standard error of measurement (SEM); which quantifies the expected 
variation from the true score with repeated testing, was +/- 0.6 with 95% confidence 
interval of +/- 1.2.  
 
Newcomer et al. (2005) evaluated the sensitivity, reliability and concurrent validity of 
the PRFEQ on 22 subjects with chronic tennis elbow of >3 months on 3 consecutive 
days who were partaking in a concurrent trial investigating the effect of exercise on 
lateral epicondylitis. The outcome trial compared the PRFEQ to VAS, PFG, Disabilities 
of the arm, shoulder and hand questionnaire (DASH) and Medical Outcomes Study 36-
item Short Form Health Survey which were completed at baseline, 6 weeks and 3 
months. 15 subjects were assessed prior to treatment and 7 after in order to determine 
whether reliability was affected by either treatment or time. Sensitivity is the ability of a 
measure to detect change overtime.  
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Measurement error was reported as a score of 1. Excellent reliability was reported for 
total PRFEQ (ICC=0.96), pain (ICC=0.96) and function (ICC=0.92) subscales and that 
generally correlations were moderate with the other outcome measures. At 6 weeks the 
pain subscale had a SRM of 1.2 and an ES of 1.3, the highest compared to the other 
outcome measures, which is as expected due to the PRFEQ being the only functional 
measurement specifically for tennis elbow. A negative correlation with PFG was 
reported with pain (r=-0.35) and function and total (r=0.45) which supports the findings 
of Overend et al. (1999). Consequently, although PFG measures an important aspect of 
tennis elbow PRFEQ is a better functional measure. They concluded that the ‘PRFEQ is 
reliable, reproducible and sensitive for assessment of lateral epicondylitis’ and ‘should 
be a standard primary outcome measure in lateral epicondylitis research’.  
 
Newcomer et al. (2005) made some minor changes to some of the wording in order for 
the activities to be more familiar and subsequently easier to understand by their 
American population. MacDermid (2005) agreed with the need for terms which can be 
applied across a broader population, both gender and cultural to provide clarification 
and to identify more clearly the nature of the activity. The scoring was also revised with 
both pain and function each contributing 50% to the total score (0 to 100) to bring it in 
line with its sister outcome measures. Consequently, with these relatively minor 
modifications in terminology and scoring the PRFEQ became the PRTEE and 
MacDermid (2005) proposed that the published data on reliability and validity remained 
applicable, although the PRTEE would be revalidated.  
 
Rompe et al. (2007) evaluated the reliability, internal consistency, reproducibility, 
construct validity and sensitivity to change of the revised version of the PRTEE. 
Internal consistency is the degree that the responses to different components of the 
questionnaire agree which indicates that each component is measuring different aspects 
of the same condition in question. Construct validity is to what extent the questionnaire 
correlates to other established outcome measures within the theoretical context.   
 
Rompe et al. (2007) reported the validation on a chronic sample, (> 1yr duration having 
had a minimum of 3 courses of conservative treatment), of 78 subjects with a mean 
duration of 2 years who presented with unilateral tennis elbow confirmed on MRI who 
played tennis recreationally and were participating in a concurrent RCT comparing low-
energy shockwave treatment with placebo. The PRTEE was compared to the VAS and 
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DASH questionnaires, the Roles and Maudsley score and the Upper extremity Function 
Scale, at baseline, (1 week and immediately before treatment), and at 12 weeks for the 
34 subjects who received treatment. Reliability and internal consistency were excellent 
(0.94). Correlation between the subscales and total were good compared to both VAS 
and DASH. Test- retest reliability was excellent (r
2
= 0.87). Sensitivity to change 
correlated well to the DASH. A SRM of 2.1 for the PRTEE was the highest for all the 
outcome measures indicating that the PRTEE was the most responsive to detecting 
change. This supports the evaluation of Newcomer et al. (2005) who reported the 
superiority of the PRTEE and concluded that the PRTEE was a reliable, sensitive and 
reproducible outcome measure for chronic tennis elbow.  
 
3.6 Literature review summary 
 
The literature review highlighted the poor understanding of the pathophysiology of 
tennis elbow, which remains in contention due to a dichotomy of an inflammatory 
versus degenerative pathology and whether an inflammatory component is present in 
the early stages. This is fundamental to the myriad of treatments available and the lack 
of evidence based practice for therapeutic interventions for this challenging condition. 
Clinicians are left with a clinical dilemma as the most common treatments are injection 
which is anti-inflammatory and ultrasound which is pro-inflammatory. Injection therapy 
has been shown to be superior in the short term but with high recurrence rates in to the 
long term whilst wait and see with NSAIDs have been advocated to be superior in the 
long term, which are again anti-inflammatory.  
 
There is weak evidence, from 2 systematic reviews, in favour of therapeutic ultrasound, 
albeit only for tennis elbow. Apart from 2 small and poor methodological trials all 
utilised 1MHz ultrasound and a favourable outcome was found in those trials which 
used higher intensities which utilise thermal effects in addition to the non thermal 
effects. However, currently, low intensity ultrasound has been advocated in practice. 
One other trial using 3MHz was identified with a fair sample size but pulsed ultrasound 
was used to evaluate whether the addition of mobilisations with movement would 
improve outcome. Unfortunately, the control group was selective and subsequently 
validity became an issue.  
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CHAPTER 4: PROTOCOL DEVELOPMENTS 
 
 
Further preparatory work was undertaken to develop a novel scientifically robust model 
for thermographic analysis and to develop a robust protocol for electromyographic 
analysis through the application of concepts in a unique way. This chapter presents a 
comprehensive review of these protocol developments   
 
4.1 Thermography protocol development 
 
 
On review of the literature, as discussed in Chapter 3.5.1, previously published 
protocols for thermographic analysis have fundamental flaws and deficiencies. 
Consequently, a novel scientifically robust model had to be developed. 
   
Tsk data collection is inherently difficult to standardise due to potential intrinsic and 
extrinsic variables (Table 4.1) which affect vasomotor regulation. Consequently a strict 
standardised procedure for data collection is needed (Mayr, 1995 and Scudds and 
Helewa, 1995). 
 
Intrinsic variables Extrinsic variables 
caffeine  environmental temperature 
alcohol draughts 
smoking heat sources  
recent physical activity acclimatisation to the recording environment 
 
Table 4.1: Intrinsic and extrinsic variables affecting vasomotor control. 
 
The participants were requested to refrain from alcohol from the night before the test 
and not to apply any creams to the area on the day of the test. Any brace was needed to 
be removed and food consumption, strenuous exercise, drugs, caffeine and nicotine 
avoided for 2 hours prior to the test if possible. On arrival the patient was asked to 
expose the elbow area whilst avoiding localised sources of heat, sunlight or draughts to 
allow the elbow to acclimatise to room temperature for 15 minutes (Mayr, 1995). 
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In the protocol developed the thermographic measurement was taken in a standardised 
manner using a FLIR A40M thermovision infra-red thermal imaging camera (Danderyd, 
Sweeden) mounted on a Bilora PRO 930 tripod (Kurbi and Niggeloh, Germany), Figure 
4.1, focused on the lateral epicondyle and aligned parallel with the skin overlying the 
area. The thermovision system demonstrates high and unique detection parameters with 
the manufacturer’s technical specification for the camera accuracy to within 2% of the 
data point onscreen reading. An inhouse reliability experiment for the camera, over a 3 
hour period, had already been undertaken by Eivazi and Selfe (unpublished data, 2010) 
and had demonstrated good consistency. The object and room temperature were 
maintained at a constant level and during the first 30 minutes an image was taken every 
5 minutes and then at 10 minute intervals until the end of the 3 hour period. The mean 
temperature showed a maximum variability of 0.2
0
C difference between the baseline 
mean temperature and the mean temperature of the thermal image.  
 
 
Figure 4.1: Thermal image equipment 
 
The use of thermally inert wooden anatomical markers as described by Selfe et al. 
(2006) was applied in a unique manner for tennis elbow. 
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Figure 4.2: Anatomical markers on the olecranon and cubital crease. 
 
As shown in Figure 4.2 two specific anatomic locations were used: the first was placed 
on the midpoint of the olecranon and the second placed in the same plane in the cubital 
crease whilst the patient was stood at a distance of 80cm from the camera lens with the 
elbow flexed to 90 degrees and in full forearm supination (Figure 4.3). In this manner 
the forearm was in a horizontal position and the upper arm vertical. A distance of 80cm 
gave optimal pixel viewing with optimum resolution of a full image of the ROI. This is 
supported by Karki et al. (2004) who took thermal images of a 0.5m
2 
reference object at 
a series of camera distances of 80, 100, 120 and 200cm. For the 200cm camera distance 
a pixel resolution of only 12 pixels/m
2 
was reported compared to a greater resolution of 
90 pixels/m
2
 at 80cm. At the minimum camera distance of 50cm there was an 
inadequate area of the image available for analysis and at 1 meter the resolution became 
too poor. The choice of placement on the olecranon was due to it being a bony 
prominence which is fixed and easily reproducible in a consistent manner. Both use of 
the lateral epicondyle or the radial head could lead to spurious data from the marker 
itself or ambiguity in exact location. i.e.: the lateral epicondyle is the ROI and the radial 
head too ill defined in the sagital plane and similarly in close proximity of the ROI. The 
choice of the cubital crease as the second marker was chosen as it could be easily 
reproduced in relation to the olecranon and enables the ROI to be located within a fixed 
anatomical area.  
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Figure 4.3: Set up for recording thermal images. 
 
This procedure enabled a reliable and accurate method for the thermal image data 
collection using FLIR Systems ThermaCAM Research Pro 2.8 software and the 
subsequent analysis through the development of a novel scientifically robust model. 
 
A unique method of measuring the Tsk of the insertion of ECRBr was developed in a 
standardised manner which was both easy and consistently reproducible. The ROI 
quadrant (AR02) was compared with the unaffected quadrant (AR03) which acts as a 
control (Figure 4.4). The thermal difference between the maximum Tsk (AR02 – AR03) 
for the ROI was then recorded. 
 
22.3°C
33.6°C
AR02
AR03
 
Figure 4.4: ROI quadrant (AR02) and unaffected quadrant (AR03). 
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(
0
C) Min Max Range Mean SD 
AR02 30.1 33.7 3.7 32.3 0.8 
AR03 29.7 32.4 2.6 31.3 0.4 
 
Table 4.2: Thermal image analysis of the symptomatic patient in Fig. 4.4 
 
As can be seen in the patient shown in Figure 4.4 and Table 4.2 a difference of +1.3
0
C 
was found for the maximum Tsk  in the ROI: AR02 (33.7) – AR03 (32.4) = +1.3 
 
In comparison, when this patient’s contralateral non affected ROI was analysed: 
AR02 (32.7) - AR03 (32.7) = 0   
 
The method used to draw AR02 and AR03 was as follows: Draw a rectangle of the area 
of interest (AR01) which originated with the + cursor arms just touching the superior 
and distal outer extremities of the 2 anatomical markers (Figure 4.5). In this manner the 
rectangle originated from the centre of the cursor which importantly did not touch the 
marker and therefore would not lead to spurious data from the marker itself. 
 
22.3°C
33.6°C
AR01
 
   
Figure 4.5: The area of interest (AR01) 
 
Two diagonal lines were drawn (LI01 and LI02) between the opposite corners. These 
intersected at the midpoint of the rectangle AR01 (Figure 4.6). 
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Figure 4.6: Diagonal lines (LI01 and LI02) 
 
Two small rectangles (AR02 and AR03) of equal volume were then drawn originating 
from each anatomical marker (Figure 4.7). The corner of each of the small rectangles 
(AR02 and AR03) met at the midpoint of the large rectangle (AR01) which corresponds 
to the intersection of LI01 and LI02. The large rectangle (AR01) and the 2 diagonal 
lines (LI01 and LI02) were then deleted leaving the 2 quadrants (AR02 and AR03) for 
the analysis. 
 
22.3°C
33.6°C
LI01
LI02AR 1
AR02
3
 
   
Figure 4.7: Method of Tsk measurement (AR01, LI01, LI02, AR02 and AR03) 
 
Following peer review of this novel method 2 comments were identified: the validity of 
the ROI in proportion to anthropometrics and the use of the maximum Tsk in lieu of the 
mean which is used more frequently in thermal imaging work. In defence for the choice 
of standardised procedure the validity of the two specific anatomic locations in 
proportion to anthropometrics was verified by review of the thermal image, using the 
standardised procedure described, for 5 normative subjects with an additional marker 
placed on the ROI (see figure 4.8). 
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Figure 4.8: Additional marker on ROI 
 
The sample was comparative to a typical tennis elbow population: 3 females and 2 
males with a mean age of 47.8 years. The ROI did not migrate into either the control 
area or the intersection point of the ROI and control squares for any subject. 
 
The maximum Tsk was the optimum measurement as it was not dependent on the size 
of the area of interest and subsequently was more consistent. Whereas, in contrast, the 
mean was dependent and would vary with the size of the area of interest. Equally, mean 
temperature demonstrated a significant diurnal variation with an increase in the 
afternoon compared to a non significant increase in the maximum temperature (Binder 
et al., 1983). Consequently, due to the repeated measures design with data taken at 
different times convenient to the subjects the use of the maximum temperature would 
increase accuracy and negate this potential variable. 
 
By the use of an ipsilateral control in this unique method previous potential flaws in the 
accuracy of the use of thermal imaging, on both a specific occasion and on repeated 
occasions, due to the variability attributed to the intrinsic and extrinsic variables of 
vasomotor control, as detailed in Table 4.1, were negated. Furthermore, it was felt that 
an ipsilateral comparison as the control would be more accurate due to the potential 
factors of potential difference of blood flow to the affected versus the unaffected side 
and the fact that 30% of patients in Binder et al. (1983) had a hot spot on the unaffected 
elbow. However, through the use of an ipsilateral control, the temperature increase 
would affect both the ROI and control and be negated as the outcome measure is the 
difference between the 2 areas. Thomas and Savage (1989) compared the spot 
temperature of the tennis elbow region with the ipsilateral forearm temperature and 
reported that with clinical improvement after acupuncture treatment although right and 
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left elbow temperatures had become equivalent a larger temperature gradient between 
the elbow and ipsilateral forearm persisted on the affected side. They concluded that 
lateral epicondyle temperature combined with forearm gradient maybe of more clinical 
value than either lateral epicondyle temperature alone or side to side analysis.   
 
4.2 Pain free grip strength protocol  
 
The PFG was taken using a Saehan hand dynamometer manufactured by Saehan 
Corporation, Korea. As recommended by the American Society of Hand Therapists 
(ASHT) and used by studies assessing the reliability of this measure (Smidt et al., 2002 
and Turchin et al., 1998) the contact surfaces were on the second bar for all participants 
to ensure maximum grip strength (Firrell, 1996). 
 
The concept of PFG was explained to the participants who were instructed to slowly 
squeeze the dynamometer and to stop the instant any discomfort was first felt. No other 
encouragement was given. The participant was asked to only look at the dynamometer 
dial during the third grip strength in order to maintain 50% maximum on the unaffected 
side. The testing procedure was standardised as elements of arm position can affect grip 
strength (Ng and Fan, 2001): the participant stood with the shoulder adducted and in a 
neutral position, the elbow was in extension and the forearm was in neutral. In a neutral 
forearm position skin sliding over the muscles is eradicated when compared to 
pronation or supination (Duque et al.,1995). Although for assessing grip strength the 
ASHT recommended the participant to be seated with the elbow at ninety degrees, the 
standing position with the elbow extended was endorsed by a number of studies on 
tennis elbow (Stratford et al., 1993) as it reflected a more sensitive outcome. This 
protocol was used by Smidt et al. (2002). De Smet et al. (1997) found a marked 
reduction in grip strength in patients with tennis elbow with the elbow in extension 
when compared with ninety degrees of flexion.  
 
Three attempts with 20-second intervals between were recorded and the mean value, in 
kilograms (kg), calculated. Stratford et al (1989) demonstrated that no statistical 
differences existed between repetitions on different occasions or for patient repetition 
and occasion repetition interactions. They found that no fatigue or learning occurred 
during the testing and to achieve a representative estimate of the patient’s strength an 
average of three repetitions should be used. The ASHT endorsed this protocol.  
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4.3 Median frequency protocol development 
 
 
In this research the EMG studies were undertaken in a standardised manner. In order to 
acquire an optimum signal the electrical resistance of the skin must be kept below a 
certain threshold to maintain a good signal-to-noise ratio and furthermore, the skin 
resistance needs to be kept constant overtime on repeated occasions as a prerequisite to 
repeatability and accuracy of the data collected. The skin was prepared with slight 
abrasion with an alcohol wipe to ensure optimal continuous skin contact and prevent 
movement of the electrode which could cause the production of artefacts preventing 
optimum signal acquisition.  In addition, the ground or reference electrode was attached 
to the dorsum of the hand on the unaffected arm which facilitates optimal signal 
acquisition free from artefacts through providing an electrical reference of the 
surrounding electrical activity from both internal electrical activity and external 
equipment.  
 
The EMG electrodes were attached to the participant and the MPSF recordings taken 
whilst the participant undertook a sequential series of 3 PFGs, (Figure 4.9).  The MPSF 
analysis was recorded during the final PFG whilst it was maintained for 45 seconds. 
During the EMG analysis the PFG and subjective pain was recorded concurrently at 15 
second intervals. The unaffected arm was assessed first. 
 
 
Figure 4.9: EMG set up 
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The DELSYS Bagnoli EMG system (Figure 4.10) enables a high quality and reliable 
EMG to be recorded. To ensure that the optimum magnitude and fidelity of signal was 
acquired a number of components needed to be considered.  
 
 
Figure 4.10: DELSYS Bagnoli EMG system 
 
Location and standardisation of electrode placement was a requisite to be controlled to 
enable a reliable and valid EMG recording. Previously, selective EMG recording of 
ECRBr was thought to be unviable unless fine wire indwelling electrodes were used and 
even then it could not be distinguished from ECRL due to crosstalk. This was overcome 
by Riek et al. (2000) who described a new technique for the selective recording of 
ECRBr and ECRL EMG using intramuscular electrodes. They examined 10 cadaver 
specimens and their data demonstrated a significant separation of each muscle belly. 
These location data were then used on 3 healthy volunteers: The initial measurement 
was taken from the lateral epicondyle of the humerus to the styloid process of the radius 
with the elbow in 90 degrees flexion and neutral pronation/supination. The origin of 
ECRL was calculated by taking 7.8% of this initial measurement up the lateral humerus. 
The distance from the origin of ECRL to the radial styloid process was then measured 
and 47.6% along this length the ECRBr belly was identified, (Figure 4.11). Although 
they reported consistent overlap of the proximal fibres of ECRBr, (24.3% +/- 2.4%) and 
distal fibres of ECRL (39.5% +/- 2.4%) significant separation of the muscle bellies was 
identified; 47.6% +/- 3.4% and 17% +/- 2% respectively. This technique allowed the 
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optimum electrode position of in the midline of the muscle belly between the 
musculotendinous junction and nearest innervation zone to be identified.  
 
 
Figure 4.11: ECRBr muscle belly location 
 
The use of the DELSYS DE-3.1 double differential electrodes (Figure 4.12) addressed 
the issue of crosstalk (De Luca, 1997). 
 
  
Figure 4.12: DELSYS single (top) and DE-3.1 double differential electrodes 
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Where muscles are in close proximity and particularly where the muscle belly is small it 
can be difficult to differentiate the activity of a specific muscle using surface electrodes. 
The presence of EMG signals originating from muscles adjacent or deep to the muscle 
of interest is known as crosstalk and can be reduced with the use of specifically 
designed double differential electrodes. Single differential electrodes comprise of 2 bar 
electrodes placed 1 cm apart, within a single solid electrode, as depicted in figure 4.12. 
This configuration removes the signal that is common to both electrodes and amplifies 
the difference or differential, which effectively removes external noise. Double 
differential electrodes work on the same principles but have 3 bar electrodes whose 
signals are compared. This not only facilitates greater noise reduction but also has the 
advantage of reducing the pick up volume and consequently reducing any potential 
effects of the adjacent muscles and crosstalk (Kirtley, 2006). 
 
4.3.1 Double versus single differential electrode study 
 
To ensure that the optimum signal was acquired a comparative study between the use of 
double and single differential electrodes was undertaken for ECRBr during gripping to 
ascertain which gave the optimum magnitude and fidelity of signal. 
 
4.3.1.1 Method 
 
The muscle belly of ECRBr was identified and marked, as in figure 4.11, on 5 normal 
participants as per Riek et al. (2000). Each participant was asked to do 5 successive 
maximum voluntary grip contractions with an electrode in situ. After a rest of 1 minute 
the participant was asked to repeat the set of 5 successive maximum voluntary 
contractions with the alternative electrode in situ. The double and single differential 
electrodes were applied in a randomised order.    
 
The mean maximum grip strength from 5 data sets was recorded and the magnitude and 
fidelity of the signal was analysed. The PSD was visually compared and the MDF 
calculated.  
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4.3.1.2 Results 
 
As an example, the following graph 4.1 demonstrates the difference, for one healthy 
participant, between the single and double differential EMG signal.  
 
 
Frequency (Hz) 
  
Graph 4.1: Power spectral density for double versus single differential 
electrodes.  
 
The mean maximum grip strength was 30kg (range 22.5 to 41.1).  
On visual analysis of the PSD both the single and double differential electrodes 
demonstrated good consistency throughout.  
On calculation of the MDF the mean for the single electrode was 77.2Hz and the double 
was 101.88Hz. 
  
It can be seen that the power spectral frequency for the single differential electrode has 
a lower frequency spectrum with a peak @50Hz and group mean MDF of 77.2Hz 
(depicted by the blue line). This is typical of a recorded EMG which includes cross talk 
from signals which have originated from muscles further away. In contrast, the group 
mean MDF shift for the double differential electrode was 101.88Hz (depicted by the 
green line) without the lower frequency peak, demonstrates that crosstalk, originating 
from muscles further away, has been removed.  
 
Double differential 
Single differential 
 
P
o
w
er
 s
p
ec
tr
u
m
 d
en
si
ty
 (
V
2
/H
z)
 
 59 
4.3.1.3 Conclusion 
 
The double differential electrodes were utilised as they gave better magnitude and 
fidelity of signal without cross-talk. 
 
4.4 Patient preference questionnaire 
 
The patient preference questionnaire was designed for this research to provide a 
qualitative impression of patient treatment preference overtime, (Appendix 11.9). It 
included the patient’s perspective on treatment and may highlight reasons for patients 
who did not attend (DNA) and emphasise areas for development to facilitate service 
improvement. The patient’s wishes and collaboration in treatment choice is an 
important aspect to consider (Haynes, 1998).  
 
Also of paramount importance to research is the need to reduce potential bias, in 
particular when patients can not be blinded to the treatment intervention and subjective 
outcome measures are used. Through documenting patient preference an evaluation can 
be undertaken of whether the preferred treatment had some influence on success rates. 
 
4.5 Protocol developments summary 
 
In conclusion the following outcome measure data was collected using the methods 
previously described: 
 
 Thermal difference of the maximum Tsk of the ROI compared to the control 
 Mean PFG 
 MDF of ECRBr during PFG using double differential electrodes  
 PRTEE questionnaire (pain, function and total) 
 Patient preference questionnaire 
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CHAPTER 5: NORMATIVE STUDIES 
 
 
As there was no existing data for thermal difference or MDF using the developed 
models on either a healthy or tennis elbow population this chapter presents the 
preliminary studies. Normative study 1 tested the developed protocols and explored the 
range of values for thermography and EMG of a sample of 20 participants who were 
pain and pathology free and were age and gender matched to the tennis elbow 
population.  
 
In order to assess the validity of the developed thermographic model, normative study 2 
presents the evaluation of the immediate thermal effects following a treatment session 
of therapeutic ultrasound. 
 
5.1 Ethics 
 
These studies conformed to the declaration of Helsinki and ethical approval was gained 
from Faculty of Health Ethics Committee (FHEC) of the University of Central 
Lancashire (UCLan) prior to any data collection (Appendix 11.4). 
  
5.2 Normative study 1 
 
5.2.1 Normative study 1 Methods 
 
The normal population comprised of staff and students at the UCLan who did not have 
any pain or problems with either of their elbows. A request for participants was initially 
sent to the Department of Allied Health Professions staff via email and followed up 
with telephone and face-to-face requests for non responders. All participants were 
issued with an information sheet, (see appendix 11.2). Informed consent was gained 
from those who were suitable with respect to age and gender of patients who complain 
of tennis elbow, (see appendix 11.1). 
 
Using the standardised methods as described in Chapter 4.1 the maximum Tsk for the 
ROI was calculated for both elbows (Table 5.2). In order to calculate a realistic 
optimum hold to gain significant fatigue in the tennis elbow population a 70 second 
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50% maximum hold was undertaken which allowed MPSF data collection at 10, 35 and 
60 seconds. The maximum MDF was taken during the first 10 seconds to allow for the 
variability of potential subject delay on squeezing the dynamometer when requested and 
at 60 seconds to account for any potential subject anticipation of release.  
 
All data was collected on the normative study data collection sheet, appendix 11.3. 
Although data was taken bilaterally, on account of tennis elbow typically affecting the 
dominant arm the MDF was initially assessed on the dominant arm. From previous 
work by Tonks et al. (2007) 50% of the mean of the subject’s first two maximum grip 
strengths was thought to be comparable to a patient with tennis elbow performing PFG. 
This percentage is also supported by De Luca (1984) who reported that MDF 
demonstrates the greatest fall at 50% maximum contraction.  
 
5.2.2 Normative study1 Results 
 
5.2.2.1 Descriptive statistics 
 
The descriptive statistics of the normative study population was compared with the 
tennis elbow population data (n=48) from Tonks et al. (2007) in table 5.1. This showed 
that the normative study was broadly similar to the age and gender of a typical tennis 
elbow population. 
 
 Tennis elbow population 
Tonks et al. (2007) 
(n=48) 
Normative study 
Current 
(n=20) 
Female 22 (46%) 11 (55%) 
Male 26 (54%) 9 (45%) 
Mean age (range) 44.3 yrs (27-61) 40.6 yrs (27-56) 
Tennis players 2 (4%) 2 (5.5%) 
 
Table 5.1: Descriptive statistics comparison 
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This was also supported by the literature review; (Chapter 3.2) that tennis elbow is 
typically experienced in the dominant hand in equal proportions of male and female 
patients during the 3
rd 
and into the 5
th
 decades (Vicenzino and Wright, 1996). 
 
The frequency of prognostic indicators are shown in table 5.2. 
 
Prognostic indicator Number 
Smoking 0 
Diabetes 0 
Circulatory problems 0 
Elbow problems in the past 6 months 0 
Elbow problems >6 months ago 1 
 
Table 5.2: Frequency of prognostic indicators 
 
5.2.2.2 Thermography 
 
 
Graph 5.1:  Normative study 1 maximum Tsk for ROI (AR02) and control (AR03) 
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Graph 5.1 shows the box plot for the maximum Tsk (0C) for the ROI and control 
quadrants for both elbows for normative study 1.     
 
For the dominant arm the mean maximum temperature for the ROI (AR02) was 32.5
0
C 
and the control (AR03) 32.8
0
C which gave a mean thermal difference of -0.3
0
C  
 
For the nondominant arm the mean maximum temperature for the ROI (AR02) was 
32.1
0
C and the control (AR03) 32.5
0
C which gave a mean thermal difference of -0.4
0
C  
 
5.2.2.3 Pain free grip strength 
 
Graph 5.5 shows the maximum grip strength for both the dominant and nondominant 
arms for the normative study 1. 
 
 
Graph 5.2:  Mean maximum grip strength for normative study 1  
 
For the dominant arm the mean maximum grip strength was 39.9kg with a range of 
24.5-66  
 64 
For the nondominant arm the mean maximum grip strength was 37.2 with a range of 
24.5-55 
 
5.2.2.4 Median frequency 
 
 
As an example, graph 5.3 shows the MDF of maximum grip strength over 70 seconds in 
a healthy participant for ECRBr. A reduction in frequency was evident over this period 
of time which demonstrates marked fatigue.     
 
 
 
Graph 5.3:  Median frequency of 50% maximum grip strength over 70 seconds 
 
 
Graph 5.4 shows the box plots for the mean dominant MDF of 50% maximum grip 
strength at the data collection points of 10, 35 and 60 seconds for normative study 1. 
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Graph 5.4:  Mean dominant median frequency of 50% maximum grip strength 
over 70 seconds 
 
To assess over what time period significant fatigue was evident at 50% maximum grip 
strength for the dominant arm a repeated measures analysis of variance (ANOVA) was 
used with alpha set at p< 0.05 with 95% confidence levels:  
Mean difference between 10 sec and 35 sec was 20.8Hz (95% CI 16.3- 25.3) p<0.001 
Mean difference between 10 sec and 60 sec was 29.8Hz (95% CI 21.6- 38) p<0.001  
 
One can conclude that 35 seconds was required for significant fatigue to be evident in 
ECRBr at 50% maximum grip strength in an age and gender matched normal 
population.  
 
On visual analysis of the MDF of the first 20 patients a number of anomalies became 
evident and consequently on checking the PSD in the region of 20% had a 50Hz peak 
evident which was attributed to the patient data being collated in the clinical 
environment with the intermittent use of electrotherapy within the immediate 
surroundings causing some potential interference. This electrical noise interference of 
the data was removed by notch filtering which is the removal of a narrow band of 
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frequencies around the interference. This has the effect of removing both the electrical 
interference and EMG signal indiscriminately between the 2 selected frequencies which 
has the potential to distort the data, in particular the MDF, by a small degree. Although 
this was not ideal, where a large amount of interference is present it became necessary 
(Richards, 2008). Thus for consistency, all data was notch filtered IIR using a 
Butterworth at the 2
nd
 order with a band stop of 48-52Hz. The response was sharper 
using 48-52Hz when compared with 49-51Hz. Graph 5.4 shows the box plots for the 
notch filtered MDF of 50% maximum grip strength for 70 seconds. 
 
 
Graph 5.5:  Notch filtered median frequency of 50% maximum grip strength over 70 
seconds 
 
Subsequently, on repetition of the statistical analysis using a repeated measures 
ANOVA with alpha set at p< 0.05 with 95% confidence levels:  
 
For the dominant arm: 
Mean difference between 10 sec and 35 sec was 21.7Hz (95% CI 18.4- 24.9) p<0.001 
Mean difference between 10 sec and 60 sec was 30.3Hz (95% CI 24.2- 36.4) p<0.001 
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For the nondominant arm: 
Mean difference between 10 sec and 35 sec was 20.5Hz (95% CI 14.9- 26.1) p<0.001 
Mean difference between 10 sec and 60 sec was 27.3Hz (95% CI 21.3- 33.4) p<0.001 
 
Mean difference 
of MDF between 
10 seconds and: 
Prenotched data Notched data 
35 seconds 20.8Hz 21.1Hz 
60 seconds 29.8Hz 28.8Hz 
 
Table 5.3: Comparison of prenotched and notched median frequencies 
 
As can be seen on comparison of the notched and prenotched data in table 5.3 there was 
only a maximum of 1Hz difference between the mean differences and the significant 
fatigue evident over both 35 and 60 seconds remains. 
 
5.2.3 Discussion 
 
When normative study 1 was considered it can be seen that the ROI was a mean of 0.3 
to 0.4
0
C cooler when compared to the control; i.e.: a negative thermal difference. This 
was supported by Binder et al (1983) who found a positive thermal gradient from the 
olecranon to the elbow joint was often present in the 120 elbows of 60 normal subjects 
they examined. This would imply that the magnitude of the positive thermal difference, 
(i.e.: the ROI is hotter than the control), found in the symptomatic patient in Figure 4.4 
and Table 4.2 was underrepresented.   
 
If the PFG data from Tonks et al. (2007) is considered one can confirm the reduction in 
the region of 50% in symptomatic tennis elbow patients (Table 5.4). Subsequently, one 
can validate the use of 50% maximum grip strength for the unaffected side and the 
normal population. 
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Mean PFG Tonks et al. 2007 Normative study 1 
Baseline 18.5kg (range 4.7- 47) Dominant: 39.9kg 
Nondominant: 37.2kg 
7 weeks post treatment 25.7kg (range 7.3-54) N/A 
 
Table 5.4: Painfree grip comparison 
 
The MDF analysis concluded that significant fatigue was evident at 35 seconds for 
ECRBr at 50% maximum grip strength and has informed the patient study that a 45 
second hold was required to detect a significant difference on the 3
rd
 PFG to allow for a 
10 second potential delay at onset and a 10 second anticipatory release. 
 
5.3 Normative study 2: Thermal effects of ultrasound 
 
5.3.1 Normative study 2 methods 
 
 
In order to assess the validity of this model, the immediate thermal effects following a 
treatment session of therapeutic ultrasound using an EMS Medi- Link system 
(Greenham, Oxford) to the tenoperiosteal junction of ECRBr was explored, as per trial 
protocol (continuous 3 MHz using a 0.5 transducer with gel at 2W/cm
2
 for 5 minutes), 
on a healthy participant. This was repeated on a separate occasion on the same 
participant with sham ultrasound. (i.e.: the ultrasound package without the ultrasound 
switched on.  
 
A thermal image was taken immediately prior to ultrasound, within 1 minute post 
ultrasound and then at 1 minute intervals until 20 minutes inclusive. Then at 25 and 30 
minutes post ultrasound.  
 
5.3.2 Expected thermal effects of ultrasound 
 
If the expected thermal effects during the application of an ultrasound package are 
considered; the initial application of the coupling medium gel to the skin, despite being 
at room temperature, would have a marked cooling effect, a reduction in Tsk, through 
the evaporation of water. This reduction in Tsk is further accentuated by the contact of 
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the relatively cold metal transducer to the skin which creates a temperature gradient 
causing a cooling of the skin and a rise in temperature of the transducer as they attempt 
to gain thermal equilibrium.  
 
In contrast, there is the potential for a Tsk increase with the friction caused by the 
transducer juxtaposed to the skin which is in continual motion during administration 
although this would be minimal due to the use of the coupling gel. The Tsk increases 
due to the therapeutic effects of the ultrasound as mechanical vibration energy is applied 
which causes the physiological effects of vasodilatation and an increase in blood flow to 
the area.  
 
5.3.3 Normative study 2 results 
 
The novel protocol for thermographic analysis with the normative data, single case 
history and thermal effects of ultrasound was presented as a poster at the Chartered 
Society of Physiotherapy Congress in Liverpool in October 2009 (Appendix 11.16). 
 
Graph 5.6 shows the thermal difference overtime with a minimal clinically important 
difference of 0.2
0
C from baseline highlighted by the 2 pink lines for both therapeutic 
ultrasound (red) and sham ultrasound (blue). 
 
 
 
 
Graph 5.6: Thermal difference overtime for ultrasound and sham ultrasound in a healthy 
participant. 
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5.3.4 Normative study 2 discussion 
 
As can be seen during the first 2 minutes post therapeutic ultrasound the initial negative 
thermal difference reduces in magnitude, i.e.: an increase in Tsk from baseline (-0.8
0
C). 
This would be expected through the application of energy from the ultrasound 
treatment. It could also be attributed to the removal of the gel masking the cooling 
effects of the contact of both the gel and transducer and potentially, although minimal, 
to the mechanical effects of the friction of the transducer. 
 
However, from 2 minutes through to 4 minutes post ultrasound a marked increase in 
thermal difference to the region of -1.3
0
C is apparent, i.e.: a clinically important 
reduction in Tsk. This could be attributed to the cooling effect of the gel and contact 
with the transducer which are no longer masked by the friction from the actual 
application of the ultrasound. 
 
In comparison, with sham ultrasound, there is only a minimal increase in Tsk 
immediately post treatment which would substantiate this being attributable to the 
removal of the gel masking the cooling effects of the contact of both the gel and 
transducer and potentially, although minimal, to the mechanical effects of the friction of 
the transducer. Subsequently, significant cooling in the region of -1.3
0
C is evident from 
a minute post application for a longer duration of 6 minutes. The delay in cooling in the 
therapeutic ultrasound group could be attributed to the slight warmth patient’s often 
comment on during treatment due to the application of energy through therapeutic 
ultrasound. 
 
With therapeutic ultrasound, after 5 minutes through to 19 minutes a clinically 
important change of >0.2
0
C can be seen with a marked reduction in thermal difference, 
ranging from 0 to -0.4
0
C, i.e. a clinically important increase in Tsk. This can be 
attributed to the therapeutic effects of ultrasound through the application of mechanical 
energy. This is validated as no clinically important increase in Tsk is evident with sham 
ultrasound. This supports previous research which found that 3MHz ultrasound at 
1.5W/cm
2
 had to be applied for 2 minutes before the temperature increased at a depth of 
2.5cm in comparison to sham ultrasound which did not show any temperature increase 
over a 10 minute treatment (Hayes et al., 2004).  
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It is interesting to note the 5 minutes delay for the effects of ultrasound and the vascular 
response to become apparent, although it may be explained as a result of the initial 
cooling effects of the application of the gel and transducer. 
 
The duration of these effects are in the region of 20 minutes when the thermal 
difference demonstrates a trend to return to pre ultrasound levels by 30 minutes. This is 
rather longer than the approximate 12-20 minutes for the temperature at 1 cm depth to 
return to baseline during a repeated measures study comparing the use of gel versus a 
gel pad using 3MHz continuous ultrasound at 1W/cm
2
 using a 5cm
2
 transducer for 10 
minutes to an asymptomatic posterolateral ankle (Bishop et al., 2004). However, this 
may be attributed to the fact that less energy would have been applied and subsequently 
a lower maximum temperature achieved. Another study assessing the rate of 
temperature decay at 1.2cm depth of the medial gastrocnemius following a rise of a 
minimum of 5
0
C using 3MHz ultrasound at 1.5W/cm
2
 found that the temperature 
remained at greater than 3
0
C for a mean of 3.3 minutes before returning to baseline in 
18 minutes (Draper et al., 1995). However, it must be noted again that not only was the 
ultrasound at a lower intensity, but it was also undertaken on muscle which is less 
collagenous and subsequently a less efficient absorber of ultrasound energy when 
compared to tendon.  Of the little research available on the therapeutic effects of 
ultrasound on human tendon, an important paper researching the patellar tendon using 
3MHz continuous ultrasound at 1W/cm
2
 using a 5cm
2
 transducer found 50% of tendons 
had not returned to their baseline temperature after 20 minutes. They also found that 
tendon has a 3.45 faster rate of temperature increase than muscle and sustained vigorous 
heating for 120% longer than muscle (Chan et al., 1998). Subsequently, although it may 
be argued that the therapeutic window following a single ultrasound treatment is rather 
short; clinically ultrasound would be given on a regular basis and the accumulative 
nature following a course of treatment warrants further research. A multiple phase 
single case study evaluating the effectiveness of continuous 3 MHz using a 0.5 
transducer with gel comparing 0.25W/cm
2
 versus 2W/cm
2
 for 5 minutes to the 
tenoperiosteal junction of ECRBr of a symptomatic tennis elbow of 3 month duration 
was undertaken by the author (Williams, 2003). It was found that there was an 
accumulative functional improvement whilst the patient received 5 treatments over 10 
days for the higher intensity. This was supported by a paper which found a continuation 
in functional improvement, until follow up at 4 weeks, post 8 sessions of pulsed 1MHz 
ultrasound at 1W/cm
2 
on a tennis elbow sample (Davidson et al., 2001). Both the initial 
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delay in progress and continuation of improvement following ultrasound may be 
explained by the proposed pro-inflammatory nature of ultrasound promoting tissue 
healing which may take a number of weeks to complete.  
 
5.3.5 Normative study 2 conclusion 
 
In conclusion, 3 MHz ultrasound therapy using a 0.5 transducer with gel administered at 
2W/cm
2
 to the tenoperiosteal junction of ECRBr for 5 minutes causes a clinically 
important increase in Tsk which validates both the use of the developed novel protocol 
for the thermographic analysis of tennis elbow and the clinically important thermal 
effects of therapeutic ultrasound at these parameters for tennis elbow.  
 
This protocol is particularly useful as it uses a non-invasive infra-red thermal imaging 
camera rather than thermistor needles and is therefore more user friendly in a clinical 
environment.               
 
5.4 Normative studies summary of recommendations for the 
clinical trial 
 
 Thermal difference of the maximum Tsk for the ROI compared to the control. 
 A negative thermal difference of 0.350C was found for the normative study. 
 50% maximum PFG for the MDF recording of the unaffected arm comparable 
with the PFG reduction found in symptomatic tennis elbow patients. 
 MDF of ECRBr recorded during PFG for 45 seconds demonstrated significant 
fatigue. 
 The therapeutic ultrasound parameters used in this thesis demonstrate clinically 
important thermal effects. 
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CHAPTER 6: INTERNAL PILOT 
 
 
This chapter presents the methods utilised for both the internal pilot and clinical trial. 
An internal pilot of the first 20 tennis elbow patients was undertaken to test procedures 
and explore the range of values for thermography and MDF which were compared to 
the normative study 1 data. The determination of minimum clinically important changes 
and differences and the analysis of the stability of data throughout the clinical trial, to 
confirm the adequacy of sample size, are described. A single case study is also 
presented as an illustrative example. 
 
6.1 Methods 
 
The methods (6.1), ethics (6.2) and statistical methods (6.3) from this chapter apply to 
both the internal pilot and clinical trial as the data recorded from the first 20 patients 
from the clinical trial was utilised for the internal pilot. 
 
As there is no existing data on a tennis elbow population for either, the primary 
outcome measure, thermal difference or MPSF it is not possible to pre-specify either a 
minimal clinically important difference or the likely between-patients standard 
deviation. Based on a number of previously published trials (Knebel et al., 1999, Hagg 
and Milerad, 1997 and Albrecht et al., 1997) which used surface EMG measurements 
and sample sizes in the range 18 to 29 patients per group), a preliminary sample size of 
22 per group (in line with Hagg and Milerad, 1997) was chosen to give a robust analysis 
of the efficacy of the treatment interventions.  In Tonks et al. (2007) 76 tennis elbow 
patients were referred over 11 months.  Of these 35 (46%), were eligible for inclusion. 
This trial had an overall 25% drop-out rate. Through alterations in methodology, with 
an elite team of treating physiotherapists who could offer a wider choice of both 
treatment locations and times the drop-out rate should become more in line with other 
studies. Subsequently, the sample size was inflated to allow for a dropout rate of 
approximately 15%. Thus, with proportionate recruitment a realistic sample size of 
approximately 78 (26 patients per group) was randomised and expected to be recruited 
in 2 years.  
 
Knebel et al. (1999) studied the MPSF of a normal population with and without a 
forearm support band. With an ES of 0.9 they found a mean difference in MPSF of 
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12Hz with a SD of 14Hz. With a 90% statistical power and a significance level of 5% a 
sample size of 29 patients in each group was appropriate. Hagg and Milerad (1997) 
studied EMG magnitude in a normal population to study forearm muscular exertion 
during intermittent gripping. With an effect size of 1.0 they found a mean difference in 
EMG magnitude of ECRBr of 0.065 with a SD of 0.065. With a 90% statistical power 
and a significance level of 5% a sample size of 22 patients in each group was 
appropriate. Albrecht et al. (1997) studied therapy resistant patients with tennis elbow 
pre and postoperatively and with an effect size of 1.4 found a mean difference in EMG 
latency of ECRL of 6ms with a SD of 4.2ms. With a 90% statistical power and a 
significance level of 5% a sample size of 11 patients in each group was appropriate, 
although it should be noted that this is based on within group change which is usually 
larger than between group difference and subsequently requires a smaller sample. They 
also found a mean difference in polyphasic potential EMG magnitude of ECRBr of 13% 
with a SD of 12%. With a 90% statistical power and a significance level of 5% a sample 
size of 18 patients in each group was appropriate. 
 
Subsequently, an internal pilot was used to evaluate minimum clinically important 
differences. A comparative study of the baseline values of the first 20 tennis elbow 
patients with the normative study (n=20) was undertaken to explore the range of values 
for thermography and MDF in the tennis elbow population. The range of values at 
baseline was used to determine what might be a minimum clinically important 
difference between groups (i.e. difference important to patients not to miss). The first 20 
patients were analysed up to the 6 week endpoint with the analyst blind to group codes. 
To confirm that a sufficient sample size had been recruited the stability of data was 
analysed to ensure that the group recruited was not considerably smaller or larger than 
necessary. The study was a prospective randomised, assessor-blinded trial. 
 
Barr et al.’s (2009) review of Tonks et al. (2007) highlighted the importance of 
methodological quality and facilitated the methodological development of the current 
research. Furthermore, it emphasised that it is imperative to publish comprehensive 
information and data in order to allow a more valid review of future research. In rebuttal 
extensive baseline data had been taken but only mean age had been reported, in contrast 
to the reviewers stating otherwise, without gender or duration, with the outcome 
measures. Likewise, they state that the duration and frequency of the exercise 
programme is not detailed. Although not explicitly reported, it was described as the 
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exercise programme devised by Pienimaki et al. (1996) and referenced. Outcome 
measures were assessed at baseline, 1, 4 and 7 weeks and 6 months but again not 
reported. The loss to follow up was very high at 6 months making data analysis 
unfeasible with such a low and unevenly distributed sample. An intention to treat 
analysis was undertaken but again not reported. In retrospect in defence, some of the 
under reporting may have been done unintentionally due to trimming to meet the strict 
word limit on publication. Due to the nature of the interventions including injection and 
exercise the patients could not be blinded and as there were no qualified physiotherapy 
injectors, other than the researcher, at the time of the research the therapist was unable 
to be blinded either. However, within these constraints patients were randomly allocated 
with concealed allocation to prevent bias at this stage. In this current PhD work, due to 
the research being undertaken Trust wide over a number of sites with injectors now on 
all sites an elite team of trained physiotherapists have undertaken the treatments, so 
although patients and physiotherapists are unable to be blinded due to the nature of 
treatment it has enabled the assessor to be blinded to treatment allocation and 
consequently improve the methodological quality of the current research work presented 
in this thesis. 
 
6.1.1 Sample 
 
The sample of convenience comprised of any patient referred by their GP, with tennis 
elbow, to the Musculoskeletal Clinical Assessment and Treatment Service (MSK 
CATS) or Physiotherapy Department of Ashton, Leigh and Wigan PCT or Orthopaedic 
Department of Wrightington, Wigan and Leigh NHS Trust. Members of staff were also 
eligible for inclusion through the self-referral physiotherapy scheme. All patients with 
tennis elbow were included from both those who presented with a first episode of 
symptoms to recalcitrant cases in both acute and chronic stages. Subsequently, this 
would allow improved generalisation of the study’s findings to the general tennis elbow 
population as a whole.  
 
The selection criteria for tennis elbow were based on those of Cyriax (1982) and 
Stratford et al. (1993). All patients were assessed by the researcher for consideration for 
inclusion in the study subject to the following eligibility criteria: 
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6.1.1.1 Inclusion Criteria 
 
Patients had to present with both of the following criteria: 
Pain reproduced on palpation of the common extensor origin. 
Pain reproduced on resisted wrist extension with the elbow extended. 
 
6.1.1.2 Exclusion Criteria 
 
Vulnerable patients: children under 18 or people with learning difficulties 
Cervical spine involvement. 
Previous elbow surgery. 
Other significant pathology involving the upper quadrant (e.g.: significant dupytrens 
contracture which would prevent gripping the dynamometer and subsequently limit grip 
strength causing spurious data to be collected).  
Bilateral symptoms 
Physiotherapy or steroid injection, for the presenting condition, within the previous 6 
months. 
Contraindications for injection therapy (Ashton, Leigh and Wigan Community 
Healthcare Patient Group Direction for the administration of triamcinolone acetonide 
version 1/2008): 
Heart, liver or renal failure. 
Children under 18 years. 
Haemarthrosis /recent trauma. 
Joint, local or systemic infection. 
Cancer/ HIV/ hepatitis. 
Epilepsy. 
Hypersensitivity to local anaesthetic. 
Prosthetic joint/unstable joint. 
Avascular area. 
Poorly controlled diabetes. 
Immunosuppressed. 
Anticoagulant therapy. 
Psychogenic patient. 
Bleeding disorders. 
Pregnancy/ breast-feeding. 
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 Concurrent oral steroids. 
 Known osteoporotic. 
 Allergies. 
 
The researcher assessed all patients using a standardised subjective and objective 
assessment proforma developed specifically for this research (Appendix 11.5). If the 
patient was eligible for inclusion in the study written informed consent was sought 
(Appendix 11.7). The patient would have received a patient information sheet with their 
appointment letter to allow them to have sufficient time, minimum 3 days, to consider 
participation in the research (Appendix 11.6). For those consenting, baseline study data 
were collected on a standardised data collection sheet (Appendix 11.11) and 
accumulative data collection sheet (Appendix 11.12) which included recording details 
of possible extraneous variables and potential prognostic factors. Patients were 
requested to refrain from altering any ‘treatment’ that they were already undertaking 
such as NSAID or brace use and not to divulge what treatment they have received to the 
researcher at review appointments.  
 
6.1.2 Randomisation  
 
Patients were randomised into one of the 3 treatment arms according to randomly 
permuted blocks selected by a computer random-number generator. The randomisation 
process was undertaken by a non-clinical academic third party and the treatment group 
details were sealed in a series of sequentially numbered, opaque, envelopes by Research 
and Development support staff. The envelopes were opened by the patients after 
baseline 1 data collection under supervision of administrative and clerical support who 
then arranged the appropriate treatment and review appointments. This enabled their 
initial treatment appointment to be arranged promptly after baseline 2 data collection.  
 
6.1.3 Blinding 
 
The researcher remained blinded to the randomisation of patients. The physiotherapist 
who treated the patients recorded all treatments given and any adverse reactions or side-
effects on the treatment diary sheet (Appendix 11.10). If the treatment had to be altered 
from protocol in anyway the physiotherapist informed the researcher following the 6 
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week end point data collection. As is common in trials of physical interventions it was 
not possible to blind patients from their treatment in this trial.   
 
To evaluate the blinding process and negate any potential bias the researcher 
documented which intervention, including reasons; they thought the patient had 
received at both the 10 day and 6 week reviews which were reviewed at the 6 week end-
point. 
   
6.1.4 Treatments  
 
The 3 treatment groups were injection therapy, ultrasound and physiotherapy 
rehabilitation programme. All are part of normal clinical practice and were undertaken 
by a select team of experienced physiotherapists in any of the Ashton, Leigh and Wigan 
Community Healthcare’s physiotherapy or MSK CATS departments. Although the use 
of a team of treating physiotherapists may be considered disadvantageous due to the 
potential increase of variability in the study it was strongly negated by the advantages: 
 
It enabled a more robust study as the author, who undertook all assessments and data 
collection, remained blinded to the treatment and therefore any potential bias negated. 
The use of more than one therapist meant that those patients who needed further 
treatment at the 6 week end point remained under the care of the same therapist 
enabling continuity of care, which follows normal clinical practice more closely. A 
therapist on each of the 3 sites within the Trust facilitated recruitment and retention as 
the patient could be seen at a more convenient locality to either their home or work. The 
treatment protocols were all standardised with the physiotherapists prior to the 
commencement of the study. 
6.1.4.1 Injection Therapy 
 
The experienced physiotherapist injector, who had undertaken a Diploma in Injection 
Therapy, used an aseptic technique according to the Association of chartered 
physiotherapists in orthopaedic medicine (ACPOM) guidelines (1999). The patient was 
½ lying with the elbow flexed to 90 degrees, forearm supinated and supported on a 
pillow. 
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The 25G needle was inserted in line with the cubital crease perpendicular to the lateral 
epicondylar facet to caress the bone (Figure 6.1). The solution of 10mg of kenalog 40 
(steroid) with 0.75ml of lidocaine 2% (local anaesthetic) was peppered around the 
tenoperiosteal junction (Saunders 2002).  
 
 
 
Figure 6.1: Injection technique. 
 
Recruitment started in June 2007 and 4 patients received injections as per protocol. 
However, shortly after the commencement of the clinical study the Primary Care Trust’s 
patient group directions were reviewed on account of new government guidelines 
effecting a change in practice not allowing mixing of drugs. This meant that 0.75 ml of 
lidocaine would be peppered around the tenoperiosteal junction followed by peppering 
of 0.25ml of kenalog. This would not only have the effect of increasing the length of the 
procedure but also any potential effect of twice the amount of needle peppering into the 
area. Subsequently, practice was changed accordingly to the use of a solution of 10mg 
adcortyl only. Both adcortyl and kenalog are of the same drug triamcinolone acetonide 
in different dosages and have duration of action in the region of 6 weeks (Saunders 
2002). Due to the fact that it would be difficult to effectively pepper 0.25ml of kenalog 
the more dilute 1ml of adcortyl became the drug of choice. From clinical experience 
patients find this a relatively pain free procedure and the only disadvantage of not using 
the local anaesthetic is that the therapist is unable to retest the patient’s objective 
markers immediately following the injection to assess outcome. 
 
 The patient was then requested to relatively rest for 10 days, i.e.: to avoid excessive 
elbow use in aggravating conditions as per guidelines (Saunders, 2002).  
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6.1.4.2 Ultrasound 
 
The ultrasound treatment was performed in a standardised manner. The patient received 
6 treatments of ultrasound during the first 2 to 3 weeks of treatment ensuring treatment 
was administered as a minimum of twice weekly, as per normal clinical practice. The 
patient was in ½ lying with the elbow flexed to 90 degrees, forearm supinated and 
supported on a pillow. Continuous 3 MHz ultrasound therapy using a 0.5 transducer 
with gel was administered at 2W/cm
2
 to the tenoperiosteal junction for 5 minutes 
(Figure 6.2). The EMS Medi-Link system was checked/ calibrated regularly as per 
departmental procedure.   
 
 
 
 
Figure 6.2: Ultrasound application. 
6.1.4.3 Physiotherapy rehabilitation 
 
The physiotherapist was an experienced clinician. The physiotherapy exercise 
rehabilitation followed the stretching and progressive strengthening exercise programme 
as defined by Pienimaki et al. (1996). Patients started step one immediately. The 
appropriate exercises were taught and the patient given an exercise sheet (Appendix 
11.15). Compliance was recorded on the treatment diary sheet. Patients were advised 
that each exercise should be pain free and was to be done ten times slowly to the count 
of eight. The whole exercise programme was then repeated three times prior to 
stretching both wrist flexors and extensors. The exercises were reviewed on 2 further 
occasions and progressed accordingly.  
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6.1.5 Data collection 
 
All data collection at the review appointments was undertaken by the researcher in a 
standardised manner to ensure consistency throughout. 
  
The primary outcome measure was thermographic analysis of Tsk over the ECRBr 
origin which enabled an indirect measure of inflammation through temperature changes. 
  
Secondary measures were:  
 
 PFG which provided a measure of strength  
 surface EMG MDF during PFG which enabled a direct measure of extensor 
muscle fatigue. 
 PRTEE which provided a standardised, quantitative description of pain and 
functional disability. 
 patient preference questionnaire which provided a qualitative impression of 
patient treatment preference overtime.  
 
TIME 
POINTS 
OBJECTIVE 
NUMBER 
DATA 
ANALYSED 
JUSTIFICATION 
Baseline 1  All baseline data To check homogenous groups at 
baseline 
Baseline 2  Change from 
baseline 1 
Evaluate the stability of the patient’s 
condition and any evidence of 
spontaneous healing 
10 days 1,2 and 4 Change from 
baseline 1 
Evaluate any immediate treatment effect 
6 weeks 3 Change from 
baseline 1 
Identify which treatment is sustainable 
in the short term 
6 months 3 Change from 
baseline 1 
Identify which treatment is sustainable 
in the intermediate term 
 
Table 6.1: Justification of time point data collection. 
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These were recorded at baseline 1 and baseline 2 (week 1 to 2) prior to treatment, 10 
days (after commencement of treatment), 6 weeks and 6 months (Table 6.1). Data was 
collected for both the affected and unaffected arms.  
 
The primary trial endpoint was at 6 weeks. If a patient was not asymptomatic (i.e.: 
therapy-resistant patients) at this time alternative treatment was made available as 
appropriate and recorded on the treatment diary sheet. Only those patients who 
remained in their original treatment group as per protocol were reviewed at 6 months. 
 
The patients filled in the PRTEE (Appendix 11.8) at every data collection review 
without assistance. The Patient preference questionnaire (Appendix 11.9) was also filled 
in at the 10 day, 6 week and 6 month reviews. Clarification was only given on the first 
assessment, if required. The thermographic measurement and EMG studies were then 
taken in the standardised manners as previously described in Chapter 4.1 and 4.3 
respectively. The unaffected arm was assessed first. 
 
6.2 Ethics 
 
This study conformed to the declaration of Helsinki and ethical approval was gained 
from both Wrightington, Wigan and Leigh Regional Ethics Committee (WWL REC) 
(appendix 11.13) and FHEC UCLan (appendix 11.14). All research management and 
governance was in place from Ashton, Leigh and Wigan Primary Care Trust before 
commencement of the study.   
 
No patients were from vulnerable groups, e.g.: children under 18 or people with 
learning difficulties. Patients did not receive any payment for inclusion in this study. 
Written informed consent, using the Trust consent form, was requested from all patients 
who were eligible for inclusion into the study. Each patient received the patient 
information sheet. Patients were given a minimum of 3 days to consider if they wished 
to participate and were given the opportunity to ask any questions. Subjects were 
informed that participation in the study was voluntary and that they were under no 
obligation. They had the right to withdraw at any stage without justification of their 
decision or penalty to any future treatment. 
 
All interventions were part of clinically accepted ‘normal’ care and the use of strict 
 83 
eligibility criteria minimised any potential risks. Therefore, subjects did not incur any 
further risks or potential hazards from their inclusion in the study. Their participation 
was unlikely to cause any additional discomfort or distress. Potentially beneficial 
treatment was not withheld from certain subjects according to their randomisation. 
Patients were offered the most appropriate physiotherapeutic or orthopaedic treatment 
after the six-week end point, if required.  
 
Confidentiality of personal records was maintained: stored on Trust sites as per Trust 
policies. Any data leaving Trust premises for analysis was only identifiable by the 
patient’s unique code which was documented on the front of the patient’s personal NHS 
hospital records. No patient names were stored outside of Trust premises. All patient 
data was kept confidential and individual patients were not identifiable from any 
publication of this study.  
 
6.3 Statistical Methods 
 
6.3.1 Data analysis 
 
Descriptive statistics were used to illustrate any important features of the baseline data: 
The means and standard deviations of all outcome measures and percentages for any 
categorical variables (e.g. sex, therapy resistance) were shown. 
 
Changes from baseline data were analysed using an ANOVA with the Scheffe post-hoc 
test for multiple comparisons as an intention to treat analysis (ITT) throughout the trial. 
The Scheffe was chosen over the Bonferonni as the latter is more aggressive and, 
therefore, although it would not find a false positive it has the potential to miss subtle 
clinically important differences.  
 
Patient’s data of those who withdrew or DNA was included using the last observation 
carried forward (LOCF). For all patients who DNA every effort was made to contact 
them in order to arrange a convenient appointment for follow-up. The data was also 
analysed as per protocol with LOCF and with exclusion of patients who had either 
withdrawn or had missing data to check the sensitivity of the findings to the 
‘assumptions’ about any data from patients who drop-out: i.e.: the assumption that the 
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patients who DNA are better. For all analyses the significance level was set a priori at 
5% ( <0.05) and 95% CIs were reported. 
 
The patient preference questionnaire was analysed qualitatively by categorising answers 
to identify themes for each treatment group and data reported as percentages for each 
theme. 
 
6.4 Pilot results 
 
The internal pilot was presented as a poster at the British Elbow and Shoulder Society’s 
20
th
 annual scientific meeting held at UCL, London, in June 2009 (Appendix 11.17). 
 
6.4.1 Pilot sample 
 
The 20 tennis elbow patients were randomised by a third party prior to the onset of the 
clinical trial, into 3 treatment arms in equal numbers: injection (n= 7), ultrasound (n=6) 
and exercise rehabilitation (n=7). 
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Figure 6.3: Patient flowchart through the study up to the 6 week endpoint. 
 
As can be seen from the flowchart (Figure 6.3) 15% of patients (n=3) had withdrawn 
prior to the 6 week endpoint and a further 10% of patients (n=2) DNA their 6 week 
review. Subsequently, 30% of patients (n=6) required further treatment at the 6 week 
endpoint leaving the remaining 55% of the patient population (n=11) to be offered a 6 
month review. 
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6.4.2 Pilot descriptive statistics 
 
The healthy subjects were age and gender matched to the presenting tennis elbow 
population (Table 6.2).  
 
 Patients Normals 
Gender  F 11 11 
              M 9 9 
Mean age (range)  47yrs (23-61) 40.6yrs (27-56) 
Dominance R    * 18 16 
 
 
Table 6.2: Descriptive statistics for the internal pilot. 
 
* It interesting to note that the 2 patients who were left handed both complained of 
tennis elbow affecting their right nondominant elbows. 
 
 The descriptives of the 20 patients in the internal pilot are shown in table 6.3. 
 
Mean symptom duration 
(range) 
7 months  
(0.5-24) 
Dominant affected 11 
Previous treatment         * 3 
NSAID 2 
Analgesia use 3 
Brace use 4 
Aggravating occupation 13 
Aggravating hobbies    ** 8 
Positive Smoking status 2 
Previous smoker 3 
 
Table 6.3: Descriptive statistics for the internal pilot patients. 
 
* Previous treatment included repeated injections, exercise and ultrasound. 
** Aggravating hobbies included golf, fishing, squash, gardening, painting, 
dressmaking and playing the guitar. 
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6.4.3 Minimum clinically important differences 
 
 
The aim of any clinical research is to evaluate the effectiveness of treatment and 
although statistical significance is indispensable, alone it may be insufficient to 
establish a difference in effect between 2 treatment approaches. The clinical importance 
of any effect must also be identified to ensure that results are clinically relevant to 
patient care. The minimum clinically important change (MCIC) is the threshold value of 
a change which is considered meaningful and worthwhile to a patient such that if it was 
necessary, and if the patient had the choice, they would consider repeating the treatment 
(Copay et al., 2007). The MCIC is the within group change and the MCID is the 
difference between change in 2 or more groups which is used for the interpretation of 
treatment effects in a randomised trial.   
 
However, determination of a MCIC is difficult, especially when the subjective nature of 
pain, for example, is considered for which one has to rely entirely on the patient for 
assessment which is further exacerbated due to the large variation in patient 
interpretation of measurement scales (Farrar et al., 2001). Secondly, a mismatch 
between clinical measures and patient evaluation of improvement, in terms of pain and 
disability, do not always correspond. The determination of the MCID is even more 
difficult; however it is usually smaller than the MCIC which therefore requires a larger 
sample, particularly if all the interventions under investigation are potentially effective.  
 
Determination of a MCIC can be derived from 2 different methods; anchor-based and 
distribution-based. The former compares the change in a patient-reported outcome with 
a measure such as a global assessment rating. Ideally, an established association 
between the two should exist so that meaningful inferences can be made. Distribution-
based approaches compare the change in a patient-reported outcome with a measure of 
variability such as the ES, the standard error of measurement (SEM) or smallest 
detectable change (SDC), with reliance on either of the latter ensuring statistical 
soundness. However, the purpose of a MCIC is to distinguish clinical importance from 
statistical significance which may potentially be limited due to the dependence on the 
variability of the scores within a sample. The changes in scores corresponding to the 
small ES, of 0.2, is considered the MCIC (Copay et al., 2007). However, others would 
argue that 0.2 is small for a MCID with very few trials having sufficient power to 
achieve a sample size in the region of 400 patients per group. 
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 Mean (SD) 
 Tennis elbow Patients Normative participants 
 Affected Unaffected Dominant Nondominant 
Thermal difference 
(
0
C) 
0.4 (0.42) -0.2 (0.46) -0.3 (0.51) -0.4 (0.43) 
MPFS 10sec (Hz) 130.2(14.42) 128.7(17.71) 124.1(12.24) 121.3(15.19)  
MPFS 35sec (Hz) 111.6(10.99) 102.2(20.21) 102.4(10.95) 
 
100.7(17.97) 
MDF shift (Hz) -18.6 (13.15) -26.5 (13.45) -21.7 -20.6 
Grip strength (kg) 17.4 (12.5) 31 (13.5) 39.9 (13.6) 37.2 (9.5) 
 
Table 6.4: Internal pilot and normal baseline outcome measures: mean (SD). 
 
A reduction in Tsk of 0.2
0
C can be accepted as a MCIC. If the MCIC is calculated using 
effect size, using the baseline SD of 0.4 in table 6.5 and multiplying by 0.2, (a small 
effect size), this gives a MCIC of  0.1
0
C. The body is generally accepted as being 
thermally symmetrical. Selfe et al. (2008) concluded from a narrative literature review 
that a 0.5
0
C Tsk difference in asymmetry at the anterior knee is clinically important 
which is inline with the mean Tsk difference of 0.6 
0
C found between the affected and 
unaffected elbows in table 6.4. Vardasca et al. (2007) evaluated the thermal symmetry 
in the extremities of normal subjects, using high resolution digital thermal imaging 
technology, in which a maximum Tsk difference of 0.16
0
C was reported on regional 
views which is in line with the 0.1
0
C difference found between the normative 
participants elbow shown in table 6.4. However, both Selfe et al. (2008) and Vardasca 
et al. (2007) have assessed the difference between the mean temperature for left and 
right limbs whereas the thermal protocol utilised in this research is the mean thermal 
difference found between the ROI and an ipsilateral control. When the baseline Tsk are 
considered, it is interesting to note that the patient’s affected elbow has a mean positive 
thermal difference when compared to either the patient’s unaffected elbow or either of 
the normal elbows (Table 6.4). A mean difference of 0.6 
0
C is found between the 
affected and unaffected elbows and an even greater 0.75
0
C when compared to the 
normative data. Subsequently, to accept a MCIC as 0.5
0
C equates to an improvement in 
return of temperature in the region of 2/3rds which would be questionable at the very 
least to be classed as minimal. A reduction in Tsk of 33% or 0.2
0
C would be more 
acceptable. Furthermore, the 0.2
0
C MCIC is supported by Binder et al. (1986) who 
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evaluated the maximum temperature at the lateral elbow of 50 patients with tennis 
elbow. Using the data provided to calculate the effect sizes, with a SD of 0.93
0
C in the 
morning and 0.72
0
C in the afternoon this gives MCICs of 0.19
0
C and 0.14
0
C 
respectively. It is interesting to note when considering the SD there is less variability in 
the current research in comparison to that of Binder et al. (1986) which can be attributed 
to both the advances in thermal image technology and the robust protocol developed. 
Thomas et al. (1992), who applied the methods of Binder et al. (1983) on 35 cases of 
tennis elbow, reported a SD of mean elbow spot temperature of 0.88
0
C which gives a 
MCIC of 0.18
0
C. A MCIC of 0.2
0
C is also larger than the SDD of 0.03
0
C reported by 
Uematsu et al. (1988), although as suggested by Selfe et al. (2008) this is somewhat 
ambitious considering this was using predigital thermal technology.            
 
It is also of interest that the MDF shift of the patient’s affected elbow is 30% less than 
the patient’s unaffected elbow. The difference between the affected and unaffected side 
may be attributable to the fact that the patient was performing a PFG and was able to 
reduce their grip if they should experience any pain during the test. Whereas, in 
comparison, on the unaffected arm they maintained 50% of their maximum grip 
strength by virtue of having visual feedback from the dynamometer dial.  
 
A 38% change in MDF of 3Hz can be accepted as a MCIC. There is a lack of previous 
work available to identify a MCIC with MDF. If the MCIC is calculated using effect 
size, using the baseline SD of 13.1 in table 6.5 and multiplying by 0.2, (a small effect 
size), this gives a MCIC of 3Hz.  
 
An increase in PFG of 3kg can be accepted as a MCIC. If the MCIC is calculated using 
effect size, using the baseline SD of 12.5 in table 6.5 and multiplying by 0.2, (a small 
effect size), this gives a MCIC of 2.5kg which is larger than the SDD of 1.4kg Smidt et 
al. (2002) reported. On validating outcome measures for tennis elbow Stratford et al. 
(1987) reported a baseline SD of 10.37kg and 11.27kg for a failures and successes 
comparison which gives MCICs of 2.1kg and 2.25kg respectively, using effect size 
calculations. This is also supported by Abbott (2001) who evaluated the effect of 
mobilisation with movement on PFG in patients with tennis elbow. They reported a 
baseline SD of 12.3kg which gives a MCIC of 2.5kg and described a 17% increase in 
PFG to be clinically significant. The PFG of the affected elbow was 56% less than the 
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unaffected maximum grip strength and subsequently a 22% increase in PFG of 3kg can 
be accepted as a MCIC. 
 
For PRTEE pain and function a 25% reduction in pain or increase in function which 
equates to a reduction in score of 5 points could be classed as a MCIC. If the MCIC is 
calculated using effect size, using the baseline SD in table 6.5 for pain = 9, function 
=10.2 and total =18.6, calculated by multiplying by 0.2, (a small effect size), this gives a 
MCIC of 2, 2 and 4 respectively. However, due to the scoring protocol of 5x items for 
pain, 10x items for function which is then divided by 2 so that both pain and function 
subscales contribute 50% to the total this would equate to a mean change for each item 
of 0.4 which is not only less than the minimum change detectable in score of 1 but also 
less than the SEM of 0.6 reported by Overend et al. (1999) for the PRFEQ. In contrast, 
1 SEM may be used as the yardstick for true change (Copay et al., 2007) which equates 
to a 25% reduction in pain and disability if the mean scores at baseline for PRTEE are 
considered: Pain subscale = 21.3, function subscale = 17.8 and total 39.2 which, due to 
the scoring protocol, equate to a mean individual score for each item of 4.3 for pain, 3.6 
for function and 3.9 for total. Furthermore, if the mean for each PRTEE item is taken as 
4 this MCIC is supported by data using an anchor-based method from the evaluation of 
the clinical importance of changes in chronic pain intensity measured on an 11-point 
numerical rating scale (Farar et al., 2001) who reported that a reduction in 1 point or a 
percent change of -14.5% would be classed as minimal, much or very much improved 
on a standardised 7-point patient global impression of change. This was supported by 
Bot et al. (2005) who reported that although the MCIC of the modified pain free 
function index, which has a maximum score of 100, was unknown in most cases the 
MCIC appears to be in the region of ½ a SD, i.e.: an ES of 0.5, which they calculated as 
10 points. Subsequently, the MCIC for PRTEE pain or function subscale can be 
accepted as a reduction in score of 5 and the MCIC for PRTEE total can be accepted as 
10.  
 
6.4.4 Patient pilot study analysis 
 
 
A repeated measures ANOVA was used with alpha set at p< 0.05 with 95% confidence 
levels.  
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For the sample population as a whole no statistical differences were found at any time 
interval for the patient’s unaffected arm and are not reported on further. Similarly, no 
statistical difference was found between baseline 1 and baseline 2 for any outcome 
measure which demonstrates the stability of the patient’s condition and suggests that 
there is no evidence of spontaneous healing in the study population.   
 
Table 6.5 shows the outcome measures means and SD overtime of the affected elbow. 
 
 Mean (SD) 
 Baseline 1 Baseline 2 10 days 6 weeks 
Thermal difference (
0
C) 0.4 (0.4) 0.3 (0.6) -0.03 (0.5) 0.1 (0.5) 
MPFS shift 10s-35s (Hz) -18.6 (13.1) -20.1 (9.1) -18.5 (11.5) -23.3 (13.4) 
PFG (kg) 17.4 (12.5) 16.8 (11.2) 21.4 (13.9) 21.6 (13.8) 
PRTEE pain 21.2 (9.0) 21.5 (9.8) 17.9 (9.9) 12.8 (9.0) 
PRTEE function 17.2 (10.2) 18.5 (11.1) 13.6 (9.3) 10.1 (8.9) 
PRTEE total 38.4 (18.6) 40.0 (20.0) 31.5 (18.4) 22.9 (17.0) 
 
Table 6.5: Outcome measures means (SD) overtime for the affected elbow. 
 
6.4.4.1 Thermal difference 
 
Mean change between baseline 1 and baseline 2 was -0.09 
0
C p= 0.5 with a 95% CI  
(-0.2 to 0.38) 
Mean change between baseline and 10 days was -0.35 
0
C p= 0.07 with a 95% CI 
(-0.04 to 0.74) 
Mean change between baseline and 6 weeks was -0.18 
0
C p= 0.2 with a 95% CI  
(-0.13 to 0.48) 
 
This analysis of the patient study population demonstrates no statistically significant 
reduction at any time intervals. A MCIC (0.2
0
C) in Tsk of the ROI at 10 days was found 
although it was not maintained through to the 6 week endpoint.  
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6.4.4.2 Median frequency shift 
 
Mean change between baseline 1 and baseline 2 was -3.8Hz p= 0.215 with a 95% CI  
(-2.7 to 10.3) 
Mean change between baseline and 10 days was -3.7Hz p= 0.37 with a 95% CI  
(-5.2-12.7) 
Mean change between baseline and 6 weeks was 0.2Hz p= 0.96 with a 95% CI  
(-9.3-8.9) 
 
This analysis of the patient study population demonstrates no statistical changes were 
found for median frequency shift at any time intervals, although a MCIC (3Hz) was 
found at both baseline and 10 days which was not maintained through to 6 weeks. 
 
6.4.4.3 Pain free grip strength 
 
Mean change between baseline 1 and baseline 2 was -2.7kg p= 0.08 with a 95% CI  
(-5.9 to 0.4) 
Mean change between baseline and 10 days was 0.4kg p= 0.80 with a 95% CI  
(-3.1 to 3.9) 
Mean change between baseline and 6 weeks was 1.5kg p= 0.45 with a 95% CI  
(-2.8 to 5.9) 
 
This analysis of the patient study population demonstrates no statistical change or 
MCIC (3kg) was found for PFG at any time intervals. 
 
6.4.4.4 Patient rated tennis elbow evaluation total 
 
Mean change between baseline 1 and baseline 2 was 1.1 p= 0.59 with a 95% CI    
(-5.3 to 3.2) 
Mean change between baseline and 10 days was -5.2 p= 0.35 with a 95% CI  
(-6.6 to 17.1) 
Mean change between baseline and 6 weeks was -14.9 p= 0.003 with a 95% CI  
(6.4 to 23.5) 
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This analysis of the patient study population demonstrates a statistically significant 
reduction in pain and disability at the 6 week endpoint with treatment of either injection, 
ultrasound or exercise. A MCIC (10) was found at 6 weeks only.   
 
6.4.5 Treatment group analysis 
 
Treatment group analysis of the pilot data was undertaken to refine the data analysis and 
presentation of data plans for the clinical trial. A repeated measures ANOVA comparing 
all groups found no statistically significant differences between the 3 treatment groups 
for any of the outcome measures for either the affected or unaffected elbows. This result 
in the affected elbow was expected due to the small study population and subsequent 
lack of power of the internal pilot. 
 
However, it is interesting to consider the means profiles of the affected elbow to 
identify any early trends demonstrable within the internal pilot. Obviously, any 
conclusions must be regarded with caution due to the small numbers involved and 
subsequently may not be comparable to the tennis elbow population as a whole. 
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6.4.5.1 Thermal difference 
 
Graph 6.1: Means profile plot for thermal difference (
0
C). 
 
The thermal difference profile plot (Graph 6.1) demonstrates that all 3 treatments have 
an effect of reducing the Tsk by a MCIC (0.2
0
C) in the ROI at 10 days which is most 
marked in the injection group and which is maintained in this group through to the 6 
week endpoint. With both the ultrasound and exercise groups despite the initial 
reduction in Tsk at 10 days both rise to approach near pre-treatment levels at 6 weeks.  
 
On statistical analysis of the injection group alone by a repeated measures ANOVA. 
The mean change between baseline and 10 days was -0.7 
0
C p =0.005 with a 95% CI 
(0.35- 1.05) 
The mean change between baseline and 6 weeks was -0.64 
0
C p =0.007 with a 95% CI 
(0.29- 0.99) 
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This demonstrates that the MCIC and statistically significant immediate reduction in 
Tsk of the ROI at 10 days is maintained through to the 6 week endpoint in the injection 
therapy group.  
   
6.4.5.2 Median frequency shift  
 
Graph 6.2: Means profile plot for median frequency. 
 
The MDF shift profile plot (graph 6.2) demonstrates that all 3 treatments have an effect 
on reducing the ECRBr fatigue at 10 days which is most marked in the exercise group 
where a MCIC (3Hz) is found. The fatigue increases at the 6 week endpoint in all 
treatment groups to varying degrees and although to a markedly lesser extent in the 
exercise group a MCIC is no longer evident. The fatigue in the ultrasound group returns 
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to near baseline levels and returns to a markedly greater than baseline level in the 
injection group.  
 
6.4.5.3 Pain free grip strength 
 
Graph 6.3: Means profile plot for pain free grip strength. 
 
The PFG profile plot (Graph 6.3) demonstrates that there was a MCIC (3.4kg) increase 
in PFG for the injection group only which was maintained through to the 6 week 
endpoint. The PFG reduced for the ultrasound group by a MCIC and by less for the 
exercise group at 10 days prior to returning to near baseline levels at the 6 week 
endpoint.  
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6.4.5.4 Patient rated tennis elbow evaluation total 
 
 
Graph 6.4: Means profile plot for patient rated tennis elbow evaluation total. 
 
The PRTEE total profile plot (Graph 6.4) demonstrates a reduction in pain and 
disability in all treatment groups with a MCIC (10) found in the injection group at 10 
days and both the injection and exercise group at the 6 week endpoint.  
 
6.5 Stability of grouped data 
 
To confirm that a sufficient sample size had been recruited the stability of data was 
analysed throughout the clinical trial on an ongoing basis. The stability of the data was 
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determined by calculating the cumulative means and the cumulative standard deviations 
of the change. The change in SD for each consecutive patient was calculated and 
described as a percentage change of the cumulative mean: 
 
Percentage change in SD = SD (n+1) - SD (n) x 100 
                   Cumulative mean (n+1)  
 
When the SD varied in absolute terms by less than 5% of the cumulative means values 
for at least 3 consecutive patients it was accepted that the data had stabilised and a 
sufficient number of patients had been recruited (Selfe et al., 2006). If the sample size is 
too small the variability may be too large for an, albeit subtle, MCIC to be detected. 
6.5.1 Methods 
 
Both the thermal difference primary outcome measure and MDF shift at baseline and 
the 6 week endpoint was considered for each of the 3 treatment arms. The cumulative 
means and SDs of the change were plotted against patient number for visual analysis.    
6.5.2 Results 
 
 
 
Graph 6.5 Thermal difference cumulative mean and SD of thermal difference  
for the injection group. 
 
As can be seen in graph 6.5 the injection group data has stabilised as the changes of the 
cumulative SD of difference and cumulative mean difference show a trend around the 
parallel over the last 11 consecutive patients with < 0.05 
0
C difference.  
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Graph 6.6 Thermal difference cumulative mean and SD of difference for the 
exercise group. 
 
As can be seen in graph 6.6 the exercise group data has stabilised as the changes of the 
cumulative SD of difference and cumulative mean difference have become parallel over 
the last 3 consecutive patients. The cumulative SD of difference is significantly larger 
(0.3
0
C) than the cumulative mean difference.   
 
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Patient number
T
h
e
rm
a
l 
d
if
fe
re
n
c
e
cumulative sd of difference
cumulative mean difference
 
 
Graph 6.7 Thermal difference cumulative mean and SD of difference for the 
ultrasound group. 
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As can be seen in graph 6.7 the ultrasound group shows greater variability and the 
cumulative SD of difference and cumulative mean difference did not show any 
convincing trend towards stabilisation in the ultrasound group until the last 2 patients.  
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Graph 6.8 Median frequency shift cumulative mean and SD of shift for the 
injection group. 
 
 
If the secondary outcome measure MDF shift is considered. As can be seen in graph 6.8 
the injection group data has stabilised as the changes of the cumulative SD of shift and 
cumulative mean shift have become parallel over the last 11 consecutive patients. The 
cumulative SD of shift is significantly larger (15Hz) than the cumulative mean shift.  
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Graph 6.9 Median frequency shift cumulative mean and SD of shift for the 
exercise group. 
 101 
As can be seen in graph 6.9 the exercise group data has stabilised as the changes of the 
cumulative SD of shift and cumulative mean shift show a trend around the parallel over 
the last 6 consecutive patients. The cumulative SD of shift is significantly larger (20Hz) 
than the cumulative mean shift.   
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Graph 6.10 Median frequency shift cumulative mean and SD of shift for the 
ultrasound group. 
 
Again as can be seen in graph 6.10 the ultrasound group data shows a trend towards 
stabilisation over the last 7 consecutive patients. The cumulative SD of shift is 
significantly larger (15Hz) than the cumulative mean shift.   
 
 
6.5.3 Discussion 
 
Of the 3 groups, the injection group demonstrates the greatest stability of data. For the 
primary outcome measure of thermal difference, as the cumulative SD of difference 
equals the cumulative mean difference (< 0.05 
0
C) there is likely to be a significant 
clinical difference evident. In the exercise group, although the data has stabilised, there 
is likely to be no clinical difference evident as the cumulative SD of difference is 
significantly larger (0.3
0
C) than the cumulative mean difference. The ultrasound group 
is the only group to not demonstrate a convincing stabilisation of data and this could be 
attributed to the fact that we are applying energy into this patient group through the use 
of the therapeutic ultrasound which is a proinflammatory modality.  
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When the MDF shift is considered all 3 groups demonstrate stability of data. However, 
as the cumulative SD of shift is significantly larger, in the region of 15 to 20Hz, than the 
cumulative mean shift there is likely to be no clinically significant MDF shift evident.  
  
6.5.4 Conclusion 
 
One can conclude that the data has stabilised in both the injection and exercise groups 
and is showing a trend towards stabilisation over the last 2 to 3 consecutive patients in 
the ultrasound group which would indicate that a sufficient sample size has been 
recruited to detect a clinically important within group change. 
 
However, if the between group differences are considered; the cumulative mean thermal 
difference was 0.45 
0
C for the injection group and 0.2 
0
C for both the ultrasound and 
exercise groups. Therefore, there is a maximum of 0.25 
0
C difference between groups 
which is greater than the a priori defined 0.2 
0
C MCIC. As the SD is in the region of 
0.4- 0.5 for all groups this would give a moderate ES of 0.5 for the clinical trial. To 
detect this minimum clinically important between group difference a sample size of 60 
patients in each group would be required, which was unfortunately beyond the scope of 
this clinical trial and has contributed to a lack of power with respect to this aspect of this 
clinical trial.     
 
6.6 Single case history 
 
A left-handed 38 year old female in the normative study 1 developed tennis elbow in 
her non dominant elbow 3 months after testing and was willing to be retested at 8 weeks 
post onset when she claimed to be 70% improved with NSAID and exercise. 
6.6.1 Results 
 
 Normal elbow Symptomatic elbow 
 AR02 AR03 Diff  AR02 AR03 Diff 
 
Pre 31.1 31.6 -0.5 31.1 32 -0.9 
Retest 31.6 31.9 -0.3 31.7 31.9 -0.2 
 
Table 6.6: Maximum temperature (
0
C) for single case study participant 
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If one considers her thermal data in table 6.6 it can be seen that pre symptoms there was 
a difference of -0.9 
0
C whereas on retesting the difference was reduced to -0.2 
0
C. 
In comparison when her normal elbow is considered less change was evident: -0.5 to 
 -0.3
0
C although this was classed as a MCIC.  
 
If the grip strength data of the symptomatic elbow was considered: 
Pre mean grip strength 36.5kg  
Retest    18kg 
 
This demonstrates in the region of a 50% reduction (18.2kg) which supports the use of 
50% maximum grip strength for both the normative and unaffected elbow of the tennis 
elbow population. 
 
In comparison when the normal side was considered little change was evident: 
Pre mean grip strength  26.5kg 
Retest     28kg 
 
Table 6.7 details her EMG data: 
 
Normal elbow Symptomatic elbow 
 10sec 35 sec MDF 
shift 
 10sec 35sec MDF 
shift 
Pre 116 101 -15 Pre 117.5 108.5 -9 
Retest 140.5 123 -17.5 Post 118.5 101 -17.5 
 
Table 6.7: Dominant versus nondominant median frequency shift overtime for single 
case study participant 
 
For the symptomatic elbow the MDF shift between 10 sec and 35 sec increased with a 
MCIC from 9Hz pre to 17.5Hz on retest with a marked increase in fatigue apparent.  
 
However, in comparison there was little change and no MCIC evident overtime in the 
normal elbow with the MDF shift between 10 sec and 35 sec 15Hz pre and 17.5Hz on 
retest. 
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6.6.2 Discussion 
 
When the single case study participant’s thermal data was considered the thermal 
difference of the presymptomatic elbow was -0.9
0
C, the reason for which remains in 
question. Garagiola and Giani (1990) stated that a hypothermic image demonstrated a 
degenerative process. The MCIC apparent when the unaffected elbow was considered 
may be due to increased use so as to protect the symptomatic elbow. 
 
It is also of interest to note that presymptoms her grip strength was greater on her 
nondominant arm which is generally thought to be atypical. If the grip strength was 
reconsidered for all left handed participants in the normative study 1, all had greater 
grip strength on their nondominant (right) arm. In comparison when right dominance 
was considered only 2 participants (12.5%) had greater grip strength on their 
nondominant arm with a further 2 participants recorded with equal grip strength 
bilaterally. Strizac et al (1983) proposed that the inability to acquire the typically greater 
wrist extensor strength in the dominant arm was associated with tennis elbow.  
 
The variation in the magnitude of the fatigue pre symptoms when compared to the 
dominant arm is again atypical as the fatigue is generally considered to be less in the 
dominant and generally accepted stronger arm. Although with this case there was 
greater grip strength in the nondominant arm evident. However, in contrast, when the 
normative study 1 data is reconsidered there is little difference in MDF shift, between 
dominant and nondominant elbows.  DeLuca et al. (1986) found that with sustained 
activity of the 1
st
 dorsal interosseous the MDF reduced faster in the nondominant hands 
of right hand dominant subjects. In contrast no statistically significant difference was 
found in left hand dominant which was attributed to the fact that the subjects were 
ambidextrous.  
 
It is also interesting to note that the MDF shift was identical to the normal elbow on 
retesting. There is a high probability that this as a chance finding because the 
symptomatic elbow would have performed a PFG and been able to reduce their grip 
strength if pain was elicited whereas with the unaffected elbow they had visual feedback 
to maintain 50% maximum. Furthermore, the internal pilot found a reduction in MDF 
with exercise from baseline at both 10 days and 6 weeks and baseline measurements are 
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not available for this participant who already claims 50% improvement 8 weeks after 
onset.   
  
6.7 Internal pilot study summary of recommendations for the 
clinical trial 
Minimal clinically important changes: 
 33% change in thermal difference of 0.2 0C 
 38% change in MDF shift of 3Hz 
 22% change from baseline for PFG of 3kg 
 25% change from baseline for PRTEE pain of 5 
 25% change from baseline for PRTEE function of 5 
 25% change from baseline for PRTEE total of 10 
The MCIC is assumed to be an acceptable estimate for the difference in change between 
groups (MCID) 
 
Data analysis: 
 
 For the sample population as a whole no statistical differences were found at any 
time interval for the patient’s unaffected arm and are not to be reported on 
further. 
 
 For the sample population as a whole no statistical difference was found 
between baseline 1 and baseline 2 for any outcome measure which demonstrates 
stability of the patient’s condition and that there is no evidence of spontaneous 
healing and is not to be reported on further. 
 
 A repeated measures ANOVA for treatment group analysis and ANOVA for 
between group analyses with presentation of means profile plots. 
 
 Analysis of the stability of data confirmed that sufficient patients were recruited 
to the clinical trial when a minimum of 21 patients were in each group to detect 
a MCIC, i.e.: a within group change. However, in the region of 60 patients in 
each group would be required to detect a MCID, i.e.: a between group difference 
with a moderate ES of 0.5. 
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CHAPTER 7: CLINICAL TRIAL 
 
As the methods (6.1), ethics (6.2) and statistical methods (6.3) apply to the clinical trial 
and have been previously described in chapter 6: internal pilot, this chapter focuses on 
the results of the clinical trial. The flow of patients through the trial is presented with 
the sample descriptives. Both the within group and between group changes are 
presented in the short and long terms. Treatment preference analysis is also described.  
 
7.1 Results 
7.1.1 Sample 
 
64 tennis elbow patients were randomised by a third party prior to the onset of the 
clinical trial into the 3 treatment arms in equal numbers: injection (n= 21), exercise 
rehabilitation (n=22) and ultrasound (n=21). 
 
As can be seen from the flowchart (Figure 7.3) 9% of patients (n=6) had withdrawn 
prior to the 6 week endpoint: 2 patients from the injection group, 3 from the exercise 
group and 1 from the ultrasound group. Both patients from the injection group declined 
injection and 1 patient from the exercise group all withdrew, stating that they were 
better prior to treatment. The other 2 complained that the exercises aggravated their 
pain. The ultrasound patient was unable to attend (UTA) for regular treatment 
appointments. A further 6% of patients (n=4) DNA their 6 week review: 2 patients from 
the injection group and 1 from both the exercise and ultrasound groups. Subsequently at 
the 6 week endpoint, 36% of patients (n=23) required further treatment: 6 in the 
injection group, 5 in the exercise group and 12 in the ultrasound group, not as per 
protocol, which included braces, ice massage, laser, acupuncture, deep transverse 
frictions, lateral glides, stretches, exercise, ultrasound or injection.  
 
The remaining 55% of the patient population (n=35) were offered a 6 month review, as 
per protocol: 13 in the injection group, 14 in the exercise group and 8 in the ultrasound 
group. Unfortunately, 46% of these patients (n=16) DNA their 6 month review: 2 
patients from the injection group and 7 from both the exercise and ultrasound groups. 
Of those patients who attended their 6 month review all 7 patients in the exercise group 
and the patient in the ultrasound group did not require further treatment. However, 38% 
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of patients (n=5) in the injection group required further treatment with 1 patient referred 
for repeat injection and 4 referred for physiotherapy. 
 
Figure 7.1: Patient flowchart through the study up to the 6 month endpoint. 
 
7.1.2 Descriptives 
 
Table 7.1 illustrates the baseline characteristics according to group. Mean (SD) are 
given for thermal difference, lateral elbow skin fold and body fat percentage. Mean 
(range) for age and median (range) for duration. Percentages are given for all other 
BASELINE 
 
n= 64 
ULTRASOUND 
 
n= 21 
INJECTION 
 
n= 21 
EXERCISE 
REHABILITATION 
 
n= 22 
n= 19 
DNA= 1 
Withdrawn= 1 
n= 20  
DNA= 1 
Withdrawn= 0 
n= 16  
DNA= 3 
Withdrawn= 2 
n= 17  
DNA=3 
Withdrawn= 1 
PRE-
TREATMENT 
n= 21 
DNA= 
Withdrawn= 
10/7 
n= 11  
DNA= 8 
Withdrawn= 3 
n= 17  
DNA= 2 
Withdrawn= 2 
n= 19 
DNA= 1 
Withdrawn= 1 
6/52 
n=18  
DNA= 1 
Withdrawn= 3 
6/12 
n= 7  
DNA= 7 
Withdrawn= 3 
Treatment= 5 
n= 11  
DNA= 2 
Withdrawn= 2 
Treatment= 6 
 
n= 1  
DNA= 7 
Withdrawn= 1 
Treatment= 12 
 
0  
DNA= 2 
Withdrawn= 0 
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categorical data. Vascular co morbidities included diabetes, high cholesterol, high blood 
pressure, transient ischaemic attacks and Raynauds.  
 
 
 Injection Ultrasound Exercise 
Age (years) 45.6 (30-61) 45.2 (37-56) 45.6 (23-64) 
Gender M:F 42.9%: 57.1% 47.6%: 52.4% 45.5%: 54.5% 
Dominant elbow 
affected 
80.9% 52.4% 68.2% 
Duration (weeks) 16 (2-104) 16 (4-86) 18 (6-104) 
Aggravating 
occupation 
90.5% 85.7% 77.3% 
Aggravating 
sport/ hobby 
76.2% 71.4% 81.8% 
Previous 
episode(s) 
9.6% 9.6% 13.6% 
Previous 
treatment for  
present episode 
4.8% 4.8% 9.1% 
Vascular co 
morbidity  
19% 14.3% 18.2% 
Unrelated 
cervical spine 
problem 
28.6% 9.5% 27.3% 
Lateral 
epicondyle skin 
fold 
7.3 (2.1) 6.0 (1.9) 6.3 (3.1) 
Body fat % 24 (4.7) 21.2 (4.2) 22.8 (4.3) 
Smoke 14.3% 14.3% 18.2%  
Past smoker 19% 9.5% 9.1% 
Analgesic use 19% 19% 13.6% 
Tubigrip use 33.3% 47.6% 31.8% 
NSAID gel 19% 38.1% 31.8% 
Thermal 
difference 
0.35 (0.4) 0.1 (0.4) 0.02 (0.4) 
 
Table 7.1: Baseline characteristics. 
 
As can be seen randomisation was to a fair effect, given the sample size, and the 3 
groups were fairly well matched at baseline, although a fairly large mean difference for 
the primary outcome measure was evident between the injection and both the ultrasound 
and exercise groups. The mean age was 45 years with an equal male: female ratio and a 
median duration of 4-5 months with a range of 2 weeks to 2 years. It is interesting to 
note that the dominant elbow was not characteristically symptomatic in either the 
exercise or even more so in the ultrasound group in this population. Between 70-90% of 
patients presented for treatment due to their symptoms being aggravated markedly by 
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their occupation or sporting/ hobby activities. In the region of 10% had at least one 
recurrence of symptoms and between 5-10% had received treatment, greater than 6 
months ago, for their presenting condition, from which they had not gained significant 
improvement. It can, therefore, be concluded that the sample population included both 
acute and chronic cases and the results can be generalised to the tennis elbow population 
as a whole. No adverse reactions were reported for any of the treatment groups.  
  
7.1.3 Statistical analysis 
 
A repeated measures ANOVA was used with alpha set at p <0.05 with 95% confidence 
levels for each of the treatment groups. All reported data is of the primary ITT analysis 
using LOCF. The sensitivity was as per protocol with similar differences between 
groups and p values evident.  So as not to compromise the power due to loss to follow 
up, the long term 6 month data was analysed separately, thereby reducing the standard 
error and increasing the precision in the short term, at 6 weeks.  
7.1.3.1 Injection Group 
 
Table 7.2 shows the outcome measures means and standard deviations overtime for the 
injection group.   
 
 Mean (SD) 
Baseline  10 days 6 weeks 6 months 
Thermal difference (
0
C) 0.4 (0.4) 0.01 (0.6) -0.005 (0.6) -0.1 (0.6) 
MPFS shift 10s-35s (Hz) -16.8 (9.2) -17.3 (10.7) -20.7 (10.5) -19.8 (14.1) 
 
Change from baseline 
to: 
10 days 6 weeks 6 months 
PFG (kg) 10.3 (10.8) 12.0 (14.6) 4.0 (13.0) 
PRTEE pain -9.2 (13.5) -13.3 (12.3) 0.2 (12.9) 
PRTEE function -9.6 (14.8) -13.1 (11.9) -2.6 (14.3) 
PRTEE total -18.8 (27.7) -26.4 (23.6) -2.4 (26.5) 
 
Table 7.2: Outcome measures means (SD) overtime for the injection group. 
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Thermal difference 
Mean change between baseline and 10 days was -0.3 
0
C p= 0.01 with a 95% CI  
(-0.6 to -0.1) 
Mean change between baseline and 6 weeks was -0.4 
0
C p= 0.005 with a 95% CI  
(-0.6 to -0.1) 
Mean change between baseline and 6 months was -0.3
0
C p= 0.01 with a 95% CI      
(-0.6 to -0.1) 
This analysis demonstrates a MCIC (0.2
0
C) and a statistically significant reduction in 
Tsk of the ROI at 10 days which was maintained through 6 weeks to the 6 month 
endpoint.  
 
Median frequency shift 
No statistical difference was found for median frequency shift at any time intervals. A 
MCIC was found at 6 weeks which was sustained through to 6 months. 
 
Pain free grip strength 
A MCIC (3kg) and statistically significant increase in PFG from baseline at 10 days was 
maintained through to the 6 week endpoint but not to 6 months.  
 
PRTEE pain 
A MCIC (5) and a statistically significant reduction in pain from baseline at 10 days 
was maintained through to the 6 week endpoint but not to 6 months.  
 
PRTEE function 
A MCIC (5) and a statistically significant increase in function from baseline was 
maintained through to the 6 week endpoint but not to 6 months.  
 
PRTEE total 
A MCIC (10) and a statistically significant reduction in pain and disability from 
baseline at 10 days was maintained through to the 6 week endpoint but not to 6 months. 
 
7.1.3.2 Ultrasound Group 
 
Table 7.3 shows the outcome measures means and SD overtime for the ultrasound 
group. 
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 Mean (SD) 
Baseline  10 days 6 weeks 6 months 
Thermal difference (
0
C) 0.1 (0.4) -0.2 (0.6) -0.1 (0.6) -0.2 (0.5) 
MPFS shift 10s-35s (Hz) -15.6 (17.3) -20.9 (15.4) -20.9 (17.2) -28.1 (17.1) 
 
Change from baseline 
to: 
10 days 6 weeks 6 months 
PFG (kg) -1.2 (5.6) 0.8 (6) 4.0 (7.5) 
PRTEE pain 0.9 (5.6) -2.0 (7.5) -3.4 (8.2) 
PRTEE function 1.7 (7.8) -2.0 (10.2) -5.2 (12.3) 
PRTEE total 2.6 (11.4) -4.0 (15.5) -8.6 (17.3) 
 
Table 7.3: Outcome measures means (SD) overtime for the ultrasound group. 
 
Thermal difference 
Mean change between baseline and 10 days was -0.3 
0
C p= 0.02 with a 95% CI  
(-0.6 to -0.05) 
Mean change between baseline and 6 weeks was -0.25 
0
C p= 0.03 with a 95% CI  
(-0.5 to -0.03) 
Mean change between baseline and 6 months was -0.2
0
C p= 0.2 with a 95% CI      
(-0.5 to 0.1) 
This analysis demonstrates a MCIC (0.2
0
C) and a statistically significant reduction in 
Tsk of the ROI at 10 days which was maintained through to 6 weeks. However, only the 
MCIC, not the statistical difference was sustained through to the 6 months endpoint. 
 
Median frequency shift 
No statistical difference was found for median frequency shift at any time intervals. A 
MCIC (3Hz) was found at 10 days which was maintained through 6 weeks to 6 months. 
 
Pain free grip strength 
A statistically significant increase in PFG from baseline at 6 weeks was sustained 
through to the 6 month endpoint. A MCIC (3kg) was only found at 6 months. 
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PRTEE pain 
A statistically significant reduction in pain from baseline to 6 weeks was sustained 
through to the 6 month endpoint. A MCIC (5) was only found at 6 months.  
 
PRTEE function 
A MCIC and a statistically significant increase in function from baseline to 6 weeks was 
sustained through to the 6 month endpoint.  
 
PRTEE total 
A statistically significant reduction in pain and disability from baseline to 6 weeks was 
sustained through to the 6 month endpoint. A MCIC (5) was only found at 6 months.  
 
7.1.3.3 Exercise Group 
 
Table 7.4 shows the outcome measures means and SD overtime for the exercise group. 
 
 Mean (SD) 
Baseline  10 days 6 weeks 6 months 
Thermal difference (
0
C) 0.02 (0.4) -0.06 (0.5) -0.2 (0.5) -0.2 (0.5) 
MPFS shift 10s-35s (Hz) -17.3 (18.4) -16.8 (10.1) -21.3 (10.7) -23.6 (11.9) 
 
Change from baseline 
to: 
10 days 6 weeks 6 months 
PFG (kg) 1.3 (4.4) 2.7 (6.4) 5.7 (9.9) 
PRTEE pain -1.1 (7.5) -5.6 (10.7) -9.1 (10.9) 
PRTEE function -1.9 (8.6) -4.7 (11.2) -8.4 (10.7) 
PRTEE total -3.2 (14.9) -8.9 (21.4) -17.5 (20.3) 
 
Table 7.4: Outcome measures means (SD) overtime for the exercise group. 
 
Thermal difference 
Mean change between baseline and 10 days was -0.08 
0
C p= 0.5 with a 95% CI  
(-0.3 to 0.1) 
Mean change between baseline and 6 weeks was -0.2 
0
C p= 0.095 with a 95% CI  
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(-0.4 to -0.04) 
Mean change between baseline and 6 months was -0.1
0
C p= 0.4 with a 95% CI      
(-0.3 to 0.1) 
This analysis demonstrates no statistically significant reduction in Tsk of the ROI at any 
time intervals. A MCIC (0.2
0
C) was evident at 6 weeks only. 
 
Median frequency shift 
No statistical difference was found for median frequency shift at any time intervals. A 
MCIC (3Hz) was found at 6 weeks which was sustained through to 6 months. 
 
Pain free grip strength 
A statistically significant increase in PFG from baseline at 10 days was maintained 
through 6 weeks to the 6 month endpoint. A MCIC (3kg) was evident at 6 weeks which 
was sustained through to 6 months.  
 
PRTEE pain 
A MCIC and a statistically significant reduction in pain from baseline through 6 weeks 
to the 6 month endpoint.  
 
PRTEE function 
A MCIC (5) and a statistically significant increase in function from baseline to the 6 
month endpoint only. 
 
PRTEE total 
A MCIC (10) and a statistically significant reduction in pain and disability from 
baseline to the 6 month endpoint only.  
 
7.1.3.4 Short term between group analysis 
 
For the primary outcome measure thermal difference, due to the fairly large mean and 
MCID between the injection and ultrasound and exercise groups at baseline, a 
univariate analysis of variance with thermal difference at baseline as a covariate was 
used to reduce the standard error and increase the precision. This analysis was also used 
for MDF. For all other outcome measures, which were analysed using change from 
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baseline, an ANOVA was used with alpha set at p< 0.05 with 95% confidence levels 
and the Scheffe post hoc test for the between group analysis.  
 
The mean differences between groups and the significance level with 95% confidence 
intervals are given for the primary outcome measure thermal difference over time in 
Table 7.5 with the profile plot in Graph 7.1. 
 
 
Thermal diff  Groups Mean 
difference 
Significance 
level 
95% CI 
10 days Ex: U/S 0.2
0
C 0.2 -0.1 to 0.5 
Ex: Inj 0.1
0
C 0.5 -0.2 to 0.5 
U/S: Inj -0.1
0
C 0.6 -0.4 to 0.2 
6 weeks Ex: U/S -0.04
0
C 0.8 -0.3 to 0.3 
Ex: Inj -0.07
0
C 0.7 -0.2 to 0.4 
U/S: Inj -0.03
0
C 0.9 -0.3 to 0.3 
 
Table 7.5: Mean differences, significance and 95% CI for thermal difference. 
 
No statistically significant differences for thermal difference between groups were 
found. A MCID (0.2
0
C) was found between the exercise and ultrasound group at 10 
days only.  
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Graph 7.1 Profile plot for thermal difference. 
 
The mean differences between groups and the significance level with 95% confidence 
intervals are given for median frequency over time in Table 7.6 with the profile plot in 
Graph 7.2. 
 
MDF Groups Mean 
difference 
Significance 
level 
95% CI 
10 days Ex: U/S 4.5 Hz 0.2 -2.8 to 11.8 
Ex: Inj 0.7 Hz 0.9 -6.7 to 8 
U/S: Inj -3.8 Hz 0.3 -11.2 to 3.5 
6 weeks Ex: U/S 0.004 Hz 1 -10.7 to 9.9 
Ex: Inj -0.5 Hz 0.9 -11 to 9.8 
U/S: Inj -0.5 Hz 0.9 -10.6 to 10.2 
 
Table 7.6: Mean differences, significance and 95% CI for median frequency shift. 
 
No statistically significant differences were found for the secondary outcome measure 
median frequency shift at any time interval. A MCID (3Hz) was found between the 
ultrasound and both the exercise and injection groups at 10 days only. 
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Graph 7.2 Profile plot for median frequency shift. 
 
Table 7.7 shows the mean differences between groups and the significance level with 
95% confidence intervals for the PFG over time with the profile plot shown in Graph 
7.3.  
 
PFG change 
from baseline 
Groups Mean 
difference 
Significance 
level 
95% CI 
10 days Ex: U/S 2.5 kg 0.6 -3.2 to 8.2 
Ex: Inj -9.0 kg 0.001 -14.7 to -3.3 
U/S: Inj -11.5 kg 0.000 -17.3 to -5.8 
6 weeks Ex: U/S 1.9 kg 0.8 -5.6 to 9.4 
Ex: Inj -9.3 kg 0.01 -16.8 to -1.8 
U/S: Inj -11.2 kg 0.002 -18.8 to -3.6 
 
Table 7.7: Mean differences, significance and 95% CI for pain free grip strength. 
 
A MCID (3kg) and a statistically significant difference was found for PFG change from 
baseline between the injection group and both the exercise and ultrasound groups at 10 
days and this was maintained through to the 6 week endpoint.  
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Graph 7.3 Profile plot for pain free grip strength. 
 
Table 7.8 shows the mean differences between groups and the significance level with 
95% confidence intervals for the PRTEE pain over time with the profile plot shown in 
Graph 7.4.  
 
PRTEE pain 
change from 
baseline  
Groups Mean 
difference 
Significance 
level 
95% CI 
10 days Ex: U/S -1.9 0.8 -9.15 to 5.3 
Ex: Inj 8.2 0.02 0.9 to 15.4 
U/S: Inj 10.1 0.004 2.8 to 17.4 
6 weeks Ex: U/S -3.7 0.5 -11.6 to 4.2 
Ex: Inj 7.7 0.059 -0.2 to 15.6 
U/S: Inj 11.4 0.003 3.4 to 19.4 
 
Table 7.8: Mean differences, significance and 95% CI for patient rated tennis elbow 
evaluation pain. 
 
A MCID (5) and a statistically significant difference was found for PRTEE pain change 
from baseline between the injection group and both the exercise and ultrasound groups 
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at 10 days which was only maintained between the injection group and the ultrasound 
group at the 6 week endpoint. However, although a MCID was also maintained through 
to the 6 week endpoint between the injection and exercise group it was not statistically 
significant. 
 
Graph 7.4 Profile plot for patient rated tennis elbow evaluation pain. 
 
Table 7.9 shows the mean differences between groups and the significance level with 
95% confidence intervals for the PRTEE function over time with the profile plot shown 
in Graph 7.5.  
PRTEE 
function change 
from baseline 
Groups Mean 
difference 
Significance 
level 
95% CI 
10 days Ex: U/S -3.6 0.5 -11.9 to 4.6 
Ex: Inj 7.7 0.08 -0.6 to 15.9 
U/S: Inj 11.3 0.005 2.9 to 19.7 
6 weeks Ex: U/S -2.6 0.7 -11.1 to 5.9 
Ex: Inj 8.4 0.054 -0.1 to 16.9 
U/S: Inj 11.0 0.009 2.4 to 19.7 
 
Table 7.9: Mean differences, significance and 95% CI for patient rated tennis elbow 
evaluation function. 
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A MCID (5) and a statistically significant difference was found for PRTEE function 
change from baseline between the injection group and the ultrasound group at 10 days 
which was maintained through to the 6 week endpoint. A MCID was also found 
between the injection and exercise group at both 10 days and 6 weeks although not 
statistically significant. 
 
Graph 7.5 Profile plot for patient rated tennis elbow evaluation function. 
 
Table 7.10 shows the mean differences between groups and the significance level with 
95% confidence intervals for the PRTEE total over time with the profile plot shown in 
Graph 7.6.  
 
 
 
 
 
 
 
 
 
 120 
PRTEE total 
change from 
baseline  
Groups Mean 
difference 
Significance 
level 
95% CI 
10 days Ex: U/S -5.8 0.6 -20.5 to 9 
Ex: Inj 15.6 0.04 0.9 to 30.4 
U/S: Inj 21.4 0.003 6.5 to 36.3 
6 weeks Ex: U/S -4.9 0.7 -20.6 to 10.8 
Ex: Inj 17.5 0.03 1.8 to 33.2 
U/S: Inj 22.4 0.003 6.5 to 38.2 
 
Table 7.10: Mean differences, significance and 95% CI for patient rated tennis elbow 
evaluation total. 
 
A MCID (10) and a statistically significant difference were found for PRTEE total 
change from baseline between the injection group and both the exercise and ultrasound 
groups at 10 days which was maintained through to the 6 week endpoint.  
 
 
Graph 7.6 Profile plot for patient rated tennis elbow evaluation total. 
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7.1.3.5 Long term between group analysis 
 
The mean differences for the sample population as a whole and the significance level 
with 95% confidence intervals are given for the primary outcome measure thermal 
difference over time in Table 7.11. 
 
Thermal difference Mean difference Significance 
level 
95% CI 
10 days 0.2
0
C 0.06 -0.006 to 0.3 
6 weeks 0.2
0
C 0.01 0.05 to 0.4 
6 months 0.2
0
C 0.007 0.06 to 0.4 
 
Table 7.11: Mean differences, significance and 95% CI for thermal difference for all 
groups. 
 
For all groups, at 10 days a MCIC (0.2
0
C) was evident, although not statistically 
significant, which was maintained through 6 weeks to the 6 month endpoint. A 
statistically significant change for thermal difference was found only at 6 weeks which 
was sustained through to 6 months. 
 
The mean differences between groups and the significance level with 95% confidence 
intervals are given for the primary outcome measure thermal difference at 6 months in 
Table 7.12 with the profile plot in Graph 7.7. 
 
Thermal 
difference 
Groups Mean 
difference 
Significance 
level 
95% CI 
6 months Ex: U/S -0.06
0
C 0.7 -0.3 to 0.4 
Ex: Inj -0.07
0
C 0.7 -0.3 to 0.4 
U/S: Inj -0.01
0
C 0.95 -0.4 to 0.4 
 
Table 7.12: Mean differences, significance and 95% CI for thermal difference. 
 
Neither a MCID nor a statistically significant difference for thermal difference between 
groups was found.  
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Graph 7.7 Profile plot for thermal difference. 
 
The mean differences between groups and the significance level with 95% confidence 
intervals are given for median frequency over time in Table 7.13 with the profile plot in 
Graph 7.8. 
 
MDF Groups Mean 
difference 
Significance 
level 
95% CI 
6 months Ex: U/S 4.7 Hz 0.4 -7.6 to 16.9 
Ex: Inj -3.7 Hz 0.5 -14.7 to 7.3 
U/S: Inj -8.3 Hz 0.2 -20.9 to 4.3 
 
Table 7.13: Mean differences, significance and 95% CI for median frequency shift. 
 
Although no statistically significant differences for median frequency between groups 
were found a MCID (3Hz) was found between ultrasound and both the exercise and 
injection groups and between the exercise and injection groups.  
 
 123 
 
Graph 7.8 Profile plot for median frequency. 
 
Table 7.14 shows the mean differences between groups and the significance level with 
95% confidence intervals for the PFG over time with the profile plot shown in Graph 
7.9.  
 
PFG change 
from baseline 
Groups Mean 
difference 
Significance 95% CI 
6 months Ex: U/S 1.7kg 0.9 -9.6 to 12.9 
Ex: Inj 1.7kg 0.9 -8 to 11.4 
U/S: Inj 0.04kg 1 -11.5 to 11.6 
 
Table 7.14: Mean differences, significance and 95% CI for pain free grip strength. 
 
No MCID or statistically significant difference for PFG between groups was found.  
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Graph 7.9 Profile plot for pain free grip strength. 
 
Table 7.15 shows the mean differences between groups and the significance level with 
95% confidence intervals for the PRTEE pain over time with the profile plot shown in 
Graph 7.10.  
 
PRTEE pain 
change from 
baseline 
Groups Mean 
difference 
Significance 95% CI 
6 months Ex: U/S -5.7 0.5 -17.4 to 6 
Ex: Inj -9.3 0.08 -19.6 to 0.9 
U/S: Inj -3.6 0.75 -15.8 to 8.5 
 
Table 7.15: Mean differences, significance and 95% CI for patient rated tennis elbow 
evaluation pain. 
 
No statistically significant differences for PRTEE pain between groups were found. A 
MCID (5) was evident between the exercise group and both the ultrasound and injection 
groups.  
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Graph 7.10: Profile plot for patient rated tennis elbow evaluation pain. 
 
Table 7.16 shows the mean differences between groups and the significance level with 
95% confidence intervals for the PRTEE function over time with the profile plot shown 
in Graph 7.11.  
 
PRTEE 
function change 
from baseline 
Groups Mean 
difference 
Significance 95% CI 
6 months Ex: U/S -3.2 0.8 -16.3 to 9.8 
Ex: Inj -5.8 0.4 -17.2 to 5.6 
U/S: Inj -2.6 0.9 -16.1 to 10.9 
 
Table 7.16: Mean differences, significance and 95% CI for patient rated tennis elbow 
evaluation function. 
 
No statistically significant differences for PRTEE function between groups were found. 
A MCID (5) was found between the exercise and injection group only. 
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Graph 7.11: Profile plot for patient rated tennis elbow evaluation function. 
 
Table 7.17 shows the mean differences between groups and the significance level with 
95% confidence intervals for the PRTEE total over time with the profile plot shown in 
Graph 7.12.  
 
PRTEE total 
change from 
baseline 
Groups Mean 
difference 
Significance 95% CI 
6 months Ex: U/S -8.9 0.6 -32.1 to 14.4 
Ex: Inj -15 0.2 -35.4 to 5.3 
U/S: Inj -6.2 0.8 -30.3 to 17.9 
 
Table 7.17: Mean differences, significance and 95% CI for patient rated tennis elbow 
evaluation total. 
 
No statistically significant differences for PRTEE total between groups were found. A 
MCID (10) was found between exercise and injection only.  
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Graph 7.12: Profile plot for patient rated tennis elbow evaluation total. 
 
7.1.4 Treatment preference analysis 
 
The patient preference questionnaires were analysed by group, by identifying themes. 
As can be seen in table 7.18, apart from all groups having an aversion to exercise, 
patient preference was unequally distributed across the treatment groups with those in 
the injection group having a strong preference for injection whilst the majority of 
patients in both the ultrasound and exercise groups preferred ultrasound.   
 
Preference (%) Injection group Ultrasound group Exercise group 
Injection 68 10.5 25 
Ultrasound 10 47 56 
Exercise 5 5 6 
No preference 5 26 12.5 
 
Table 7.18: Patient preference for treatment. 
 
 128 
7.1.4.1 Injection group 
 
At 10 days 68% of patients in the injection group stated a preference for injection, 10% 
ultrasound and 5% each of exercise, exercise with ultrasound, no preference and 
surgery. Subsequently, this rose to 84% of patients with a preference for injection with 
those who initially had a preference for ultrasound or exercise changing their opinion 
following treatment. 
 
Patients favoured injection therapy as it was perceived as a ‘quick fix’ giving quick pain 
relief in 44% and pain relief within a week in a further 33%. The remaining 22% 
commented that the treatment only required one visit.  In comparison, when dislikes 
were considered, 56% of patients complained of pain or discomfort during the injection, 
19% did not like needles, 12.5% found the injection only gave short term relief and the 
remaining 12.5% had no complaints. Following on from this, 79% of patients had no 
suggestions for improving the injection therapy they had received. 16% felt that the 
time taken from first presenting at the GP to treatment could be shorter and 5% 
suggested reintroduction of the use of local anaesthetic with the steroid injection. 
 
67% of patients would prefer to have a repeat injection if their problem returned and 
14% had no preference. 9.5% of patients would like ultrasound or exercise and the 
remaining 9.5% would prefer surgery. 
 
7.1.4.2 Ultrasound group 
 
At 10 days 47% of patients in the ultrasound group stated a preference for ultrasound 
and 26% had no preference. 10.5% would prefer an injection with 5% each preferring 
exercise, physiotherapy or injection/ surgery. Subsequently, this dropped to 35% of 
patients with a preference for ultrasound and rose to 35% of patients with no preference. 
10% of each would prefer an injection or physiotherapy and only 5% of each would 
prefer exercise or surgery  
 
Patients favoured ultrasound as it was perceived as a quick pain free treatment in 67% 
and 22% praised their physiotherapist for their professional, attentive and polite manner. 
The remaining 11% commented that the treatment felt good. In comparison, when 
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dislikes were considered, 61% of patients had no complaints, 28% did not think the 
treatment was effective and 5% each found the treatment only gave short term relief or 
was momentarily painful during treatment. Following on from this, 85% of patients had 
no suggestions for improving the ultrasound treatment they had received. 5% each 
suggested it was combined with an exercise programme, a longer course of ultrasound 
or treatment sessions were planned in advance. 
 
37% of patients would prefer to have a repeat course of ultrasound if their problem 
returned and 31.5% had no preference. 10.5% of patients would like an injection with 
5% each preferring ultrasound/ injection, exercise, acupuncture or injection/ surgery. 
Following treatment an increase to 55% of patients would prefer to have a repeat course 
of ultrasound if their problem returned with only 20% having no preference and with 
5% each preferring injection, ultrasound/ injection, exercise, acupuncture or injection/ 
surgery. 
 
7.1.4.3 Exercise group 
 
At 10 days 56% of patients in the exercise group stated a preference for ultrasound, 25% 
injection, 12.5% no preference and 6% for exercise and ultrasound. Subsequently, this 
dropped to 44% of patients with a preference for ultrasound, 17% injection and 17% no 
preference. A further 11% preferred exercise and 5.5% each preferred injection with 
ultrasound or ‘radiotherapy’ following treatment. 
 
Patients favoured exercise therapy as 53% found the exercises helped their problem and 
37% stated that they were easy to do/ done at home at anytime. A further 5% each liked 
‘understanding how it all worked’ and trying different exercises. In comparison, when 
dislikes were considered whilst 43% of patients had no complaints, 14% each found the 
exercises time consuming or slow/ queried their efficacy and 9.5% complained that the 
exercises aggravated their pain. 5% each complained that there was not enough variety 
and specifically wanted massage, found it difficult to remember to do the exercises, the 
theraband did not smell nice or would prefer for the treatment to last a bit longer. 
Following on from this, 58% of patients had no suggestions for improving the exercise 
therapy they had received. 10.5% felt that they would have benefited from treatment 
earlier and 5% each suggested possible short cuts on repetitions, less amount of 
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exercise, longer between visits, to include massage and more variety, to include 
ultrasound initially, or a more strenuous programme. 
 
33% of patients would prefer to have ultrasound if their problem returned and 28% had 
no preference. 17% would like further exercise and 11% of patients would like an 
injection. 5.5% each would prefer ultrasound/ injection or ‘radiotherapy’. 
 
7.1.5 Summary of results 
 
64 patients were recruited into the clinical trial which sustained a 15% dropout rate, (9% 
withdrew and 6% DNA). Only 60% of the patient population, (68% injection, 40% 
ultrasound and 73% exercise), did not require further treatment at the 6 week end point 
and were offered review at 6 months. Strong preference for the treatment the patient 
received was found for injection therapy (68%) but not for ultrasound (47%) or exercise 
(6%). 
 
The data from this RCT assessing the effectiveness of 3 common conservative 
treatments for tennis elbow: injection, ultrasound and exercise rehabilitation programme 
through the collective outcome measures of thermal difference, MDF, PFG, PRTEE and 
patient preference are summarised in the following series of tables:  
 
Table 7.19 summarises the key MCIC and statistically significant changes (SSC) for the 
injection group overtime. 
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Injection 
group 
time 
point 
Thermal 
difference 
MDF PFG PRTEE 
pain 
PRTEE 
function 
PRTEE 
total 
10 days MCIC 
SSC 
- 
- 
MCIC 
SSC 
MCIC 
SSC 
MCIC 
SSC 
MCIC 
SSC 
6 weeks MCIC 
SSC 
MCIC 
- 
MCIC 
SSC 
MCIC 
SSC 
MCIC 
SSC 
MCIC 
SSC 
6 months MCIC 
SSC 
MCIC 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
Table 7.19 MCIC and statistically significant changes (SSC) summary for the injection 
group overtime. 
 
 
Table 7.20 summarises the key MCIC and SSC for the ultrasound group overtime. 
 
Ultrasound 
group time 
point 
Thermal 
difference 
MDF PFG PRTEE 
pain 
PRTEE 
function 
PRTEE 
total 
10 days MCIC 
SSC 
MCIC 
- 
- 
- 
- 
- 
- 
- 
- 
- 
6 weeks MCIC 
SSC 
MCIC 
- 
- 
SSC 
- 
SSC 
MCIC 
SSC 
- 
SSC 
6 months MCIC 
- 
MCIC 
- 
MCIC 
SSC 
MCIC 
SSC 
MCIC 
SSC 
MCIC 
SSC 
 
Table 7.20 MCIC and statistically significant changes (SSC) summary for the 
ultrasound group overtime. 
 
 
Table 7.21 summarises the key MCIC and SSC for the exercise group overtime. 
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Exercise 
group 
time 
point 
Thermal 
difference 
MDF PFG PRTEE 
pain 
PRTEE 
function 
PRTEE 
total 
10 days - 
- 
- 
- 
- 
SSC 
- 
- 
- 
- 
- 
- 
6 weeks MCIC 
- 
MCIC 
- 
MCIC 
SSC 
MCIC 
SSC 
- 
- 
- 
- 
6 months - 
- 
MCIC 
- 
MCIC 
SSC 
MCIC 
SSC 
MCIC 
SSC 
MCIC 
SSC 
 
Table 7.21 MCID and statistically significant changes (SSC) summary for the exercise 
group overtime. 
 
 
Table 7.22 and 7.23 summarise the key MCID and statistically significant differences 
found between groups in the short term at 10 days and 6 weeks respectively. 
 
 
Between 
group 
analysis 
Thermal 
difference 
MDF PFG PRTEE 
pain 
PRTEE 
function 
PRTEE 
total 
Exercise: 
ultrasound 
MCID 
- 
MCID 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Exercise: 
injection 
- 
- 
- 
- 
MCID 
SSD 
MCID 
SSD 
MCID 
- 
MCID 
SSD 
Ultrasound: 
injection 
- 
- 
MCID 
- 
MCID 
SSD 
MCID 
SSD 
MCID 
SSD 
MCID 
SSD 
Profile plot 
trend 
Ultrasound 
and 
injection 
Ultrasound Injection Injection Injection Injection 
 
Table 7.22 MCID and statistically significant differences (SSD) summary at 10 days. 
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Between 
group 
analysis 
Thermal 
difference 
MDF PFG PRTEE 
pain 
PRTEE 
function 
PRTEE 
total 
Exercise: 
ultrasound 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Exercise: 
injection 
- 
- 
- 
- 
MCID 
SSD 
MCID 
- 
MCID 
- 
MCID 
SSD 
Ultrasound: 
injection 
- 
- 
- 
- 
MCID 
SSD 
MCID 
SSD 
MCID 
SSD 
MCID 
SSD 
Profile plot 
trend 
- Injection 
and 
exercise 
- - - - 
 
Table 7.23 MCID and statistically significant differences (SSD) summary at 6 weeks. 
 
 
Table 7.24 summarises the key MCID and statistical differences in the long term at 6 
months. 
 
 
Between 
group 
analysis 
Thermal 
difference 
MDF PFG PRTEE 
pain 
PRTEE 
function 
PRTEE 
total 
Exercise: 
ultrasound 
- 
- 
MCID 
- 
- 
- 
MCID 
- 
- 
- 
- 
- 
Exercise: 
injection 
- 
- 
MCID 
- 
- 
- 
MCID 
- 
MCID 
- 
MCID 
- 
Ultrasound: 
injection 
- 
- 
MCID 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Profile plot 
trend 
- - Injection Injection Injection Injection 
 
Table 7.24 MCID and statistically significant differences (SSD) summary at 6 months. 
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Table 7.25 summarises the between group differences overtime with both MCID and 
statistically significant differences highlighted and the treatment groups also ranked by 
the size of the difference depicted by a traffic light scheme.  
 
Outcome 
measure 
10 days 6 weeks 6 months 
Injection U/S Ex Injection U/S Ex Injection U/S Ex 
Thermal 
difference 
X MCID        
MDF  MCID     MCID MCID MCID 
PFG MCID 
SSD 
  MCID 
SSD 
     
PRTEE 
pain 
MCID 
SSD 
  MCID 
SSD* 
    MCID 
PRTEE 
function 
MCID 
SSD* 
 
  MCID 
SSD* 
   X MCID 
PRTEE 
total 
MCID 
SSD 
  MCID 
SSD 
   X MCID 
Patient 
preference 
         
 
Table 7.25: MCID, SSD and group ranking summary. 
 
 
 
MCID found between the most effective treatment group and the other 2 groups, 
except for MDF at 6 months when a MCID was also found between the 
exercise and injection groups.  
X no MCID found 
*  SSD between injection and ultrasound group only 
 
Most effect   
Least effect   
 
Intermediate effect   
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This table clearly depicts that the overall outcome in the short term at both 10 days and 
6 weeks found injection therapy to be the most effective with both a statistically 
significant and minimum clinically important difference. Exercise therapy was the least 
effective at 10 days and ultrasound the least effective at 6 weeks and although no 
statistically significant differences between the 2 groups were found MCIDs were found 
in favour of ultrasound at 10 days for thermal difference and MDF. In contrast, in the 
long term at 6 months the converse was found with exercise the most effective and 
injection the least effective. However, no significant differences between the 3 groups 
were found. A MCID for PRTEE pain was found in favour of exercise over both the 
injection and ultrasound groups and a MCID for PRTEE function and total in favour of 
exercise over the injection group. A MCID was also found between all 3 groups for 
MDF in favour of ultrasound.  
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CHAPTER 8: DISCUSSION 
 
This chapter discusses the clinical trial results sequentially as reported in the previous 
chapter: the sample, within group changes, short term and long term between group 
analyses and patient preference. The clinical implications, in addition to the limitations 
of the clinical trial are also highlighted. 
8.1 Results 
8.1.1 Sample 
 
From the flow chart for the clinical trial (figure 7.1) it can be seen that at the 6 week 
endpoint 9% (n=6) of patients had withdrawn and 6% (n=4) of patients DNA which 
gave a dropout rate of 15%. This was inline with other studies and was successfully 
reduced from previous work undertaken by Tonks et al. (2007) through the use of a 
team of treating physiotherapists who could offer a wider range of localities and times 
more convenient to the patient. This highlights the fact that patient choice is an 
important factor in treatment compliance, which should be offered, even in the current 
climate. When the withdrawals are considered it is interesting to note that 3 patients 
spontaneously settled to a sufficient extent for them to decline any treatment and 
withdraw from the clinical trial. This supports the self-limiting natural evolution of 
tennis elbow (Assendelft et al., 2003).   
 
Only 60% (n=35) of the patient population did not require further treatment at the 6 
week endpoint and were offered a 6 month review. This implies that for in the region of 
1 in 2 of patients the individual treatment has failed to address all the problems the 
patient was presenting with, which is most markedly evident in the ultrasound group 
with 60% requiring further treatment at 6 weeks. Whether this is due to the patients not 
receiving the optimum duration of treatment or that the treatment is inadequate at 
addressing all of the problems remains in question. The latter suggests that success is 
more likely with a comprehensive treatment programme which includes a variety of 
modalities given simultaneously to address all aspects of the problems a patient presents 
with which is the norm in clinical practice. Alternatively, it may be due to the higher 
expectations from patients to achieve 100% improvement, due to the advances in 
medicine, and remaining unsatisfied with an occasional minor discomfort. 
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In retrospect, on consideration of the design of the 6 month follow up it would have 
been more advantageous to have continued with the ITT analysis from the short term 
into the long term with detailed analysis of co interventions. As the 6 month analysis 
was undertaken on a per protocol analysis, this limited the long term follow up to a 
much smaller sample and selective subgroup of the patient population. Consequently, 
this has led to a reduction in power, in addition, to an increased risk of bias of the long 
term follow up at 6 months.     
 
If the injection group is considered, it can be seen that 32% of those patients who 
received a steroid injection required further treatment at 6 weeks. This implies that 
2/3rds of patients who received an injection became asymptomatic by 6 weeks. Of those 
patients who remained in the trial through to the long term of 6 months 38% complained 
of recurrence of symptoms and sought further treatment. Again, this implies that nearly 
2/3rds of those patients who received an injection remained asymptomatic through to 6 
months. This is supported by a survey of the prevalence of humeral epicondylitis in 77 
patients over a 2 year period. Hamilton (1986) reported that the majority received a 
steroid injection and only a third (36%) complained of a recurrence of symptoms within 
6 months. This is in contrast to the reported high recurrence rates following steroid 
injection (Smidt et al., 2002). Indeed, Bisset et al. (2006) reported a 72% recurrence rate 
with 47/ 65 successes regressing. However, it could be explained through the 
dependency on the definition of recurrence used. If the profile plots for PFG, (graph 
7.9), and PRTEE, (graphs 7.10- 7.12), are reviewed it would appear that there is a 
prominent fall back in the injection group at 6 months which could be construed as a 
very large recurrence rate until the sample data is evaluated. Of course it may be 
attributable to the selective subgroup of the sample analysed at the 6 month long term 
follow up. 
 
In addition, in contrast to tennis elbow being generally described as almost invariably 
affecting the dominant arm, in this research the dominant arm was affected in only 67% 
of patients. Indeed, this is comparable to the 67%, 78% and 63% reported by Bisset et 
al. (2006), Smidt et al. (2002) and Hay et al. (1999) respectively.  
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The mean age was 45 years and would comply with the histological view that tennis 
elbow is a degenerative process. However, this peak incidence questions why the 
incidence of tennis elbow does not continue to increase into older age past 50-60 years 
when a degenerative process would continue to increase with age, as supported by the 
cadaveric findings of Milz et al. (2004). Although barely plausible, a vast reduction in 
activity levels after 45 years could account for a reduction in the stresses placed on 
ECRBr and subsequently reduce the incidence of tennis elbow. It would be hard to 
comprehend how the age related changes of stiffer and more load resistant tendons with 
a reduced collagen turnover rate could preclude one from tennis elbow.     
 
8.1.2 Injection group 
 
There was a MCIC and a statistically significant reduction in thermal difference and all 
aspects of PRTEE and a significant increase in PFG in the short term, between baseline 
and both 10 days and 6 weeks, but this was only sustained for thermal difference 
through to the long term at 6 months.  A MCIC was found for MDF in the short term of 
6 weeks which was sustained through to the long term of 6 months (Table 7.19, p.131). 
This supports the superiority of injection in the short term which is not extended into the 
long term as reported in the systematic review of Smidt et al. (2002). 
  
Pizzeti et al. (1984) proposed that thermography can detect subclinical involvement. As 
the significant reduction in thermal difference was sustained through to the long term 
follow up of 6 months this implies that the underlying biochemical processes which 
have modified the pathological process are still evident although a fall back in PFG and 
pain and disability is noted. However, this may be due to the lack of power evident at 6 
months due to the reduction in patient population through only those patients who 
remained as per protocol being offered an appointment at 6 months and subsequently 
being reduced further due to a high DNA rate. Even so, sustainable thermal change has 
been found which supports Thomas et al. (1992) who reported thermography as a 
sensitive and objective measure for tennis elbow assessment.  
 
So in summary, injection therapy has an immediate effect in reducing temperature, pain 
and disability and increasing PFG within 10 days which is maintained in the short term 
for a minimum of 6 weeks. However, by the long term follow up of 6 months, in the 
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selective subgroup, although the reduction in temperature is sustained this is albeit at a 
subclinical level (Pizzeti et al., 1984). These results highlighted that 2 out of 3 remained 
sufficiently improved not to require further treatment due to a recurrence of symptoms. 
 
8.1.3 Ultrasound group 
 
There was a MCIC and a statistically significant reduction in thermal difference in the 
short term at both 10 days and 6 weeks but only the MCIC was sustained into the long 
term of 6 months. A MCIC was also found for MDF shift from 10 days which was 
maintained through 6 weeks to 6 months, although not statistically significant. In 
contrast, there was a significant increase in PFG and significant reduction in all aspects 
of PRTEE in both the short term at 6 weeks and the long term at 6 months but not at 10 
days. A MCIC was found for PFG and all aspects of PRTEE only in the long term of 6 
months, apart from for PRTEE function where a MCIC was also found at 6 weeks 
(Table 7.20, p.131).    
 
The heat energy gains during a session of therapeutic ultrasound, versus sham, have 
demonstrated a clinically important increase in skin temperature of 0.5 
0
C for 5 to 19 
minutes following a single treatment, (as discussed in Chapter 5.3.3), and these thermal 
effects optimising the healing process are evident through a reduction in temperature 
from 10 days, during which the patient should have received a minimum of 3 treatment 
sessions, equivalent to 50% of their course of treatment.  This demonstrates that 
ultrasound is having an immediate therapeutic effect which is sustained in to the long 
term, albeit sub clinically. 
 
Ultrasound not only appears to increase the efficiency of the normal healing process but 
also enhances the quality of repair through a reduction in fatigue, as can be seen by the 
MCIC for MDF shift in the short term at 10 days although not statistically significant, 
which is sustained through 6 weeks and continues to improve two-fold through to the 
long term at 6 months. In addition the latter finding supports the accumulative 
therapeutic effects of ultrasound. This is further supported by both a statistically 
significant and MCIC found for function at 6 weeks which is sustained through to 6 
months. 
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However, despite the reduction in temperature and fatigue seen at 10 days, albeit 
surprisingly so early, it is interesting to note the concurrent clinical lack of a reduction 
in pain and disability and increase in PFG. The author hypothesises that this initial delay 
in progress is due to the pro inflammatory nature of ultrasound which promotes the 
tissue healing process which may take a number of weeks to complete. The statistically 
significant increase in PFG and reduction in pain and disability by the short term of 6 
weeks was sustained with a MCIC by the long term of 6 months, although the lack of 
power and selectivity at the 6 month follow up must be considered. The increase in PFG 
supports the enhanced quality of repair and return to normal muscle function. This 
continued improvement following the course of treatment, supports the findings of 
Davidson et al. (2001) and Williams (2003) of a continuation in functional improvement 
in the short term with the addition of treatment effects being maintained into the long 
term of 6 months. 
 
So in summary, within 10 days of the commencement of a course of therapeutic 
ultrasound a reduction in both temperature and fatigue was evident which was sustained 
through to the long term of 6 months in the selective subgroup. By 6 weeks, a reduction 
in pain and increase in PFG and function were evident which were sustained through to 
6 months.   
 
8.1.4 Exercise group 
 
No statistically significant thermal differences or MDF shift were found, although a 
MCIC was found at 6 weeks only for thermal difference and at both 6 weeks and 6 
months for MDF shift. There was a statistically significant increase in PFG in the short 
term of 10 days through 6 weeks into the long term of 6 months with a MCIC evident in 
the short term of 6 weeks which was sustained in the long term at 6 months. There was 
a MCIC and a statistically significant reduction in PRTEE pain from the short term of 6 
weeks which was sustained through to long term at 6 months, but not at 10 days. 
However, for PRTEE function and total a MCIC and statistically significant reduction 
was only found in the long term of 6 months (Table 7.21, p.132).  
The MCIC and statistically significant reduction in PRTEE function and total in the 
long term at 6 months was expected and supports the findings of Smidt et al. (2002) and 
Bisset et al. (2005). However, in contrast, it is interesting that PFG was significantly 
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increased, although not a MCIC, within 10 days of commencing their exercise 
rehabilitation programme. Although changes in collagen reorganisation and 
upregulation are generally accepted to take longer than 10 days, neuromotor control has 
the potential to be established within this time frame through the nature of the exercise 
programme done slowly under control, without pain, and, furthermore, the first exercise 
the patient is shown is clenching the fist. In addition to improved neuromotor control, it 
may also be hypothesised that there is an increase in patient confidence in using their 
symptomatic elbow and the knowledge that use and exercise does not equate to harm 
has an effect.  
Similarly, to find a MCIC and a statistically significant reduction in PRTEE pain and a 
MCIC in thermal difference in the short term of 6 weeks, is surprising as pain relief 
through rebalance of the biochemical milieu, (Khan et al., 2000), would only happen 
with collagen repair which is generally accepted to take months rather than weeks.  
 
Although not statistically significant, there is greater than a MCIC for the MDF shift in 
the short term of 6 weeks which is sustained through to the long term at 6 months which 
demonstrates a reduction in fatigue and a return to normal muscle function as expected 
following a 6 week course of physiotherapy exercise rehabilitation programme. 
 
So in summary, the increase in PFG was isolated as the only improvement seen in the 
exercise group by 10 days which was sustained through to the long term of 6 months. A 
reduction in both temperature and fatigue is only evident from 6 weeks with the 
reduction in fatigue only being sustained through to the long term of 6 months. A 
reduction in pain was evident from 6 weeks through to the long term of 6 months with 
an improvement in function only found in the long term of 6 months. However, the lack 
of power and selectivity at the 6 month follow up must be considered.  
 
8.1.5 Short term group analysis 
 
Although randomisation was to a fair effect it was surprising to find an isolated MCID 
for the mean thermal difference between the injection and both the ultrasound and 
exercise groups at baseline. However, this was overcome through the use of a univariate 
analysis of variance with thermal difference at baseline as a covariate. 
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No statistically significant differences for the primary outcome measure thermal 
difference were found between groups although a MCID was found between the 
ultrasound and exercise group at 10 days only (Table 7.22 and Table 7.23, p.132-133). 
When the means profile plot, (Graph 7.1, p.115) is considered alongside with the 
individual group repeated measures analysis one can see a MCID in thermal difference 
for both the injection and ultrasound groups at 10 days which continues to improve 
slightly in the injection group at 6 weeks but decrease slightly in the ultrasound group.  
 
Although no statistically significant differences for the MDF shift were found between 
groups a MCID was found between the ultrasound and both the injection and exercise 
groups concurrently to the thermal difference at 10 days, which could be attributable to 
the power issue. When the ultrasound repeated measures analysis and the means profile 
plot, (Graph 7.2, p.116), is considered a marked MCID reduction in MDF shift is seen 
in the ultrasound group at 10 days which is mirrored in both the injection and more 
markedly in the exercise group by 6 weeks. Again, this challenges the theory of the 
need for exercise rehabilitation as a prerequisite for a reduction in fatigue and a return to 
normal muscle function. It appears that the therapeutic effects of ultrasound, and to an 
extent with injection, so that the patient can subsequently resume normal activities, can 
have an impact on reducing fatigue and prompt a return to normal muscle function.  
 
A MCID and statistically significant difference for PFG was found between the 
injection group and both the ultrasound and exercise groups in the short term at 10 days 
with maintenance through to 6 weeks. No MCID or statistical differences were found 
between the ultrasound and exercise groups in the short term at either 10 days or 6 
weeks. The means profile plot, (Graph 7.3, p.117), highlights the marked increase in 
PFG in the injection group which again supports that due to injection therapy giving 
immediate pain relief this treatment subsequently enables greater grip strength to be 
employed.  
 
This theory is supported by the MCID in PRTEE pain found between the injection 
group and both the ultrasound and exercise groups in the short term at 10 days which is 
sustained through to 6 weeks. Although a statistically significant difference was found 
in the short term of 10 days this was only maintained between the injection and 
ultrasound group at 6 weeks. No MCID or statistically significant differences were 
found between the ultrasound and exercise groups in the short term at either 10 days or 
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6 weeks. The means profile, (Graph 7.4, p.118), highlights the marked reduction in pain 
in the injection group at 10 days which continues to improve through to 6 weeks. The 
exercise group reduces pain from 10 days through to 6 weeks by a similar degree, over 
this time interval, to the injection group.  
 
A MCID in PRTEE function was found between the injection group and both the 
exercise and ultrasound groups in the short term at both 10 days and 6 weeks although 
only the difference between the injection and ultrasound groups was statistically 
significant. No MCID or statistically significant difference was found between the 
exercise group and ultrasound groups in the short term of 10 days or 6 weeks. The 
marked increase in function in the injection group at 10 days is highlighted in the means 
profile plot, (Graph 7.5, p.119), and continues to improve through to 6 weeks albeit at a 
slower rate. This corroborates the findings of increased PFG and reduced pain seen in 
the injection group in the short term. 
 
A MCID and statistically significant difference for PRTEE total was found between the 
injection group and both the ultrasound and exercise groups in the short term at 10 days 
with maintenance through to 6 weeks. No MCID or statistical differences were found 
between the ultrasound and exercise groups in the short term at either 10 days or 6 
weeks. The means profile plot, (Graph 7.6, p.120), again highlights the marked increase 
in function and reduction in pain seen in the injection group at 10 days which is 
continued through to 6 weeks, albeit at a slower rate. 
 
So in summary, both a MCID and a statistically significant difference is evident for 
PFG and PRTEE total which demonstrates superior effectiveness for injection therapy 
immediately within 10 days which is sustained and continues to improve albeit by a 
lesser degree through to the short term of 6 weeks. However, no differences were found 
for thermal difference or MDF outcome measures. The only differences found between 
the ultrasound and exercise groups was a MCID for  thermal difference at 10 days and a 
MCID for MDF between the ultrasound group and both the injection and exercise 
groups at 10 days in favour of ultrasound.  
 
These results for the superior effectiveness of injection therapy in the short term support 
the findings of Smidt et al. (2002) and Bisset et al. (2005). With respect to the lack of 
difference between groups for thermal difference, when the profile plots, (Graph 7.1, 
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p.115), are considered both injection and ultrasound have a marked and an immediate 
MCID at 10 days. Subsequently, one can hypothesise that both the anti inflammatory 
effect of injection and the proinflammatory effect of ultrasound, utilising an additional 
thermal effect, both promote healing through contrasting methods which is 
demonstrated through a reduction in thermal difference which monitors, in at least a 
subgroup of the tennis elbow population, the potential underlying inflammatory 
processes through temperature change. This profile questions the current research which 
proposes, that in all cases, tennis elbow is an angiofibroblastic tendinosis which is 
distinctly non-inflammatory and supports Kjaer (2004) who could not completely 
exclude an inflammatory component. It also promotes the practice of injection therapy 
for tennis elbow patients with superior effectiveness in the short term.  
  
With respect to the lack of difference for MDF shift it appears from the means profile 
plots, (Graph 7.2, p.116), that all treatment groups have an effect on reducing fatigue 
but again work by contrasting actions. Ultrasound has an immediate effect whilst in 
contrast both injection and exercise have an effect between 10 days and 6 weeks. The 
author hypothesises that the lack of a reduction in ECRBr fatigue in the injection group 
by 10 days may be explained by the fact that as pain was relieved immediately by virtue 
of the injection the patient’s PFG increased markedly but the resulting deconditioned 
musculature still presented with fatigue. This could be due to the advice given following 
injection for relative rest for a week, which presuming the patient had been compliant, 
would mean that on retesting at 10 days this could be the first time that a patient had 
‘tried out’ their renewed grip function. However, through resumption of normal 
activities fatigue was reduced markedly by 6 weeks. This would imply that fatigue 
changes are fully reversible through injection therapy or ultrasound alone and 
physiotherapy rehabilitation is a not a prerequisite to return to normal muscle function.  
 
Apart from the marked reduction in MDF at 6 weeks, (Graph 7.2, p.116), the profiles 
demonstrate that exercise therapy has a gradual reduction in thermal difference and a 
gradual increase in PFG with more reduction in pain and disability from 10 days to 6 
weeks. The therapeutic effects of exercise take time, as was expected, but even so to 
find a change within 6 weeks is surprising and highlights the benefit that can be 
achieved through the use of this particular exercise regime. 
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8.1.6 Long term group analysis 
 
Due to the use of an as per protocol analysis at 6 months, there was a large loss of 
patients to alternative treatment at 6 weeks which was exacerbated by the high DNA 
rate in both the exercise and ultrasound groups in particular, the use of LOCF in the 
analysis highlighted the little difference found between 6 weeks and 6 months, 
excluding the injection group for whom 38% required further treatment due to 
recurrence which was highlighted in the analysis as an increase in pain and disability 
and a poorer outcome. Consequently, as previously discussed, the long term follow up 
at 6 months was limited to a much smaller sample and selective subgroup of the patient 
population which not only generated a power issue in addition to an increased risk of 
bias but also caused difficulty with interpretation and brought the value of the long term 
analysis into question.     
  
For all groups, for the primary outcome measure thermal difference a MCIC was found 
in the short term from 10 days and was maintained through 6 weeks and sustained into 
the long term at 6 months. A statistically significant change was only found in the short 
term at 6 weeks which was sustained through to the long term at 6 months. This 
supports that thermal difference is a sensitive and objective measure for both the 
diagnosis and assessment of tennis elbow (Haake et al., 2002 and Thomas et al., 1992). 
However, no MCID or statistically significant difference was found between groups in 
the long term at 6 months (Table 7.24, p.133). If the profile plot, (Graph 7.7, p.122), is 
considered no significant change from the short term at 6 weeks to the long term at 6 
months is evident. This would imply that the temperature changes evident through 
thermal difference have been sustained even despite the increase in pain and decrease in 
function seen which subsequently means a subclinical temperature change persists. 
Consequently, it leads one to question why the injection group’s effectiveness 
deteriorated so markedly after the short term. One theory to be proposed is that adcortyl 
has a duration of action in the region of 6 weeks (Saunders, 2002) and that as not all 
aspects of the cause of the problem have been addressed it has recurred due to a 
potential predisposition to tendinopathy. However, if the drugs therapeutic action was 
only for 6 weeks one would question why the subclinical thermal difference persists 
through to 6 months. This implies that injection only temporarily treats part of a 
complex problem and unless all components are addressed resistance to treatment may 
persist. 
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No statistically significant differences were found between any groups for MDF in the 
long term at 6 months. However, a MCID was found between all groups. If the profile 
plot, (Graph 7.8, p.123), is considered no significant change from the short term at 6 
weeks to the long term at 6 months is evident apart from a slight reduction in the 
exercise group which has led to a MCID at 6 months to be evident again. 
 
No statistically significant differences were found between any groups for PFG in the 
long term at 6 months. However, when the means profile plot, (Graph 7.9, p.124), is 
considered it highlights the marked decrease in PFG for the injection group in the long 
term of 6 months back to near baseline levels, whereas for both the ultrasound and 
exercise groups an increase in PFG continues, albeit small.  
 
No statistically significant differences were found between any groups for PRTEE pain 
although a MCID was found between the exercise group and both the ultrasound and 
injection groups in the long term at 6 months. This MCID was also found between the 
exercise and injection groups only for PRTEE function and total scores. However, when 
the means profile plots, (Graph 7.10, 7.11 and 7.12, p.125-7), are considered they 
highlight the marked increase in pain and decrease in function for the injection group 
from the long term at 6 months back to near baseline levels. This supports the findings 
of Hay et al. (1999), Smidt et al. (2002) and Bisset et al. (2006) who all reported that the 
superior effectiveness of injection therapy in the short term was not maintained into the 
long term and there were more favourable outcomes for pain relief and grip strength 
with physiotherapy.  
 
8.1.7 Patient preference 
 
From clinical experience patients tend to fall into 2 categories: those with definite 
strong preference, with respect to injection in particular, and those who just want their 
problem resolved by ‘whatever’ following your ‘expert’ advice on best practice. 
Although on evaluation of preference with this research strong preference was found 
with injection therapy at 68%, this was not the case with either of the ultrasound or 
exercise groups with 47% and 6% respectively having a strong preference for the 
treatment they were receiving. This was further highlighted by 1 in 4 and 1 in 8 
respectively having no preference for any particular treatment. This is in contrast to 
Smidt et al. (2002) who found a large preference for physiotherapy. 
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At 10 days following treatment 68% of the injection group had a strong preference for 
injection which rose to 84%. This was surprising when 19% of patients reported a 
dislike towards needles, 12.5% found only short term relief and 56% complained of 
pain or discomfort during treatment. However, with respect to the latter, as only 5% 
suggested reintroduction of the local anaesthetic and the strong preference for injection 
rose one can hypothesise that the pain was potentially only minor in nature. This is 
supported by Lewis et al. (2005) who reported 62% of patients in the injection group 
recorded higher pain scores on day 1 of follow-up and that any post injection pain was 
perceived as acceptable. Injection was perceived as a ‘quick fix’ with 77% claiming 
pain relief within a week and 22% commenting that treatment only required one visit. 
This, again, is supported by Lewis et al. (2005) who reported significantly greater pain 
reduction within 3 days when compared to placebo and within 4 days when compared to 
naproxen.  Globally, this suggests that patients were highly satisfied with injection 
treatment. 
 
In comparison, at 10 days following treatment only 47% of the ultrasound group stated 
a preference for ultrasound with 26% having no preference which subsequently changed 
to 35% of patients having a preference for ultrasound and 35% no preference. In 
contrast ultrasound was perceived as a quick, pain free treatment by 67% of patients, 
although 28% did not think the treatment to be effective. 85% had no suggestions for 
improving their treatment whilst 10% suggested either a longer course of ultrasound or 
a combination of ultrasound and exercise.    
 
However in distinction, at 10 days following treatment only 6% of the exercise group 
stated a preference for exercise which rose to only 11% following treatment. This was 
further highlighted by 56% dropping to 44% preferring ultrasound and 25% dropping to 
17% injection. This is surprising considering that 53% of patients found the exercises 
helped and 37% found them easy to do and furthermore 58% had no suggestions for 
improving their treatment.      
 
When preference for further treatment on hypothetical recurrence is considered: whilst 
67% of patients would prefer to have a repeat injection and 55% of patients would 
prefer to have a repeat course of ultrasound only 17% of patients would prefer further 
exercise if their pain recurred.  
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This evaluation not only supports clinical experience that patients have a very strong 
preference with respect to injection but that patients also have a surprisingly strong 
aversion towards exercise. It strongly suggests that patients are more satisfied with 
either injection or, albeit to a smaller extent, ultrasound treatment and that the general 
preference of patients for passive and quick fix treatments persists.   
 
8.1.8 Summary of findings 
 
Table 7.25 (p.134) summarises the overall findings for between group differences 
overtime. The main findings of this research were that in the short term at 10 days the 
injection group was the most effective and the exercise group the least effective. The 
superior effectiveness of the injection group was maintained through to 6 weeks with 
the ultrasound group now the least effective. The short term superior effectiveness of 
injection therapy was highlighted with both statistically significant and minimum 
clinically important differences found between the injection group and both the 
ultrasound and exercise groups. However, no statistically significant or minimum 
clinically important differences were found between the ultrasound and exercise groups. 
In contrast in the long term at 6 months, the exercise group was now the most effective 
followed closely by the ultrasound group, although no statistically significant 
differences were found and only MCIDs were found in favour of exercise compared 
with injection. However, as previously discussed, due to the loss of power these long 
term findings must be regarded with caution.  
 
8.2 Clinical implications 
 
Consequently in conclusion, the results from this trial found that all 3 treatment groups 
showed improvement overtime for different aspects of the clinical picture at different 
time intervals. The results for injection therapy support the previous conclusions of 
Bisset et al. (2006) and Smidt et al. (2002) that injection has superior effectiveness in 
the short term with both statistically significant and minimum clinically important 
differences when compared with physiotherapy and exercise. However, although Bisset 
et al. (2006) and Smidt et al. (2002) found injection to be significantly worse than 
physiotherapy and wait and see in the long term, and although in this trial, exercise was 
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ranked most effective no statistically significant differences between groups were found 
just a MCID for the exercise group over injection for PRTEE. Although, these 
conclusions should be regarded with caution due to the power issue and potential risk of 
bias, this supports the findings of the pooled analysis of Smidt et al. (2002), Bisset et al. 
(2006) and Tonks et al. (2006) by Coombes et al., (2010) who reported no group being 
favoured in either the intermediate or long term.  
 
Bisset et al. (2007) and Smidt et al. (2005) found marked similarities for the course of 
pain for patients who received injection between the studies of Smidt et al. (2002) with 
Bisset et al. (2006) and Hay et al. (1999) respectively which mirror this research; an 
immediate marked reduction in pain with recurrence after 6 months although in contrast 
they reported high recurrence rates in comparison to this trial’s lower rates with PFG, 
pain and disability relapsed in only a 1/3
rd
 of patients by the long term of 6 months 
supporting Hamilton (1986). This may simply be due to a loss of power at 6 months 
although evidence has suggested that single injections are more effective (Coombes et 
al., 2010) and all conservative treatment should be fully exhausted prior to repeat 
injection which is supported by this trial and is a potential reason for less recurrence 
found in this trial which utilised only a single injection compared with Smidt et al. 
(2002) and Bisset et al. (2006) who allowed repeat injections up to 3 or 2 injections 
respectively.  
 
They query the reason for recurrence suggesting that steroids may be potentially 
harmful in the long term or that patients simply overuse their elbows too quickly due to 
the immediate resolution of symptoms. However, with respect to the former, if steroids 
were detrimental one would surely expect to at least see a reported higher incidence of 
adverse effects following injection for tennis elbow whereas steroid injections are well 
tolerated with minor and infrequent side effects (Gaujoux-Viala et al., 2009). The 
preference analysis could support the latter as a potential cause of recurrence as the 
injection group preferred the quick fix and more passive treatment wishing their pain 
and disability to be resolved without inconvenience to them and this could potentially 
cause return to previous activities without consideration of the consequences. If patients 
are informed about the superiority of injection therapy in the short term and the chance 
of 2 in 3 remaining symptom free into the long term, as found in this trial and supported 
by Hamilton (1986), one can postulate a large percentage of patients would be willing to 
take those odds.   
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From this trial continuous 3 MHz therapeutic ultrasound at 2W/cm
2
 for 5 minutes has 
demonstrated a clinically important increase in skin temperature of 0.5
0
C for 5 to 19 
minutes following a single treatment and these thermal effects have optimised the 
healing process which is evident through a reduction in thermal difference from 10 
days. The accumulative effect of ultrasound has been demonstrated with a continuous 
improvement in all outcome measures by 6 weeks which are sustained into the long 
term. The results also suggest that exercise is not necessarily a prerequisite to resolution 
of symptoms which is highlighted by a MCID for reduction in fatigue by 10 days and an 
increase in function by 6 weeks. From the findings of this trial these parameters for 
ultrasound need to be evaluated further and advocated in clinical practice as an 
alternative treatment, in particular for those patients who are unable or unwilling to be 
treated with injection therapy. 
 
From this trial, the exercise group demonstrated general slow improvement overtime 
with changes in fatigue at only 6 weeks and changes in function at 6 months when 
ranked as the most effective. In comparison to Smidt et al. (2002), it was surprising to 
find such a strong aversion to exercise and the difficulties of exercising with tennis 
elbow in the short term were highlighted by 2 patients withdrawing at 10 days and 10% 
complaining of aggravation of symptoms. 
 
Figure 8.1 (Haynes and Haines, 1998) puts the implementation of clinical findings in to 
context. The application of research findings is as important as the conduct of the 
research itself.  The aim is to transform findings into clinical policies which can be 
applied at the right place in the right way and at the right time. There is a need to 
develop evidence based practice to ensure that the patient receives optimal treatment 
improving both the quality and efficiency of our services. 
 
As can be seen the 3 important factors to be considered when making clinical decisions 
are not only the evidence but equally the individual patients’ needs and their wishes. 
Consequently, patient preference needs to be taken into account which from this 
research was a strong preference for injection or, but to a lesser degree, ultrasound over 
exercise. 
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Figure 8.1: Application of research findings (Haynes and Haines, 1998). 
 
Similarly, the patient’s individual circumstances need to be taken into account so that if 
a patient’s short term outcome is more important than their long term outcome, such as 
loss of their job or suffering financial hardship through extended sick leave for example, 
injection treatment may be offered even if it is for only an interim period (Orchard, 
2011). This is supported from the findings of Bisset et al. (2007) who reported that for 
patients with high baseline pain severity, physiotherapy was not found to be 
significantly better than wait and see in the short term. Indeed, Smidt et al. (2006) 
reported high baseline pain severity as a poor prognostic indicator at 1 month. 
Furthermore, Gaujoux-Viala et al. (2009) reported that steroid injections were more 
effective in acute or subacute tendonitis, (< 12 weeks), and concluded that the optimum 
timing for injection may be in the early weeks of symptoms where the potential benefit 
appears clearer when compared with chronic tendinopathy. 
 
Patient collaboration in treatment choice is of paramount importance and the pros and 
cons with respect to treatment options need to be discussed with the individual patient. 
An area for further research in tennis elbow is the identification of effect modifiers for 
tennis elbow patients to be able to identify best practice for different subgroups of 
patients through linear regression of a large, highly powered trial or further evaluation 
of the pooled data from a number of robust homogeneous trials to substantiate the 
reported assertions, although the latter would be difficult due to the large variability in 
physiotherapeutic interventions. 
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Further research is also needed to investigate the effectiveness of continuous ultrasound 
with exercise and advice versus injection with exercise and advice to identify whether 
the short term superior effectiveness of injection therapy is sustained in to the long term 
with the use of exercise as an adjunct or whether ultrasound and exercise has greater 
effectiveness to inform the debate on best practice for this notoriously difficult 
condition to treat. The inclusion of injection with exercise therapy is important because, 
although PFG has reduced and pain and disability recurred in the long term, thermal 
difference remained markedly improved, albeit subclinically, and MDF shift had a 
downward trend which implies that the underlying biochemical processes which have 
modified the pathological process are still evident. Similarly, it may further inform the 
debate on the reasoning for recurrence. Only 2 trials, Newcomer et al. (2001) and Tonks 
et al. (2007), have assessed a combination of injection and exercise and both trials were 
underpowered. Currently 2 study protocols, Coombes et al. (2009) and Olaussen et al. 
(2009), have been published to assess the benefits of a combination of physiotherapy 
and injection. 
 
In addition, the effects of ultrasound given over a longer time period or less frequently, 
for example in the region of once a week for 6 weeks, as such is the availability for 
treatment in some Trusts due to high patient loads and limited appointment availability 
in the current climate of financial constraints is needed to investigate the optimum 
parameters of ultrasound treatment.  
 
Also of clinical importance, when patient preference is considered 1 in 2 patients 
complained of pain or discomfort during the injection. From clinical experience this was 
surprising as the majority of patients usually comment that the injection was not as bad 
as they had expected. In contrast, when the local anaesthetic is given for other 
injections, in a bolus form, this is when the patient generally would report pain. Due to 
the peppering technique involved with the injection for tennis elbow one would expect 
the actual peppering of the local anaesthetic to be more painful not only due to the 
chemical itself but also due to the injection taking twice as long. Lewis et al. (2005) 
evaluated post injection pain and reported it to be of an insignificant magnitude. 
However, the patients’ comments need to be taken into consideration and patient 
preference to include local anaesthetic will need to be investigated further.    
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Even though Hamilton (1986) reported that patients suffered tennis elbow symptoms for 
a mean of 41 days before presentation, another ongoing issue is that 16% of injection 
and 10.5% of exercise patients felt that the time taken from first seeing their GP to 
treatment could have been shorter. The importance of this wait was highlighted by Bot 
et al. (2005) and Smidt et al. (2006) who reported longer duration of symptoms before 
consultation with the GP, due to patients often only presenting after having waited a 
while to see if their elbow settles spontaneously, increased the likelihood of an 
unfavourable outcome and potentially an increased risk for the development of a 
chronic condition. If the model proposed by Coombes et al. (2009) is considered this 
would lead to not only motor system dysfunction but also pain system impairments, 
including central sensitisation, which would lead to a more difficult condition to treat. 
There are a number of potential reasons for delay in referral, including interpretation of 
the robust trial of Smidt et al. (2002) that wait and see combined with naproxen is 
probably the most cost effective treatment for tennis elbow in the long term when 
compared to injection and pulsed ultrasound with exercise. However, in the short term 
there were both SSDs and MCIDs in favour of injection and the success rates of 
physiotherapy, even using only pulsed ultrasound, were 15% more than the wait and see 
group. Together with the patient preference data one can surmise that patients both 
expect and prefer a quick fix to enable them to both continue with their work and 
function without limitation of their activities of daily living rather than them potentially 
having to ‘put their life on hold’ for 6 to 12 months. Furthermore, the self-limiting 
nature of tennis elbow remains in contention with Bot et al. (2005) reporting poor 
recovery at 12 months. They also suggest that treatment could be an important predictor 
of outcome due to clinical decisions to treat based on prognostic indicators such as 
duration and pain severity, as recommended by the Dutch general practice guidelines to 
only offer injection or physiotherapy to patients with severe and persistent pain and 
disability.  Also, the issues surrounding the potential adverse reactions following long 
term use of NSAIDs with potential gastrointestinal bleeds and associated costs need to 
be taken into consideration in addition to the potential deleterious effects of these drugs 
on tendon healing (Orchard, 2011). However, these effects have not materialised and in 
contrast wait and see with the use of NSAIDs has been found to be of superior 
effectiveness in the long term (Smidt et al., 2002). 
 
The clinical utility of the 6 outcome measures employed in this clinical trial varied. The 
PRTEE pain, function and total used in conjunction with PFG are sensitive outcome 
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measures which can monitor treatment effects for tennis elbow patients. They are 
readily available in most clinical settings and only require a minimum of time for 
completion. In contrast, both the thermal and EMG outcome measures are more time 
consuming, with respect to the data collection, processing and analysis, in addition to 
the equipment required which is both highly technical and expensive with limited 
availability in the clinical setting. Even so, for the purposes of this clinical trial and 
research on tennis elbow they revealed some interesting, novel and useful data. It has 
not only confirmed and contested the findings of previous research on tennis elbow but 
has given greater weight to the use of thermal imaging in the clinical setting to monitor 
the progress of tennis elbow patients and their response to treatment through the 
development of a novel protocol for this trial. Thermography has also identified the 
utilisation of the thermal effects of continuous ultrasound which warrants further 
research in tendinopathy. The protocol developed for the MDF shift outcome measure 
has demonstrated that isolated ECRBr fatigue can be evaluated through surface EMG 
although EMG utility as an outcome measure in clinical practice is questionable. 
 
The analysis of the physiological data from this clinical trial could be taken further 
through identification of any relationships between thermal difference or MDF shift and 
PFG and PRTEE to explore the mechanisms through which injection and ultrasound 
work. Also of importance would be further analysis of the data to identify the extent 
that thermal difference or MDF changes mediate treatment effects. 
  
8.3 Limitations of the clinical trial 
 
A major issue was the sample size calculation for this clinical trial which was 
challenging as there was no existing data for the primary outcome measure of thermal 
difference. From the literature there was only scarce data in the field of the secondary 
outcome measure of MDF and even so this was mainly on a normal population and not 
based on between group differences. From this data the sample size required was in the 
region of 21 patients in each group with an effect size of larger than 0.9. When the 
internal pilot and the stabilisation of data was considered the data had stabilised which 
confirmed that a sufficient sample size of 21 patients per group had been recruited to 
detect a MCIC. However, when the between group differences were considered there 
was a maximum of 0.25 
0
C difference between groups which was greater than the a 
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priori defined 0.2 
0
C MCIC. As the SD was in the region of 0.4- 0.5 for all groups this 
gave a moderate ES of 0.5 which would require a sample size of 60 patients to detect 
this MCID, which was unfortunately beyond the scope of this clinical trial. 
Consequently, this clinical trial has a lack of power to detect difference between groups. 
However, due to the robust methods that have been utilised and the consistency of the 
short term results had the clinical trial been sufficiently powered where only a MCID 
was detected a statistically significant difference probably would also have been found.  
 
As previously discussed, as the 6 month analysis was undertaken on a per protocol 
analysis, this limited the long term follow up to a much smaller sample and selective 
subgroup of the patient population. Consequently, in addition to the high DNA rate at 6 
months this led to a further reduction in power and an increased risk of bias in the long 
term. Only 50% of the exercise group attended and all 7 who attended were satisfied 
with their outcomes and did not wish further treatment. Only 1 out of 8 patients 
attended at 6 months in the ultrasound group and they were satisfied with their outcome 
and declined further treatment. Although a lower DNA rate was apparent for the 
injection group 38% required further treatment.   
 
Another challenge, with respect to the data for the MDF shift outcome measure, was the 
finding of interference on the tennis elbow patient data which highlights the obstacles 
that need to be overcome when undertaking research within the clinical setting.  
 
The inability to blind patients to their allocated treatment is an ongoing issue of 
potential bias within randomised trials, although this is not so relevant in pragmatic 
trials where you compare treatments as carried out as in normal clinical practice. Patient 
treatment preference could influence both their response to treatment and their scoring 
of subjective outcome measures such as the PRTEE. This was overcome to an extent 
through the use of a select group of both objective and subjective outcome measures 
undertaken by a single researcher who was blind to randomisation and through the 
evaluation of preference for the treatments. As can be seen in table 7.18 preference was 
unequally distributed across treatment groups which increased the risk of biased 
estimation of subjective outcome.  
 
Unfortunately preference was first evaluated at 10 days after commencement of 
treatment, and not as suggested by van der Windt et al. (2000) prior to randomisation, 
 156 
so potentially the actual treatment that the patient received may have influenced their 
decision and already raised potential bias. Smidt et al. (2002) found that the large 
preference for physiotherapy in their trial showed little effect on outcome, whereas from 
subgroup analysis of frozen shoulder patients van der Windt et al. (2000) reported that 
only for patients in the injection group, allocation to the preferred treatment had some 
influence on success rates. If one considers the change in preference after 10 days of 
treatment and after completion of treatment at 6 weeks it can be postulated that due to 
the good outcome of injection although 68% had a strong preference initially this rose 
to 84% following treatment. Subsequently one would expect better success rates for the 
injection group in the long term within this trial which were evident in comparison to 
previous research. However, this was not the case when the ultrasound and exercise 
groups are considered: 47% of the ultrasound group had a preference for ultrasound 
which subsequently dropped to 35% after completion of treatment and only a minimal 
6% of the exercise group had a preference for exercise which subsequently increased by 
twofold to 11% after completion of treatment.  
 
Two other suggestions by van der Windt et al. (2000) to reduce bias from patient 
preference were to exclude patients who have previously received any treatments 
included in the trial which would have reduced this population by in the region of 9% or 
by excluding patients with a treatment preference which was acknowledged and would 
have been unacceptable through depletion of the patient population. 
 
Blinding of the researcher was successful in the most part with the researcher having 
only 25 correct guesses, 18 incorrect guesses and no idea about a further 7 patients at 
review. Only 2 patients’ treatment group was unmasked through a slip of the tongue by 
the patient or administration staff. The rationale for the guess was based on clinical 
reasoning of the outcome measures as a whole after assessment and matching with an 
expected outcome overtime following a particular intervention, most notably the quick 
resolution of pain and increase in function following injection. This implies that as the 
guess was formulated after outcome measure assessment it was unlikely to have 
influenced the actual assessment of the outcome measure itself.       
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CHAPTER 9: CONCLUSIONS 
 
In conclusion this trial supports previous findings that injection is superior in the short 
term of 6 weeks. Despite the power and selectivity issues discussed and the consequent 
questionable value of the long term findings through to 6 months, the trends observed in 
this trial found recurrence following injection but to a lesser magnitude than previously 
reported. This trial supports previous findings that outcomes are better with exercise 
rehabilitation and physiotherapy when compared to injection in the long term, although 
not of a magnitude which is statistically significant or clinically relevant.  
 
Thermal difference using the protocol developed in this trial is a sensitive outcome 
measure for tennis elbow and has been shown to track temperature changes within both 
the injection and ultrasound groups overtime. On analysis of the injection group thermal 
difference tracks the changes of both the PFG and PRTEE outcome measures in the 
short term up to 6 weeks but not at 6 months. These results support the theory that 
thermography can detect subclinical changes which implies that the underlying 
biochemical processes which have modified the pathological process are still evident 
although pain and disability have recurred. 
 
The heat energy gains during a session of continuous therapeutic ultrasound have 
demonstrated a clinically important increase in skin temperature of 0.5
0
C for 5 to 19 
minutes following a single treatment and that these thermal effects optimise the healing 
process which is evident through a reduction in thermal difference from 10 days. 
Furthermore, the theory of an accumulative effect of ultrasound has been supported by a 
continuation of improvement in to the long term of 6 months.  
 
The results also support that exercise is not necessarily a prerequisite to resolution and 
is highlighted by ultrasound treatment demonstrating a MCID for reduction in fatigue 
by 10 days and an increase in function by 6 weeks in contrast to the exercise group who 
demonstrated changes at only 6 weeks and 6 months respectively. 
 
Patient preference demonstrated strong preference for injection and to a lesser degree 
ultrasound as the modalities of choice and a strong aversion towards exercise. These 
findings need to be considered in clinical practice. The patient’s individual 
circumstances also need to be taken into account and patient collaboration in treatment 
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choice is of paramount importance; the pros and cons with respect to treatment options 
need to be discussed with the individual patient to be matched with their priority goals. 
If a patient presents with non severe pain and can cope with their current limitations 
physiotherapy or exercise may be the treatment of choice. However, conversely if a 
patient presents with severe pain and their short term outcome is of more importance 
then injection may be the treatment of choice for early resumption of activity either with 
an exercise programme or acknowledgement that 1/3
rd
 of patients will suffer a 
recurrence of symptoms with a potentially poorer prognosis.  
 
This research can be taken forward through further translational research exploring the 
associations of the physiological data of thermal difference and MDF with PFG and 
PRTEE and exploring to what extent thermal and MDF changes mediate treatment 
effects. It would also be of value to analyse the combination of treatments as is the norm 
in clinical practice: injection with exercise to see if the superior effectiveness is 
extended into the long term and any additional value of ultrasound with exercise. The 
benefit of continuous ultrasound utilising the thermal effects in the treatment of tennis 
elbow is also a notable area for further investigation. Another important area for further 
research is identification of effect modifiers for tennis elbow patients and identification 
of best practice for different subgroups of patients through linear regression of a large, 
highly powered trial to substantiate the reported assertions. 
 
In summary this randomised clinical trial found: 
 
in the short term of 10 days and 6 weeks 
 injection therapy is the most effective treatment demonstrating both statistically 
significant and minimum clinically important differences for PFG and PRTEE in 
comparison to  ultrasound and exercise.  
 patients had a strong preference for injection.  
 no statistically significant differences were found between ultrasound and 
exercise although a MCID was found in favour of ultrasound for thermal 
difference and MDF at 10 days. 
 
in the long term of 6 months 
 no statistically significant differences were found between injection, ultrasound 
or exercise. A MCID was found in favour of ultrasound for MDF and a MCID 
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was found in favour of exercise over injection for all aspects of PRTEE and 
over ultrasound for PRTEE pain only. 
 
This research supports the superior effectiveness of injection in the short term of 6 
weeks and should be advocated for patients who present early with severe limiting pain 
and have important short term goals, although patients need to be warned that a 1/3
rd
 of 
patients will suffer a recurrence of symptoms associated with a potentially poorer 
prognosis. Evidence has suggested that single injections are more effective and all 
conservative treatment should be fully exhausted prior to repeat injection (Coombes et 
al., 2010).  
 
In contrast for those patients who present with moderate to low pain physiotherapy 
including exercise and/ or ultrasound should be advocated. Further research on the 
efficacy of a combination of injection with physiotherapy is required. 
 
Continuous 3 MHz therapeutic ultrasound at 2W/cm
2
 for 5 minutes utilises thermal 
effects which optimise the healing process and demonstrate an accumulative effect of 
ultrasound in to the long term. These parameters should be advocated in clinical 
practice.  
 
Exercise is not necessarily a prerequisite to resolution. 
 
Thermal difference using the protocol developed in this trial is a sensitive outcome 
measure for tennis elbow overtime and can detect subclinical involvement.  
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CHAPTER 11: APPENDICES 
11.1 Normative study consent form 
 
CONSENT FORM 
 
 
Subject Identification Number for this trial:  
 
 
Title of Project: EMG and thermographic analysis of the lateral elbow in a pain and 
pathology free sample 
 
 
Name of Researchers: Jeanette Tonks   
 
 
     Please initial box 
 
I confirm that I have read and understood the information sheet dated 7/10/05 
(version 1) for the above study and have had the opportunity to ask questions. 
 
 
I understand that my participation is voluntary and that I am free to withdraw at any 
time, 
without giving any reason, without my legal rights being affected. 
 
 
I agree to take part of the above study 
 
 
 
 
 
       Name            Date    Signature 
 
 
       
 
 
      Researcher    Date    Signature 
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11.2 Normative study information sheet 
INFORMATION SHEET  Version No 2 Date: 20/2/07  
 
 
TITLE OF STUDY: EMG and thermographic analysis of the lateral elbow in a pain  
and pathology free sample 
  
 
NAME OF RESEARCHER: Jeanette Tonks 
      
You are being invited to take part in a research study.  Before you decide it is important 
for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and discuss it with me if you wish.  
Ask me if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part.  Thank you for reading this.  
 
 
What is the purpose of the study? 
 
We would like to invite you to take part in a research study investigating the thermal 
imaging of the outside part of the elbow and the muscle function of a group of muscles 
on the back of the forearm  
 
 
Why have I been chosen? 
 
All staff and students at UCLAN who do not have any pain or problems with either of 
their elbows are eligible for inclusion in this study. Request for volunteers will initial be 
to AHP’s via email. Those who are suitable with respect to age and gender of patients 
who complain of tennis elbow will be invited. 
 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you do decide to take part you 
will be given this information sheet to keep and asked to sign a consent form.  If you 
decide to take part you are still free to withdraw at any time.  
 
 
What will happen to me if I take part? 
 
If you agree to participate in the study a picture of both your elbows will be taken using 
a special camera that measures heat. 
 
Sticky electrodes will be placed on both your forearms to tell us how your muscles are 
working whilst your grip strength will be taken three times. 
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4 skin fold measurements will be taken on your arm, leg and abdomen. You may wish 
to bring some shorts and a short sleeve top. 
 
You will be asked not to drink alcohol from the night before and not to apply any 
creams to the area on the day of the assessment. You will be asked to avoid food 
consumption, strenuous exercise, drugs, caffeine and nicotine for 2 hours prior to the 
assessment if possible. 
 
  
What are the disadvantages/ risks of taking part? 
 
There are no known risks to you from your inclusion in the study.  
 
 
What are the benefits of taking part? 
 
As an individual probably none, however you will be helping us to understand more 
about the thermal imaging and muscle function of the outside of the elbow. This in turn 
will help us to understand more about tennis elbow which will lead to better treatment 
of this condition in the future. 
 
Will my taking part in this study be kept confidential? 
 
All information, which is collected, about you during the course of this research will be 
kept strictly confidential.  If a scientific paper is written about the results your name and 
details will be removed completely so that you cannot be recognized from it. 
 
 
Who has reviewed this study? 
 
The Faculty of Health University (UCLAN) Ethics committee have reviewed this study. 
 
 
Contact for further information. 
 
Jeanette Tonks, Orthopaedic Physiotherapy Practitioner on 01942 774605 
 
 
You will be given a copy of this information sheet as well as the consent form for taking 
part in the study.  
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11.3 Normative study data collection sheet 
NORMAL DATA COLLECTION SHEET 
 
NUMBER AGE GENDER 
 
DOMINANCE TENNIS 
 
 
SMOKE DIABETES CIRCULATION 
 
UPPER QUADRANT PROBLEM (6/12) 
 
 
PH UPPER QUADRANT PROBLEM 
 
 
 
SKIN FOLD TEST 
 
 1 2 3 MEAN 
TRICEPS 
 
    
ABDOMINAL 
 
    
SUPRAILIAC 
 
    
THIGH 
 
    
 
 
    
LATERAL 
EPICONDYLE 
    
 
%Bf - female = 0.29669(∑4sf) – 0.00043(∑4sf)2 + 0.02963(age)+1.4072 
%Bf – male = 0.29288(∑4sf)-0.0005(∑4sf)2+0.1584(age)-5.76377 
 
%Bf =  
 
ROOM TEMP  TIME  
CAMERA DIST    
 
ELECTRODE PLACEMENT 
 
A=Radius length  
(lat epicondyle-radial styloid) 
R  L  
B=0.078 x A  
(up lat humerus to ECRL origin) 
    
C=ECRL origin to radial styloid length     
D=0.476 x C =ECRBr belly     
 
GRIP STRENGTH 
 
MAX 1 R                                      L  
MAX 2     
MEAN     
50%     
ACTUAL     
+30SEC     
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11.4 Normative study faculty of health ethics committee 
approval 
 
19 October 2005 
 
 
 
 
Jeanette Tonks 
Allied Health Professions  
University of Central Lancashire 
 
 
 
 
 
Dear  
 
Re: Faculty of Health Ethics Committee (FHEC) Application - (Proposal Number 
105 ) 
 
 
The FHEC has approved your ‘normal population’ study application and will then take 
Chair’s Action on the proposal once it has received approval from LREC. 
 
 
 
Yours sincerely 
 
 
 
 
 
Bernie Carter 
Acting Chair 
Faculty of Health Ethics Committee 
 
 
 
 
Cfi:   Jim Richards 
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11.5 Standardised subjective and objective assessment 
proforma 
 
ADDRESS:  
Telephone No. 
 
TENNIS ELBOW ASSESSMENT 
 
Patient No………..                                                                             Group 
              Injection 
                                                                                                U/S 
          Physiotherapy 
     
     
  
                                                                                                            
                                                                                                                  
 
HPC 
 
 
P.C.   
X-RAY                     BLOODS                              P & N  AN 
EYES/EARS  DIZZY                  H.A.                      BLACKOUTS 
24HRS    SLEEP                    OW               OR                                   DAY                                                     
 
PH – Upper Quadrant 
 
PM.S.H.  General Health Major Surgery   H      Bp       D        A 
 
Ep           TB            RA                 weight loss           medical problems 
 
DH       A/c                                                             ST 
 
SH  Occupation  
 
Leisure 
 
Baseline Data 
Age     Previous physiotherapy 
Smoker 
Gender    Previous Injection 
 
Occupation    N.S.A.I.D 
 
Symptom Duration   Analgesia 
 
Dominant Hand   Brace use 
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O/E 
P.P 
Obs 
 
Cervical Spine F    LR   LSF 
   E    RR   RSF 
 
GHJ   Abd    HBB   LR 
 
   ROM     OP   MS 
Elb   F  
   E 
 
R/U   Sup 
   Pron 
Wr   F 
   E      E with elbow ext. 
   Rad. Deviation    3
rd
 fg. extension 
   Uln deviation 
Neuro:   L                    R   ULNT (rad) L 
                    R 
  D 
  My 
  R B T   BR       B T BR    
  
Rad H   
 
 
Palpation  SCR  Lat epicondyle Rad H  MB 
Pulses             B         R               U 
Cx. Palp 
 
Eligibility criteria 
  
 Palp P CEO      Cx. Spine/bilateral symptoms 
 
 P  MS wr E      Previous elbow surgery 
   
1              >18 yrs       
 
I             Informed consent      Other upper quadrant 
                     pathology 
 
               Information sheet                               Physiotherapy <6/12 
        
            CI injection                                                                                 Injection <6/12 
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11.6 Patient information sheet 
 
PATIENT INFORMATION SHEET  Version No 2 Date: 2/12/05  
 
TITLE OF STUDY: Evaluation of short-term conservative treatment in patients 
with tennis elbow (lateral epicondylitis): A prospective randomised, assessor-
blinded trial. 
 
NAME OF RESEARCHER: Jeanette Tonks 
      
You are being invited to take part in a research study.  Before you decide it is important 
for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and discuss it with me if you wish.  
Ask me if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part.  Thank you for reading this.  
 
What is the purpose of the study? 
We would like to invite you to take part in a research study investigating tennis elbow 
which forms part of the researcher’s PhD at UCLAN. Many patients are referred to 
physiotherapy or orthopaedics for treatment, which may incorporate a wide range of 
treatments including: ultrasound, injection or exercise. To date we do not know which is 
the best treatment for this condition. This study will provide us with valuable 
information about the efficacy of your treatment.  
 
Why have I been chosen? 
All patients referred to physiotherapy or Orthopaedics here, with this type of problem, 
who are suitable, are being invited. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you 
will be given this information sheet to keep and asked to sign a consent form.  If you 
decide to take part you are still free to withdraw at any time. Any decision to withdraw 
or not to take part will not affect the standard of care you receive.  
 
What will happen to me if I take part? 
If you agree to participate in the study you will be allocated to a treatment group at 
random. All these treatments are common treatments provided by the physiotherapy 
department here: 
 
1, Injection group: This is a single injection of local anaesthetic and steroid which is 
injected around the tender area on the outside of your elbow. 
2, Ultrasound group: Gel will be placed on the tender area on the outside of your elbow 
and the ultrasound head will be gently applied for 5 minutes. You should not feel any 
discomfort.   
3, Physiotherapy exercise group: This is a progressive series of strengthening and 
stretching exercises you need to do on a regular basis.  
For the review appointment you will be asked not to drink alcohol from the night before 
the review and not to apply any creams to the area on the day of the review. 
Any brace will need to be removed and food consumption, strenuous exercise, drugs, 
caffeine and nicotine avoided for 2 hours prior to the review if possible.  
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At each review you will be asked to fill in a short questionnaire, (which should take 3-5 
minutes to fill in), that asks you about your pain and what kind of problems you have 
with your elbow. At the 10 day, 6 week and 6 month review you will be asked to fill in 
a short additional questionnaire, (which should take less than 5 minutes to fill in), about 
your treatment preferences. A picture of both your elbows will be taken using a special 
camera that measures heat. 4 skin fold measurements will be taken on your arm, leg and 
abdomen on the first appointment only. Sticky electrodes will be placed on both your 
forearms to tell us how your muscles are working whilst your pain free grip strength 
will be taken three times. 
 
Once the tests have finished you will receive your allocated treatment as per your group. 
These tests are taken at baseline, your 1
st
 appointment and then at 10 days and 6 weeks. 
You may need to attend more regularly for your treatment. If you still require treatment 
at 6 weeks you will receive further treatment as required. You will be asked to return at 
6 months for retesting to tell us how effective your treatment was. If you are not 
receiving treatment at your 6 months review you will be given the opportunity to claim 
reimbursement for your travel expenses in order to attend your 6 month review 
appointment.   
 
What are the disadvantages/ risks of taking part? 
All treatments are as per normal care for any patient being referred with tennis elbow. 
Any small risks of treatment will be explained to you fully prior to treatment. There are 
no additional risks to you from your inclusion in the study.  
 
What are the benefits of taking part? 
As an individual probably none, however you will be helping us to understand more 
about tennis elbow which will lead to better treatment of this condition in the future. 
 
Will my taking part in this study be kept confidential? 
All information, which is collected, about you during the course of this research will be 
kept strictly confidential.  Any information about you, which leaves the hospital, will 
have your name and address removed so that you cannot be recognized from it. If a 
scientific paper is written about the results your name and details will be removed 
completely. 
 
Who has reviewed this study? 
The Wrightington, Wigan and Leigh local research and ethics committee and the 
Faculty of Health University (UCLAN) Ethics committee have reviewed this study. 
 
Contact for further information. 
Jeanette Tonks, Orthopaedic Physiotherapy Practitioner on 01942 774605 
 
Thank you for taking the time to read about this study, if you have any questions 
please do not hesitate to ask. If you agree to take part you will be given a copy of 
this information sheet as well as the consent form for taking part in the study.  
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11.7 Informed consent sheet 
 
PATIENT CONSENT FORM 
 
Version No 2 Date 2.12.05 
 
Title of Project: Evaluation of short term conservative treatment in patients with 
tennis elbow (lateral epicondylitis):  a prospective randomised, assessor blinded 
trial. 
 
Name of Researchers:  Jeanette Tonks 
 
PLEASE INITIAL BOX 
 
I confirm that I have read and understood the information sheet dated 2.12.05 (Version 
2) for the above study and have had the opportunity to ask questions. 
 
 
I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
 
 
I understand that sections of any of my medical notes may be looked at by responsible 
individuals from Wrightington Hospital or from regulatory authorities where it is 
relevant to my taking part in research.  I give permission for these individuals to have 
access to my records. 
 
 
I agree to take part in the above study 
 
 
…………………  ………………  ……………………… 
Name of Patient  Date    Signature 
 
 
…………………  ………………  ……………………… 
Name or person  Date    Signature 
Taking consent 
(if different from 
Researcher) 
 
 
…………………  ………………  ……………………. 
Researcher   Date    Signature 
 
 
 
I for patient, 1 for researcher, 1 to be kept with hospital notes 
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11.8 Patient rated tennis elbow evaluation 
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11.9 Patient preference questionnaire 
         23/05/05 V1  
PATIENT QUESTIONNAIRE 
 
Patient number 
 
Review Patient group 
 
Which treatment would you prefer to have? 
 
 
 
 
 
 
 
What did you like about the treatment you received? 
 
 
 
 
 
 
 
What did you not like about the treatment you received? 
 
 
 
 
 
 
 
Can you suggest anyway the treatment you received could have been improved? 
 
 
 
 
 
 
 
 
If you had this problem again which treatment would you prefer to have? 
 
 
 
 
 
 
Thank you for your comments 
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11.10 Treatment diary 
TREATMENT DIARY 
 
Patient number Group 
Pre study Treatment 
 
Week Rx                   Change to 
protocol 
Pre study Rx 
change 
Adverse/ side 
effects 
1     
2     
3     
4     
5     
6     
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Rx summary 6 weeks – 6 months 
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11.11 Data collection sheet 
 
DATA COLLECTION SHEET 
 
 
Patient Number…… 
 
 
 
SKIN FOLD TEST 
 
 1 2 3 MEAN 
TRICEPS 
 
    
ABDOMINAL 
 
    
SUPRAILIAC 
 
    
THIGH 
 
    
 
 
    
LATERAL 
EPICONDYLE 
    
 
%Bf - female = 0.29669(∑4sf) – 0.00043(∑4sf)2 + 0.02963(age)+1.4072 
 
%Bf – male = 0.29288(∑4sf)-0.0005(∑4sf)2+0.1584(age)-5.76377 
 
%Bf =  
 
 
 
ELECTRODE PLACEMENT 
 
A=Radius length  
(lat epicondyle-radial styloid) 
R  L  
B=0.078 x A  
(up lat humerus to ECRL origin) 
    
C=ECRL origin to radial styloid length     
D=0.476 x C =ECRBr belly     
 
 
 
 
BASELINE…….. 
 
 
ROOM TEMP  TIME  
CAMERA DIST    
 
GRIP STRENGTH 
 
PFGS 1 R                                      L  
PFGS 2     
PFGS 3      
+15 SEC     
+30 SEC     
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PRETREATMENT…….. 
 
ROOM TEMP  TIME  
CAMERA DIST    
 
GRIP STRENGTH 
 
PFGS 1 R                                      L  
PFGS 2     
PFGS 3      
+15 SEC     
+30 SEC     
 
 
10 DAYS…….. 
 
ROOM TEMP  TIME  
CAMERA DIST    
 
GRIP STRENGTH 
 
PFGS 1 R                                      L  
PFGS 2     
PFGS 3      
+15 SEC     
+30 SEC     
 
 
6 WEEKS…….. 
 
ROOM TEMP  TIME  
CAMERA DIST    
 
GRIP STRENGTH 
 
PFGS 1 R                                      L  
PFGS 2     
PFGS 3      
+15 SEC     
+30 SEC     
 
 
6 MONTHS……… 
 
ROOM TEMP  TIME  
CAMERA DIST    
 
GRIP STRENGTH 
 
PFGS 1 R                                      L  
PFGS 2     
PFGS 3      
+15 SEC     
+30 SEC     
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11.12 Accumulative data collection sheet 
ACCUMULATIVE DATA COLLECTION 
 
Patient No. GROUP AGE 
smoker 
MALE/FEMALE 
OCCUPATION 
D. 
Left/right 
Affected 
left/right 
 
 
 
 
Symptom 
duration 
Previous 
treatment 
N.S.A.I.D. f 
pre 
N.S.A.I.D f 
post 
ANALGESIA BRACE 
 
 
 
 
 
 
Affected/unaffected Baseline Pre-
treatment 
10 days 6 weeks 6 months 
MPFS 
 
     
Thermography 
 
     
PFG 1 
 
     
PFG 2 
 
     
PFG 3 
 
     
Mean 
 
     
PRFEQ pain 
 
     
PRFEQ 
Function 
     
PRFEQ 
Total 
     
Additional 
Treatment 
 
 
 
 
 
 
     
Researchers opinion 
on 
 treatment received. 
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11.13 Local regional ethics committee approval 
Wrightington, Wigan & Leigh Local Research Ethics Committee 
Room 181, Gateway House 
Piccadilly South 
Manchester 
M60 7LP 
 
Telephone: 01612372585  
Facsimile: 01612372383 
6 January 2006 
 
Private & Confidential 
Mrs J H Tonks, Orthopaedic Physiotherapy Practitioner 
Ashton, Leigh and Wigan PCT 
Physiotherapy Dept, 
Royal Albert Edward Infirmary 
Wigan Lane 
WIGAN 
WN1 2NN 
 
Dear Mrs  Tonks 
 
Full title of study: Evaluation of long-term conservative treatment in patients 
with tennis elbow (lateral epicondylitis): A randomised, 
assessor- blinded controlled trial. 
REC reference number: 05/Q1410/122 
 
Thank you for your response to the Committee’s request for further information on the 
above research and for submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised. 
 
Ethical review of research sites 
 
The Committee agreed that all sites in this study should be exempt from site-specific 
assessment (SSA).  There is no need to complete Part C of the application form or to 
inform Local Research Ethics Committees (LRECs) about the research.  The favourable 
opinion for the study applies to all sites involved in the research.  
 
Conditions of approval 
 
The favourable opinion is given provided that you comply with the conditions set out in 
the attached document.  You are advised to study the conditions carefully.  Please note 
in particular the requirements relating to the submission of progress and other 
reports in point 4. 
Approved documents 
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The final list of documents reviewed and approved by the Committee is as follows: 
 
Document Version Date 
Application  5.0 10 October 2005 
Investigator CV Jeanette Tonks  01 July 2005 
Investigator CV Prof J Richards  01 October 2004 
Protocol  6 14 September 2005 
Summary/Synopsis  2 08 August 2005 
Letter from Sponsor   28 October 2005 
Peer Review   27 September 2005 
Questionnaire Patient Rated Forearm Evaluation   
Questionnaire Patient Questionnaire  23 May 2005 
Questionnaire Tennis Elbow Assessment  10 October 2005 
Questionnaire Accumulative Data Collection  10 October 2005 
Participant Information Sheet  2 02 December 2005 
Participant Consent Form  2 02 December 2005 
Letter from Faculty of Health Ethics Committee  19 October 2005 
Physio Rehab: Exercise Programme  01 January 1996 
Treatment Diary  10 October 2005 
Letter of support from PCT  12 October 2004 
Letter of authorisation from PCT   12 October 2004 
 
Research governance approval 
 
The study should not commence at any NHS site until the local Principal Investigator 
has obtained final research governance approval from the R&D Department for the 
relevant NHS care organisation. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK.  
 
05/Q1410/122           Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
 
Yours sincerely 
 
 
Chair 
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11.14 Faculty of health ethics committee approval 
 
 
6
th
 April 2006 
 
 
 
 
 
Jeanette Tonks 
Department of Allied Health Professions 
University of Central Lancashire 
 
 
 
 
 
Dear  Jeanette 
 
Re: Faculty of Health Ethics Committee (FHEC) Application - (Proposal Number 
105 V2 – Chair’s Action on Proposal) 
 
 
As your proposal has now received LREC approval, the FHEC hereby approves your 
proposal application by way of Chair’s Action  having met the conditions set by the 
Committee and on the basis described in its ‘Notes for Applicants’. 
 
 
Yours sincerely 
 
 
 
 
Bernie Carter 
Vice Chair 
Faculty of Health Ethics Committee 
 
 
 
 
Cfi: Jim Richards 
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11.15 Exercise programme (Pienimaki et al. 1996) 
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11.16 Poster presentation Chartered Society of Physiotherapy 
Congress 
Liverpool 16-17/10/09 
 
 
NOVEL PROTOCOL FOR THE THERMOGRAPHIC ANALYSIS 
OF TENNIS ELBOW 
ILLUSTRATIVE NORMATIVE DATA, SINGLE CASE HISTORY AND THERMAL EFFECTS OF ULTRASOUND
Jeanette Tonks1, James Selfe2, Jim Richards2
1Ashton, Leigh and Wigan Community Healthcare, Wigan; PhD student University of Central Lancashire: 2School of Public Health and Clinical Sciences, University of Central Lancashire, Preston, UK
INTRODUCTION SINGLE CASE HISTORY
A left-handed 38 year old female in the normative study developed tennis elbow in 
her, non dominant, right elbow 3 months after testing and was retested at 8 weeks 
post onset when she claimed, subjectively, to be 70% improved with NSAID and 
exercise. Applying the method described her thermal data was compared pre and 
post symptoms demonstrating an increase in Tsk. It has been proposed that the 
original -0.90C hypothermic image in the presymptomatic elbow demonstrates a 
degenerative process (Garagiola and Giani 1992). In comparison when her 
unaffected elbow was considered little change was evident: -0.5 to -0.3 0C. 
pre symptoms
-0.9 0C 
post symptoms
-0.20C
Fig 4: Thermal image pre and post symptoms
PROTOCOL
A FLIR A40M thermovision infra-red thermal imaging camera was focused on the 
lateral epicondyle and aligned parallel with the skin overlying the area at a 
distance of 80cm. The concept of the use of thermally inert wooden anatomical 
markers (Selfe et al. 2006) was applied in a unique manner for tennis elbow: 
midpoint of the olecranon and in the same plane in the cubital crease with the 
elbow flexed to 900 and in full supination. This procedure enabled a reliable and 
accurate method for the thermal image data collection and subsequently analysis 
through the development of a novel scientifically robust model.
Fig 1: AR02 and AR03
A unique method of measuring the skin 
temperature (Tsk) of the insertion of extensor 
carpi radialis brevis (ECRBr) was developed in 
a standardised procedure which was both easy and 
reproducible in a consistent manner. The region 
of  interest (ROI) quadrant (AR02) was compared
With the unaffected quadrant (AR03) which acts 
as a control. The thermal difference between the 
maximum Tsk (AR02 – AR03) for the ROI was
then recorded. Fig 2: Protocol method
The immediate thermal effects following a treatment session of ultrasound 
(continuous 3 MHz using a 0.5 transducer with gel at 2W/cm2 for 5 minutes) to 
the tenoperiosteal junction of ECRBr was explored on a ‘healthy subject’ using 
this method and was repeated on a separate occasion without the ultrasound 
switched on. A thermal image was taken immediately prior to ultrasound, within 1 
minute post ultrasound and then at 1 minute intervals until 20 minutes inclusive. 
Then at 25 and 30 minutes post ultrasound. This graph shows the thermal 
difference overtime with a clinically important change of 0.50C from baseline 
highlighted by the 2 pink lines.  
Fig 5: Thermal difference overtime
With therapeutic ultrasound (red) after 5 minutes through to 19 minutes a 
clinically important change of 0.50C can be seen with a marked reduction in 
thermal difference, i.e. a clinically important increase in Tsk. This can be 
attributed to the therapeutic effects of ultrasound. This is validated as no clinically 
important increase in Tsk is evident with mock ultrasound (blue). It is interesting 
to note the 5 minutes delay for the effects of ultrasound and the vascular response 
to become apparent, which may be explained as a result of the initial masking 
cooling effects of the application of gel and metal transducer. 
NORMATIVE DATA
Normative data was collected, using this method, from 20 asymptomatic subjects 
who were age and gender matched to a typical tennis elbow population. The ROI 
was found to be a mean of 0.350C cooler when compared to the control; i.e.: a 
negative thermal difference. This was supported by previous research (Binder et 
al. 1983) who found a similar thermal gradient was often present in the 120 
elbows of 60 normal subjects they examined.
Fig 3: Table of normative data
22.3°C
33.6°C
AR02
AR03
THERMAL EFFECTS OF ULTRASOUND
Infrared thermography is a valuable technique for the diagnosis of tennis elbow 
and is reported as a ‘sensitive, objective investigational procedure for the 
assessment of tennis elbow’(Haake et al. 2002). Thermal image data collection is 
inherently difficult to standardise due to potential intrinsic and extrinsic variables 
which affect vasomotor regulation. A novel scientifically robust model for the 
thermographic analysis of tennis elbow has been developed which negates some of 
these issues and is being used clinically to analyse the effects of current treatment 
on tennis elbow. 
-0.4
(0.43)
32.532.1-0.3
(0.51)
32.832.5Mean  0C
(SD)
Non 
dominant
Thermal
Difference
Non
Dominant 
AR03
Non
Dominant
AR02
Dominant
Thermal
Difference
Dominant
AR03
Dominant
AR02
23.4°C
33.8°C
18.2°C
33.1°C
22.3°C
33.6°C
AR01
22.3°C
33.6°C
LI01
LI02AR 1
22.3°C
33.6°C
LI01
LI02AR 1
AR02
3
-1.8
-1.6
-1.4
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
time interval
th
e
r
m
a
l 
d
if
fe
r
e
n
c
e
therapeutic ultrasound
mock ultrasound
2-4 mins 5-19 mins 20-30 mins
REFERENCES         Binder, A., Parr, G., Page Thomas, P., Hazleman, B. (1983) A clinical and thermographic study of lateral epicondylitis British Journal of Rheumatology 22, p.77-81
Garagiola, U., Giani, E. (1990) Use of telethermography in the management of sports injuries Sports Medicine 10 (4), p.267-272
Haake, M., Willenberg, T., Sauer, F., Griss, P. (2002) Effect of extracorporeal shockwave therapy on vascular regulation. Infrared thermography in epicondylitis humeral radialis Swiss Surg 8 (4), p.176-180
Selfe, J., Hardaker, N., Thewlis, D., Karki, A. (2006) An accurate and reliable method of thermal data analysis in thermal imaging of the anterior knee for use in cryotherapy research  Arch Phys Med Rehabil 87, p.1630-1635  
 196 
11.17 Poster presentation British Elbow and Shoulder Society 
20th annual scientific meeting UCL, London 24-26/6/09 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
